WO2020068702A1 - Chimeric receptor proteins and uses thereof - Google Patents
Chimeric receptor proteins and uses thereof Download PDFInfo
- Publication number
- WO2020068702A1 WO2020068702A1 PCT/US2019/052492 US2019052492W WO2020068702A1 WO 2020068702 A1 WO2020068702 A1 WO 2020068702A1 US 2019052492 W US2019052492 W US 2019052492W WO 2020068702 A1 WO2020068702 A1 WO 2020068702A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- fusion protein
- carcinoma
- domain
- variant
- Prior art date
Links
- 108700010039 chimeric receptor Proteins 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 412
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 332
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 332
- 239000000427 antigen Substances 0.000 claims abstract description 161
- 108091007433 antigens Proteins 0.000 claims abstract description 160
- 102000036639 antigens Human genes 0.000 claims abstract description 160
- 230000027455 binding Effects 0.000 claims abstract description 128
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 98
- 230000014509 gene expression Effects 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 230000003834 intracellular effect Effects 0.000 claims abstract description 64
- 230000001976 improved effect Effects 0.000 claims abstract description 36
- 230000004044 response Effects 0.000 claims abstract description 17
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 157
- 102000040430 polynucleotide Human genes 0.000 claims description 129
- 108091033319 polynucleotide Proteins 0.000 claims description 129
- 239000002157 polynucleotide Substances 0.000 claims description 129
- 239000012636 effector Substances 0.000 claims description 126
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 79
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 71
- 150000001413 amino acids Chemical group 0.000 claims description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 70
- 235000018102 proteins Nutrition 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 63
- 235000001014 amino acid Nutrition 0.000 claims description 61
- 201000010099 disease Diseases 0.000 claims description 61
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 52
- 230000000139 costimulatory effect Effects 0.000 claims description 50
- -1 0X40 Proteins 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 45
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 43
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 43
- 241000282414 Homo sapiens Species 0.000 claims description 36
- 102100030886 Complement receptor type 1 Human genes 0.000 claims description 35
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 35
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 33
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108090000695 Cytokines Proteins 0.000 claims description 27
- 210000000987 immune system Anatomy 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 25
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 24
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 23
- 201000009030 Carcinoma Diseases 0.000 claims description 22
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 22
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 22
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 21
- 208000009956 adenocarcinoma Diseases 0.000 claims description 20
- 230000005754 cellular signaling Effects 0.000 claims description 20
- 230000026731 phosphorylation Effects 0.000 claims description 20
- 238000006366 phosphorylation reaction Methods 0.000 claims description 20
- 239000013603 viral vector Substances 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 19
- 206010039491 Sarcoma Diseases 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 17
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- 201000003076 Angiosarcoma Diseases 0.000 claims description 15
- 238000003209 gene knockout Methods 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 230000002759 chromosomal effect Effects 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 13
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 13
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 12
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 12
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims description 12
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 12
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 12
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 12
- 230000004083 survival effect Effects 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 11
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 210000000822 natural killer cell Anatomy 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 238000010361 transduction Methods 0.000 claims description 10
- 230000026683 transduction Effects 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 9
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- 230000016396 cytokine production Effects 0.000 claims description 9
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 230000002147 killing effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 210000003515 double negative t cell Anatomy 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 7
- 230000003463 hyperproliferative effect Effects 0.000 claims description 7
- 230000008629 immune suppression Effects 0.000 claims description 7
- 201000008968 osteosarcoma Diseases 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 6
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 6
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 6
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 102100023123 Mucin-16 Human genes 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 6
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 210000000244 kidney pelvis Anatomy 0.000 claims description 6
- 206010024627 liposarcoma Diseases 0.000 claims description 6
- 201000005296 lung carcinoma Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 206010042863 synovial sarcoma Diseases 0.000 claims description 6
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 5
- 101710185679 CD276 antigen Proteins 0.000 claims description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 230000001603 reducing effect Effects 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 230000006450 immune cell response Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000000649 small cell carcinoma Diseases 0.000 claims description 4
- 230000002459 sustained effect Effects 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 3
- 208000017925 Askin tumor Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 206010006143 Brain stem glioma Diseases 0.000 claims description 3
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 3
- 108700012439 CA9 Proteins 0.000 claims description 3
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100035793 CD83 antigen Human genes 0.000 claims description 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 3
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 3
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 3
- 206010059352 Desmoid tumour Diseases 0.000 claims description 3
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims description 3
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 3
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims description 3
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 108010043942 Ephrin-A2 Proteins 0.000 claims description 3
- 102100033919 Ephrin-A2 Human genes 0.000 claims description 3
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 3
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 3
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 3
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 claims description 3
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims description 3
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 3
- 101710088083 Glomulin Proteins 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 208000006050 Hemangiopericytoma Diseases 0.000 claims description 3
- 206010073069 Hepatic cancer Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 3
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 3
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 3
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 3
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 3
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 3
- 201000003791 MALT lymphoma Diseases 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 3
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 108060006580 PRAME Proteins 0.000 claims description 3
- 102000036673 PRAME Human genes 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 claims description 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 3
- 208000002163 Phyllodes Tumor Diseases 0.000 claims description 3
- 206010071776 Phyllodes tumour Diseases 0.000 claims description 3
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 3
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims description 3
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 3
- 208000021388 Sezary disease Diseases 0.000 claims description 3
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 208000009311 VIPoma Diseases 0.000 claims description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 102000040856 WT1 Human genes 0.000 claims description 3
- 108700020467 WT1 Proteins 0.000 claims description 3
- 101150084041 WT1 gene Proteins 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 3
- 201000005179 adrenal carcinoma Diseases 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims description 3
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 201000005389 breast carcinoma in situ Diseases 0.000 claims description 3
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 claims description 3
- 201000010983 breast ductal carcinoma Diseases 0.000 claims description 3
- 208000002458 carcinoid tumor Diseases 0.000 claims description 3
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 3
- 201000010276 collecting duct carcinoma Diseases 0.000 claims description 3
- 201000006827 desmoid tumor Diseases 0.000 claims description 3
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 3
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 3
- 208000018529 duodenal adenocarcinoma Diseases 0.000 claims description 3
- 208000027858 endometrioid tumor Diseases 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 claims description 3
- 230000003328 fibroblastic effect Effects 0.000 claims description 3
- 102000006815 folate receptor Human genes 0.000 claims description 3
- 108020005243 folate receptor Proteins 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 208000010749 gastric carcinoma Diseases 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 claims description 3
- 201000004933 in situ carcinoma Diseases 0.000 claims description 3
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 3
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 3
- 208000003849 large cell carcinoma Diseases 0.000 claims description 3
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000002250 liver carcinoma Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000011059 lobular neoplasia Diseases 0.000 claims description 3
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 3
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 3
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 3
- 208000025036 lymphosarcoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000004058 mixed glioma Diseases 0.000 claims description 3
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 3
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 claims description 3
- 201000010174 renal carcinoma Diseases 0.000 claims description 3
- 201000006845 reticulosarcoma Diseases 0.000 claims description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 3
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 101150047061 tag-72 gene Proteins 0.000 claims description 3
- 208000001608 teratocarcinoma Diseases 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 2
- 101150091887 Ctla4 gene Proteins 0.000 claims description 2
- 206010015848 Extraskeletal osteosarcomas Diseases 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 2
- 208000016154 cervical small cell carcinoma Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
- 230000011664 signaling Effects 0.000 abstract description 26
- 230000002829 reductive effect Effects 0.000 abstract description 11
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 abstract 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 abstract 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 description 100
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 100
- 150000007523 nucleic acids Chemical class 0.000 description 68
- 102000039446 nucleic acids Human genes 0.000 description 66
- 108020004707 nucleic acids Proteins 0.000 description 66
- 125000003275 alpha amino acid group Chemical group 0.000 description 60
- 229940024606 amino acid Drugs 0.000 description 58
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 52
- 210000002865 immune cell Anatomy 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 102000014914 Carrier Proteins Human genes 0.000 description 11
- 102100031780 Endonuclease Human genes 0.000 description 11
- 108010042407 Endonucleases Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 108091008324 binding proteins Proteins 0.000 description 11
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 10
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 10
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108091079001 CRISPR RNA Proteins 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000005782 double-strand break Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 230000006780 non-homologous end joining Effects 0.000 description 9
- 238000004885 tandem mass spectrometry Methods 0.000 description 9
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- 102000017578 LAG3 Human genes 0.000 description 7
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 108010070047 Notch Receptors Proteins 0.000 description 6
- 102000005650 Notch Receptors Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 102100033467 L-selectin Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010459 TALEN Methods 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000214054 Equine rhinitis A virus Species 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 229960000640 dactinomycin Drugs 0.000 description 4
- 230000000779 depleting effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000007781 signaling event Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001663880 Gammaretrovirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 230000001400 myeloablative effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 102220193876 rs786204758 Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 229940123414 Folate antagonist Drugs 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 101150065403 NECTIN2 gene Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- OTJHLDXXJHAZTN-BYPYZUCNSA-N S-(2-boronoethyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCCB(O)O OTJHLDXXJHAZTN-BYPYZUCNSA-N 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102100023407 Uracil nucleotide/cysteinyl leukotriene receptor Human genes 0.000 description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 238000011467 adoptive cell therapy Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 230000001275 ca(2+)-mobilization Effects 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 238000003198 gene knock in Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 210000000428 immunological synapse Anatomy 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 230000032965 negative regulation of cell volume Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 102220191892 rs199825512 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- HFKKMXCOJQIYAH-YFKPBYRVSA-N (S)-2-amino-6-boronohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCB(O)O HFKKMXCOJQIYAH-YFKPBYRVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 229940080328 Arginase inhibitor Drugs 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 101500007118 Bovine leukemia virus Transmembrane protein Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 229940121697 CD27 agonist Drugs 0.000 description 1
- 229940123205 CD28 agonist Drugs 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101100273713 Homo sapiens CD2 gene Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229940125563 LAG3 inhibitor Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- FQWRAVYMZULPNK-BYPYZUCNSA-N N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NO FQWRAVYMZULPNK-BYPYZUCNSA-N 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KOBHCUDVWOTEKO-VKHMYHEASA-N Nomega-hydroxy-nor-l-arginine Chemical compound OC(=O)[C@@H](N)CCNC(=N)NO KOBHCUDVWOTEKO-VKHMYHEASA-N 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000713747 Ovine lentivirus Species 0.000 description 1
- 101150096038 PTH1R gene Proteins 0.000 description 1
- 102000007497 Patched-2 Receptor Human genes 0.000 description 1
- 108010071083 Patched-2 Receptor Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 1
- 108010023649 Tripartite Motif Proteins Proteins 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000010856 establishment of protein localization Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 102000052073 human NGFR Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- FIGS 1A-1N show design and testing of bi-specific T cells for selective analysis of TCR- and CAR-induced signaling and effector functions in a single-cell- type population.
- A Schematic of bi-specific T cells that express an endogenous EBV- specific T cell receptor (TCR) and were transduced to express a ROR1 -specific chimeric antigen receptor (CAR).
- B Flow cytometry analysis of EBV-tetramer binding and CDl9t expression in expanded T cells. FACS plot shows stained (black) and isotype (grey) CD8 + singlet lymphocytes.
- C Schematic of magnetic beads coated with HLA-B8/EBV-RAK single chain trimer (SCT), ROR1 ectodomain, or SCT and CD28 mAh.
- D Western blot analysis for O ⁇ 3z, O ⁇ 3z pTyr 142 , and PLC-yl pTyr 783 in lysates from T cells incubated for 45 minutes with microbeads coated with various molar ratios of SCT or ROR1. 30pL beads were used per million cells.
- SCT solid line
- SCT/CD28 solid line
- H Flow cytometry analysis of T cell proliferation as measured by CFSE dye dilution at 72 hours after co-culture with: K562/B8 cells or control beads; K562/B8/EBV cells or SCT/CD28 beads; or K562/B8/RORl + cells or RORl-coated beads. Histogram plots show CD8 + lymphocytes and are representative of 2-3 independent experiments.
- (I)-(L) Flow cytometry analysis showing IFN-g, IL-2, and TNF-a production 5 hours after co-culture of bi-specific T cells with: K562/B8 cells; K562/B8/EBV cells; K562/B8/ROR1 + cells; control beads; SCT/CD28 beads; or ROR1 -coated beads.
- (I, K) FACS plots show CD45 + singlet lymphocytes. The frequency of IFN-y + IL-2 + TNFa + cells is shown in (I). Data are means ⁇ standard deviation (SD) of 2-3 independent experiments. The indicated P values were calculated by unpaired two-tailed t test. Cytokine production is quantified in Figures 1 J and 1L.
- Figures 2A-2M relate to experiments identifying protein phosphorylation events by mass spectrometry (MS) following TCR or CAR stimulation.
- A Schematic of experimental design stimulating bi-specific T cells with microbeads coated with TCR (SCT/CD28) or CAR (ROR1) antigens.
- B Flow cytometry analysis of T cell markers in the three experiments.
- C Venn diagram of the overlap among phosphorylation sites.
- D Histogram of the SD of the fold-change (log2FC) values across all tandem MS/MS experiments.
- E Total number of pSer, pThr and pTyr peptides identified by MS/MS.
- F -(H) Volcano plots of log2FC and false discovery rate (FDR) for phosphorylation sites identified by tandem MS/MS at the indicated timepoints after stimulation. Dots in the upper right portion indicate sites with increased
- Figures 3A-3H provide data from MS/MS experiments showing that CAR stimulation induces less intense P0 4 of CD3 chains and signaling adaptors as compared to TCR stimulation.
- (A)-(C) Comparison of the log2FC of P0 4 sites identified by tandem MS/MS at the indicated timepoints after TCR or CAR stimulation. Dots above and below dashed lines specify sites that possessed mean log2FC values differing by >
- FIGS. 4A-4R show that T cells expressing CARs that incorporate CD3e ITAM and protein recruitment sequences display improved recognition of tumor cells with low antigen density.
- A Schematic of CD3e-containing CAR designs that included (not shown) a CD 19-specific scFv derived from FMC63 or (shown) a ROR1- specific scFv derived from R12 antibody.
- B Western blot analysis for E03z in the indicated CAR T cell lysates. Blots are representative of 2 independent experiments.
- C Flow cytometric analysis of EGFRt and STII (CAR) expression on sort purified and expanded CD8 + EGFRt + T cells.
- N 4 healthy T cell donors.
- (J) Flow cytometry analysis of CAR T cell proliferation as measured by CFSE dye dilution at 72 hours after co-culture with the indicated tumor cells having medium ( M RORl med NCI-H358") or low ("RORl lo MDA- MB-231”) surface expression of ROR1. Histogram plots show 4- 1 BB/E ⁇ 3z (solid line) and 4-lBB/CD3ePRS_ITAMAHI ⁇ (dashed line) CD8 + lymphocytes and are representative of one experiment.
- n 3 independent experiments.
- P Survival curves of NSG mice that were injected with Raji/ffluc cells and, 7 days following engraftment, received with a single infusion of the indicated CAR T cells. Data were pooled from two independent experiments, with 6 or 10 mice per treatment group.
- Q Survival curves of NSG mice injected with RORl mt Jeko-l cells and administered CD28/CD3 ⁇ 4- 1 BB/E ⁇ 3z, or 4- 1 BB/CD3CPRS P AM/E ⁇ 3z CAR T cells.
- N 8 mice per group.
- R ROR1 expression (solid line) by MDA-MB-231 breast adenocarcinoma and NCI-H358 lung
- FIG. 5 shows characterization of ROR1 expression on various tumor cell lines. Flow cytometry analysis of ROR1 expression on the indicated tumor lines. Histograms show stained (solid line) and isotype (dashed line) singlets.
- the present disclosure provides chimeric receptor proteins with improved signaling properties and/or activities over existing immunoreceptor proteins (e.g ., chimeric antigen receptors (CARs), T cell receptors (TCRs), or the like), which improved properties include, in certain embodiments, initiating, generating, propagating, and/or amplifying a signal in a host cell (e.g., an immune cell such as a T cell) expressing the fusion protein when the fusion protein binds to an antigen.
- a host cell e.g., an immune cell such as a T cell
- the antigen bound by the fusion protein is expressed at a low level, or at an intermediate level, or in some embodiments, at a high level, by a target antigen-expressing cell, such as, for example, a cancer cell.
- Exemplary fusion proteins of this disclosure comprise (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain (e.g, connecting the extracellular component and intracellular component); and (c) an intracellular component comprising an effector domain or a functional portion or variant thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (IT AM) from CD3e, or a functional portion or variant thereof ; (ii) an ITAM from CD3y, or a functional portion or variant thereof; (iii) an ITAM from CD35, or a functional portion or variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or E03z, or a functional portion or variant thereof; or (vi) any combination of (i)-(v).
- a fusion protein comprises: (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain; and (c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof (i.e., a functional variant of the IT AM); (ii) an ITAM from CD3y, or a functional variant thereof; (iii) an IT AM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or 0)3z, or a functional variant thereof; or (vi) any combination of (i)-(v), and does not comprise an ecto
- ITAM Intracellular
- an effector domain or a functional portion or variant thereof from a CD3e is not a full-length CD3e and is not an endodomain (also referred to herein as a cytoplasmic domain) from CD3e.
- an intracellular component of a fusion protein comprises a PRS and an ITAM from CD3e.
- a fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
- the effector domain of the fusion protein comprises a BRS from CD3e, or a functional variant thereof (i.e., of the BRS).
- the intracellular component further comprises an ITAM from CD3z, or a functional variant thereof (i.e., of the ITAM).
- the intracellular component comprises a cytoplasmic domain (also referred to as an endodomain) from a human 003z, or a functional portion or variant thereof.
- the intracellular component further comprises a costimulatory domain or a functional portion or variant thereof (e.g ., from 4-1BB).
- the intracellular component comprises a costimulatory domain, an endodomain or effector domain from CD3 z, or a functional portion or variant thereof, and an effector domain from CD3e, or a functional portion or variant thereof.
- the effector domain from CD3e (or functional portion or variant of an effector domain from CD3e) is disposed between the costimulatory domain (or functional portion or variant of the costimulatory domain) and the endodomain or effector domain from O ⁇ 3z (or functional portion or variant of the endodomain or effector domain from 003z).
- a fusion protein of the present disclosure does not comprise a TCR extracellular domain, preferably does not comprise a TCR ectodomain.
- a fusion protein of the present disclosure when expressed by a T cell, does not associate with or form a TCR complex (e.g ., a TCR complex as described herein, which can include one or more endogenous or
- the extracellular component comprises a CH1, a CH2, a CH3, a CL (i.e., from an immunoglobulin), or comprises an amino acid sequence derived therefrom, a CD8 extracellular domain, a CD4 extracellular domain, a CD28 extracellular domain (e.g., amino acids 19-152 of the CD28 amino acid sequence provided in UniProt entry P 10747) or a functional variant or portion thereof, or comprises a combination thereof.
- the presently disclosed fusion proteins can be useful in cellular
- immunotherapies comprising host cells (e.g, an immune system cell such as, for example, a T cell, NK cell, or NK-T cell, or a hematopoietic progenitor cell) that express the fusion proteins and specifically bind to antigens that are expressed by or are otherwise associated with a disease or condition, such as, for example, a cancer.
- host cells e.g, an immune system cell such as, for example, a T cell, NK cell, or NK-T cell, or a hematopoietic progenitor cell
- a disease or condition such as, for example, a cancer.
- a host cell expressing a fusion protein of the instant disclosure has improved (e.g, increased and/or sustained) cell signaling (e.g, cytokine production and/or release (for example, IFN-g, TNFa, IL-2), phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as phosphorylation of LAT, PLC-g I , SLP-76, or any combination thereof) and/or activity (e.g, mobilization of intracellular calcium, killing activity, secretion of a cytokine, proliferation, earlier activation following stimulation, or the like) in response to antigen relative to a host cell expressing a reference fusion protein that does not comprise in an intracellular component a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein.
- cell signaling e.g, cytokine production and/or release (for example, IFN-g, TNFa, IL-2), phosphorylation of
- a host cell expressing a fusion protein of this disclosure has improved (e.g, earlier and/or stronger, relative to a host cell expressing a reference fusion protein) cell signaling and/or activity upon binding to a target antigen that is expressed at a low level or an intermediate level on a target cell (e.g., solid tumor cell) surface, and/or in certain embodiments, upon binding to a target antigen that is expressed at a high level on a target cell surface.
- a host cell expressing a fusion protein of the present disclosure is capable, when administered to a subject having a tumor comprising cells that expresses an antigen that is specifically bound or recognized by the fusion protein, of reducing or suppressing growth, area, volume, and/or spread of the tumor, of killing tumor cells, and/or of increasing survival of the subject to a greater degree and/or for a longer period of time as compared to a reference subject administered a cell therapy wherein the cells do not comprise a fusion protein as provided herein (e.g, comprise a reference fusion protein that has a similar structure to the fusion protein of the present disclosure but does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein).
- a host cell expressing a fusion protein of the present disclosure is capable of greater antitumor activity as compared to a reference host cell expressing a fusion protein that does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein; e.g, host cells expressing a fusion protein of the present disclosure may infiltrate a tumor in a number that is statistically not significantly different as compared to the number of reference host cells infiltrating a reference tumor, but the host cell expressing a fusion protein of the present disclosure has improved antitumor activity (e.g, causes slower growth or stops growth of the tumor, or reduces tumor size, or spread, or the like) versus the reference host cell.
- antitumor activity e.g, causes slower growth or stops growth of the tumor, or reduces tumor size, or spread, or the like
- a fusion protein of the present disclosure can, following stimulation with antigen, promote (i.e., directly or indirectly) phosphorylation of LAT, SLP-76, and/or PLC-g I more efficiently than a reference fusion protein that does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein.
- a fusion protein of the present disclosure is expressed in a host cell (e.g, an immune cell such as, for example, a T cell) and comprises (i) a sequence or motif from a CD3e, CD3y, and/or CD35 protein and (ii) a O ⁇ 3z IT AM or endodomain, and binding of the fusion protein to antigen results in decreased phosphorylation of the O ⁇ 3z ITAM or endodomain as compared to binding of a reference fusion protein comprising a CD3z ITAM or endodomain to antigen, but results in a similar or increased phosphorylation of a downstream cell signaling protein, such as, for example, LAT, PLC-g I , or both.
- a host cell e.g, an immune cell such as, for example, a T cell
- a host cell e.g, an immune cell such as, for example, a T cell
- a downstream cell signaling protein such as, for example, LAT, PLC-g I , or both.
- a host cell e.g ., an immune cell such as a T cell
- a fusion protein of the present disclosure has improved sensitivity to antigen as compared to a host cell expressing a reference fusion protein that does not contain a sequence or motif from a CD3e, CD3y, and/or CD35 protein, but does not produce more, or does not produce substantially more, of a pro-inflammatory cytokine (e.g., IFN-g, IL-2, TNF-a) as compared to the host cell expressing the reference fusion protein.
- a pro-inflammatory cytokine e.g., IFN-g, IL-2, TNF-a
- marked increases in production of pro- inflammatory cytokines may cause toxicities.
- fusion proteins and host cells expressing the same have, in certain embodiments, improved sensitivity for antigen (i.e., at a low, intermediate, and/or high level of antigen expression) but do not increase, or do not substantially increase, a risk of an antigen
- a fusion protein according to the present disclosure comprises a sequence or motif from a CD3e, CD3y, and/or CD35 protein and further comprises a 4-1BB costimulatory domain.
- a reference fusion protein comprises a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
- any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
- any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness is to be understood to include any integer within the recited range, unless otherwise indicated.
- the term “about” means ⁇ 20% of the indicated range, value, or structure, unless otherwise indicated. It should be understood that the terms “a” and “an” as used herein refer to “one or more" of the enumerated components.
- a protein domain, region, or module e.g ., a binding domain, hinge region, or linker
- a protein which may have one or more domains, regions, or modules
- substantially affect i.e., do not reduce the activity by more than 50%, such as no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) the activity of the domain(s), region(s), module(s), or protein (e.g, the target binding affinity of a binding protein).
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g, hydroxyproline, g-carboxyglutamate, and O-phosphoserine.
- Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g ., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
- Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a naturally occurring amino acid.
- mutation refers to a change in the sequence of a nucleic acid molecule or polypeptide molecule as compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively.
- a mutation can result in several different types of change in sequence, including substitution, insertion or deletion of nucleotide(s) or amino acid(s).
- a “conservative substitution” refers to amino acid substitutions that do not significantly affect or alter binding characteristics of a particular protein. Generally, conservative substitutions are ones in which a substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include a substitution found in one of the following groups: Group 1 : Alanine (Ala or A), Glycine (Gly or G), Serine (Ser or S), Threonine (Thr or T); Group 2: Aspartic acid (Asp or D), Glutamic acid (Glu or Z); Group 3 : Asparagine (Asn or N), Glutamine (Gln or Q); Group 4: Arginine (Arg or R), Lysine (Lys or K), Histidine (His or H); Group 5: Isoleucine (Ile or I), Leucine (Leu or L), Methionine (Met or M), Valine (Val or V); and Group 6: Phenylalanine (Phe or F), Tyrosine (Tyr
- amino acids can be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g, acidic, basic, aliphatic, aromatic, or sulfur-containing).
- an aliphatic grouping may include, for purposes of substitution, Gly, Ala, Val, Leu, and Ile.
- conservative substitutions groups include: sulfur-containing: Met and Cysteine (Cys or C); acidic: Asp, Glu, Asn, and Gln; small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gln; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information can be found in Creighton (1984) Proteins. W.H. Freeman and Company. Variant proteins, peptides, polypeptides, and amino acid sequences of the present disclosure can, in certain embodiments, comprise one or more conservative substitutions relative to a reference amino acid sequence.
- protein or “polypeptide” refers to a polymer of amino acid residues. Proteins apply to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid and non-naturally occurring amino acid polymers.
- fusion protein refers to a protein that, in a single chain, has at least two distinct domains or motifs, wherein the domains or motifs are not naturally found together ( e.g ., in the specified arrangement, order, or number, or at all) in a protein.
- a fusion protein comprises at least two distinct domains or motifs that are not naturally found together in a single peptide or polypeptide.
- a polynucleotide encoding a fusion protein may be constructed using PCR, recombinantly engineered, or the like, or such fusion proteins can be synthesized.
- a fusion protein may further contain other components, such as a tag, a linker, or a transduction marker.
- a fusion protein expressed or produced by a host cell locates to the cell surface, where the fusion protein is anchored to the cell membrane (e.g, via a transmembrane domain) and comprises an extracellular portion or component (e.g, containing a binding domain and, in certain embodiments, a linker, a spacer, or both) and an intracellular portion or component (e.g, containing a sequence or motif from a CD3 protein as provided herein).
- Nucleic acid molecule refers to a polymeric compound including covalently linked nucleotides, which can be made up of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine ring).
- Purine bases include adenine, guanine, hypoxanthine, and xanthine
- pyrimidine bases include uracil, thymine, and cytosine.
- Nucleic acid molecules include polyribonucleic acid (RNA), polydeoxyribonucleic acid (DNA), which includes cDNA, genomic DNA, and synthetic DNA, either of which may be single or double-stranded.
- the nucleic acid molecule may be the coding strand or non-coding (anti-sense strand).
- a nucleic acid molecule encoding an amino acid sequence includes all nucleotide sequences that encode the same amino acid sequence. Some versions of the nucleotide sequences may also include intron(s) to the extent that the intron(s) would be removed through co- or post-transcriptional mechanisms. In other words, different nucleotide sequences may encode the same amino acid sequence as the result of the redundancy or degeneracy of the genetic code, or by splicing.
- Variants of nucleic acid molecules of this disclosure are also contemplated. Variant nucleic acid molecules are at least 70%, 75%, 80%, 85%, 90%, and are preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical a nucleic acid molecule of a defined or reference polynucleotide as described herein, or that hybridize to a polynucleotide under stringent hybridization conditions of 0.015M sodium chloride, 0.0015M sodium citrate at about 65-68°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at about 42°C. Nucleic acid molecule variants retain the capacity to encode a fusion protein or a binding domain thereof having a functionality described herein, such as specifically binding a target molecule.
- Percent sequence identity refers to a relationship between two or more sequences, as determined by comparing the sequences. Preferred methods to determine sequence identity are designed to give the best match between the sequences being compared. For example, the sequences are aligned for optimal comparison purposes e.g ., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment). Further, non-homologous sequences may be disregarded for comparison purposes. The percent sequence identity referenced herein is calculated over the length of the reference sequence, unless indicated otherwise. Methods to determine sequence identity and similarity can be found in publicly available computer programs.
- Sequence alignments and percent identity calculations may be performed using a BLAST program (e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX).
- BLAST program e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX.
- the mathematical algorithm used in the BLAST programs can be found in Altschul et al ., Nucleic Acids Res. 25: 3389-3402, 1997.
- sequence analysis software is used for analysis, the results of the analysis are based on the "default values" of the program referenced. "Default values" mean any set of values or parameters which originally load with the software when first initialized.
- isolated means that the material is removed from its original environment (e.g ., the natural environment if it is naturally occurring).
- a naturally occurring nucleic acid or polypeptide present in a living animal is not isolated, but the same nucleic acid or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated.
- Such nucleic acid could be part of a vector and/or such nucleic acid or polypeptide could be part of a composition (e.g., a cell lysate), and still be isolated in that such vector or composition is not part of the natural environment for the nucleic acid or polypeptide.
- gene means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region ("leader and trailer") as well as intervening sequences (introns) between individual coding segments (exons).
- a “functional variant” refers to a polypeptide or polynucleotide that is structurally similar or substantially structurally similar to a parent or reference compound of this disclosure, but differs, in some contexts slightly, in composition (e.g., one base, atom or functional group is different, added, or removed; or one or more amino acids are mutated, inserted, or deleted), such that the polypeptide or encoded polypeptide is capable of performing at least one function of the encoded parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%,
- a functional variant of a polypeptide or encoded polypeptide of this disclosure has "similar binding,” “similar affinity” or “similar activity” when the functional variant displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide, such as an assay for measuring binding affinity (e.g, Biacore® or tetramer staining measuring an association (K a ) or a dissociation (KD) constant) or avidity; or an assay measuring phosphorylation or activation of, or by, an immune cell protein such as, for example, Lck, ZAP70, Fyn, PLOy-l, SLP-76, LAT, or the like, including the assays described herein.
- a polypeptide or encoded polypeptide of this disclosure may be determined by examining the activity, structure, chemical state (e.g., phosphorylation), or interactions of or between the variant polypeptide and an immune cell protein that directly acts (e.g. , binds to) therewith, or by examining the activity, localization, structure, expression, secretion, chemical state (e.g, phosphorylation), or interactions of or between other biomolecules known or thought to participate in or be affected by the cell signaling event or events.
- a cell signaling event or events e.g ., T cell signaling in response to antigen binding
- a polypeptide or encoded polypeptide of this disclosure may also be determined by using functional assays of host cell activity, including those described herein for measuring the ability of a host cell to release cytokines, proliferate, selectively kill target cells, or treat a subject having a disease or condition expressing or otherwise associated with an antigen bound by a fusion protein of this disclosure.
- a “functional portion” or “functional fragment” refers to a polypeptide or polynucleotide that comprises only a domain, motif, portion or fragment of a parent or reference compound, and the polypeptide or encoded polypeptide retains at least 50% activity associated with the domain, portion or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide, or provides a biological benefit (e.g, effector function).
- a biological benefit e.g, effector function
- a “functional portion” or “functional fragment” of a polypeptide or encoded polypeptide of this disclosure has “similar binding” or “similar activity” when the functional portion or fragment displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide (preferably no more than 20% or 10%, or no more than a log difference as compared to the parent or reference with regard to affinity), such as an assay for measuring binding affinity or measuring effector function (e.g, cytokine release).
- a functional portion refers to a "signaling portion" of an effector molecule, effector domain, costimulatory molecule, or costimulatory domain.
- heterologous or non-endogenous or exogenous refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a host cell or a subject, or any gene, protein, compound, nucleic acid molecule, or activity native to a host cell or a subject that has been altered.
- Heterologous, non-endogenous, or exogenous includes genes, proteins, compounds, or nucleic acid molecules that have been mutated or otherwise altered such that the structure, activity, or both is different as between the native and altered genes, proteins, compounds, or nucleic acid molecules.
- heterologous, non-endogenous, or exogenous genes, proteins, or nucleic acid molecules may not be endogenous to a host cell or a subject, but instead nucleic acids encoding such genes, proteins, or nucleic acid molecules may have been added to a host cell by conjugation, transformation, transfection, electroporation, or the like, wherein the added nucleic acid molecule may integrate into a host cell genome or can exist as extra-chromosomal genetic material (e.g., as a plasmid or other self-replicating vector).
- the polynucleotide is "heterologous" to progeny of the host cell, whether or not the progeny were themselves manipulated (e.g, transduced) to contain the polynucleotide.
- homologous or homolog refers to a gene, protein, compound, nucleic acid molecule, or activity found in or derived from a host cell, species, or strain.
- a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure, sequence, expression level, or any combination thereof.
- a non- endogenous polynucleotide or gene, as well as the encoded polypeptide or activity may be from the same species, a different species, or a combination thereof.
- endogenous or “native” refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or a subject.
- expression refers to the process by which a polypeptide is produced based on the encoding sequence of a nucleic acid molecule, such as a gene.
- the process may include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post- translational modification, or any combination thereof.
- An expressed nucleic acid molecule is typically operably linked to an expression control sequence (e.g ., a promoter).
- operably linked refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other.
- a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
- Unlinked means that the associated genetic elements are not closely associated with one another and the function of one does not affect the other.
- expression vector refers to a DNA construct containing a nucleic acid molecule that is operably linked to a suitable control sequence capable of effecting the expression of the nucleic acid molecule in a suitable host.
- control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation.
- the vector may be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself.
- "plasmid,” “expression plasmid,” “virus” and “vector” are often used interchangeably.
- the term "introduced” in the context of inserting a nucleic acid molecule into a cell means “transfection", or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell wherein the nucleic acid molecule may be incorporated into the genome of a cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).
- a cell e.g., chromosome, plasmid, plastid, or mitochondrial DNA
- transiently expressed e.g., transfected mRNA
- the term "engineered,” “recombinant” or “non-natural” refers to an organism, microorganism, cell, nucleic acid molecule, or vector that includes at least one genetic alteration or has been modified by introduction of an exogenous nucleic acid molecule, wherein such alterations or modifications are introduced by genetic engineering (i.e., human intervention).
- Genetic alterations include, for example, modifications introducing expressible nucleic acid molecules encoding proteins, fusion proteins or enzymes, or other nucleic acid molecule additions, deletions, substitutions or other functional disruption of a cell’s genetic material. Additional modifications include, for example, non-coding regulatory regions in which the modifications alter expression of a polynucleotide, gene or operon.
- more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof.
- the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule ( e.g ., on a single vector), on separate vectors, integrated into the host chromosome at a single site or multiple sites, or any combination thereof.
- the number of referenced heterologous nucleic acid molecules or protein activities refers to the number of encoding nucleic acid molecules or the number of protein activities, not the number of separate nucleic acid molecules introduced into a host cell.
- construct refers to any polynucleotide that contains a recombinant nucleic acid molecule.
- a construct may be present in a vector (e.g., a bacterial vector, a viral vector) or may be integrated into a genome.
- a "vector” is a nucleic acid molecule that is capable of transporting another nucleic acid molecule.
- Vectors may be, for example, plasmids, cosmids, viruses, a RNA vector or a linear or circular DNA or RNA molecule that may include chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acid molecules.
- Vectors of the present disclosure also include transposon systems (e.g, Sleeping Beauty, see, e.g, Geurts et al., Mol. Ther. 5: 108, 2003: Mates el al, Nat. Genet. 41:153, 2009).
- Exemplary vectors are those capable of autonomous replication (episomal vector), capable of delivering a polynucleotide to a cell genome (e.g, viral vector), or capable of expressing nucleic acid molecules to which they are linked (expression vectors).
- the term "host” refers to a cell (e.g., T cell) or microorganism targeted for genetic modification with a heterologous nucleic acid molecule to produce a polypeptide of interest (e.g ., a fusion protein of the present disclosure).
- a host cell may optionally already possess or be modified to include other genetic modifications that confer desired properties related or unrelated to, e.g., biosynthesis of the heterologous protein (e.g, inclusion of a detectable marker; deleted, altered or truncated endogenous TCR; or increased co-stimulatory factor expression).
- enriched or “depleted” with respect to amounts of cell types in a mixture refers to an increase in the number of the "enriched” type, a decrease in the number of the “depleted” cells, or both, in a mixture of cells resulting from one or more enriching or depleting processes or steps.
- a mixture or composition may contain 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more (in number or count) of the "enriched" cells.
- Cells subjected to a depleting process can result in a mixture or composition containing 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% percent or less (in number or count) of the "depleted" cells.
- amounts of a certain cell type in a mixture will be enriched and amounts of a different cell type will be depleted, such as enriching for CD4 + cells while depleting CD8 + cells, or enriching for CD62L + cells while depleting CD62L- cells, or combinations thereof.
- T cell receptor TCR
- TCR complex refers to a multi-protein complex known as an immunoglobulin superfamily member (having a variable binding domain, a constant domain, a transmembrane region, and a short cytoplasmic tail; see, e.g., Janeway el al., Immunobiology: The Immune System in Health and Disease, 3 rd Ed., Current Biology Publications, p. 4:33, 1997) capable of specifically binding to an antigen peptide bound to a MHC receptor.
- a TCR can be found on the surface of a cell or in soluble form and generally is comprised of a heterodimer having a and b chains (also known as TCRa and TOIb, respectively), or g and d chains (also known as TCRy and TCR6, respectively).
- TCR chains e.g, a-chain, b-chain
- the extracellular portion of TCR chains e.g, a-chain, b-chain
- a variable domain e.g, a-chain variable domain or Vo, b-chain variable domain or Vp; typically amino acids 1 to 116 based on Rabat numbering (Rabat et al., "Sequences of Proteins of Immunological Interest, US Dept.
- variable domains contain complementary determining regions (CDRs) separated by framework regions (FRs) (see, e.g., Jores et al., Proc. Nat’l Acad. Sci. U.S.A. 57:9138, 1990;
- the source of a TCR as used in the present disclosure may be from various animal species, such as a human, mouse, rat, rabbit or other mammal.
- a TCR is found on the surface of T cells (or T lymphocytes) and associates with the CD3 complex.
- a TCR complex comprises a TCR or a functional portion thereof; a dimer comprising two H03z chains, or functional portions or variants thereof; a dimer comprising a CD35 chain and a CDe chain, or functional portions or variants thereof; and a dimer comprising a CD3y chain and a CDe chain, or functional portions or variants thereof, any one or more of which may be endogenous or heterologous to the T cell.
- a "TCR extracellular domain” refers to a portion of a TCR that comprises a TCR ectodomain or a portion thereof, such as a constant domain from a TCRa chain or a TOIb chain, or an ectodomain from CD3e, CD35, or CD3y;
- a TCR extracellular domain comprises or consists of a TCR ectodomain, or a portion thereof; (ii) does not comprise a TCR variable domain (e.g, does not comprise a Va and/or a Vp), or (iii) comprises or consists of a TCR constant domain or ectodomain, or a portion thereof, and does not comprise a TCR variable domain.
- a fusion protein of the instant disclosure does not comprise a TCR ectodomain.
- CD3 is a multi-protein complex of six chains (see, Abbas and Lichtman, 2003; Janeway et al, p. 172 and 178, 1999).
- the complex In mammals, the complex generally comprises a CD3y chain, a CD35 chain, two CD3e chains, and a homodimer of CD3z chains.
- the CD3y, CD35, and CD3e chains are related cell surface proteins of the immunoglobulin superfamily containing a single immunoglobulin domain.
- the transmembrane regions of the CD3y, CD35, and CD3e chains are negatively charged, which is thought to allow these chains to associate with positively charged regions of T cell receptor chains.
- ITAM immunoreceptor tyrosine-based activation motif
- an ITAM comprises a motif YxxL/Ix (6 -8 ) YxxL/I (SEQ ID NO:2), wherein x may be any amino acid (i.e., a same or different amino acids over the length of the ITAM).
- an ITAM motif can comprise an amino acid sequence motif according to SEQ ID NO:3, SEQ ID NO:4, or both.
- Exemplary ITAMs of the present disclosure include those that comprise an amino acid sequence as shown in any one of SEQ ID NOs:6, 12, 15, and 18-20.
- ITAMs from human proteins include those found in B cell receptor-associated proteins (e.g ., Iga, Igp), Fc receptor proteins (e.g., FcRyl, FcRy2a, FcRy2bl, FcRy2al, FcRy2b2, FcRy3a, FcRy3b, FcRpl, FceR), Natural Killer cell receptor proteins (e.g, DAP12), CD5, CDl6a,
- CDl6b CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, and CD66d.
- Exemplary amino acid sequences of these ITAM sequences and those from viruses are described in Paul, Fundamental Immunology 307 (Wolters Kluwer; Lippincott; Wilkins & Wilkins; Seventh Ed., 2008).
- These ITAMs and functional fragments and variants thereof are also contemplated for use in the presently disclosed fusion proteins and host cells, and are hereby incorporated by reference.
- CD3 as well as the protein subunits, domains, and sequences therefrom, may be from various animal species, including human, mouse, rat, or other mammals.
- CD3e and O ⁇ 3z possess additional sequence features that may be involved in or required for T cell signaling; e.g, following recognition of antigenMHC by a TCR.
- Human CD3e includes a proline-rich sequence (PRS) that is N-terminal to the ITAM in the CD3e cytoplasmic domain.
- PRS proline-rich sequence
- An exemplary PRS amino acid sequence is provided in SEQ ID NO:7.
- An exemplary fragment of a CD3e cytoplasmic domain (also referred to as an endodomain) comprising a PRS and an ITAM is provided in SEQ ID NO:8.
- CD3e and O ⁇ z both contain at least one Basic Residue Sequence (BRS).
- BRS Basic Residue Sequence
- a BRS is generally located near the junction of the transmembrane and cytoplasmic domains.
- An exemplary BRS from CD3e is provided in SEQ ID NO:9.
- An exemplary sequence of a human CD3e cytoplasmic domain containing a BRS, a PRS, and an ITAM is provided in SEQ ID SEQ ID NO: 111.
- an effector domain or a functional portion or variant thereof from a CD3e does not comprise a full-length CD3e and does not comprise an endodomain from CD3e.
- two BRS are generally located between ITAMs (a) and (b), and a third BRS is located between IT AMs (b) and (c).
- Exemplary BRS from O ⁇ 3z are provided in SEQ ID NOs:2l-23.
- An exemplary sequence of a human O ⁇ 3z cytoplasmic domain containing ITAMS and BRS is provided in SEQ ID NO: 17.
- a fusion protein of the instant disclosure can comprise an amino acid sequence having least 75% (e.g., at least 75% shampoo 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
- a fusion protein of the present disclosure when expressed by a T cell, does not associate with or form a TCR complex (i.e., does not form or associate with a TCR complex comprising a TCR, a dimer comprising two O ⁇ 3z chains, a dimer comprising a CD35 chain and a CDe chain, and a dimer comprising a CD3y chain and a CDe chain, any one or more of which components may be endogenous or heterologous to the T cell).
- Whether two or more proteins form a complex can be determined by any suitable technique, such as, for example, imaging a T cell that expresses a detectably labeled (e.g, fluorescently labeled or bound by a labeled antibody) fusion protein of this disclosure and a fluorescently labeled TCR, co- precipitating a fusion protein and a TCR, or the like.
- a detectably labeled e.g, fluorescently labeled or bound by a labeled antibody
- a fusion protein does not comprise an ectodomain and/or a transmembrane domain from CD35, CDe, or CD3y, or any combination thereof.
- a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD35.
- a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e.
- a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3y.
- MHC molecules refer to glycoproteins that deliver peptide antigens to a cell surface.
- MHC class I molecules are heterodimers consisting of a membrane spanning a chain (with three a domains) and a non-covalently associated b2 microglobulin.
- MHC class II molecules are composed of two transmembrane glycoproteins, a and b, both of which span the membrane. Each chain has two domains.
- MHC class I molecules deliver peptides originating in the cytosol to the cell surface, where a peptide:MHC complex is recognized by CD8 + T cells.
- MHC class II molecules deliver peptides originating in the vesicular system to the cell surface, where they are recognized by CD4 + T cells.
- An MHC molecule may be from various animal species, including human, mouse, rat, cat, dog, goat, horse, or other mammals.
- CD4 refers to an immunoglobulin co-receptor glycoprotein that assists the TCR in communicating with antigen-presenting cells (see, Campbell & Reece, Biology 909 (Benjamin Cummings, Sixth Ed., 2002); ETniProtKB P01730).
- CD4 is found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells, and includes four immunoglobulin domains (Dl to D4) that are expressed at the cell surface.
- CD4 is recruited, along with the TCR complex, to bind to different regions of the MHCII molecule (CD4 binds MHCII b2, while the TCR complex binds MHCII a ⁇ /b ⁇ ).
- CD8 co-receptor means the cell surface glycoprotein CD8, either as an alpha-alpha homodimer or an alpha-beta heterodimer.
- the CD8 co-receptor assists in the function of cytotoxic T cells (CD8 + ) and functions through signaling via its cytoplasmic tyrosine phosphorylation pathway (Gao and Jakobsen, Immunol. Today 27:630-636, 2000; Cole and Gao, Cell. Mol. Immunol. 7:81- 88, 2004).
- cytotoxic T cells CD8 +
- cytoplasmic tyrosine phosphorylation pathway Gao and Jakobsen, Immunol. Today 27:630-636, 2000; Cole and Gao, Cell. Mol. Immunol. 7:81- 88, 2004.
- ETniProtKB identifier P 10966 see ETniProtKB identifier P 10966
- ETniProtKB identifier P01732 see ETni
- CAR Chimeric antigen receptor
- fusion protein of the present disclosure engineered to contain two or more naturally occurring (or engineered) amino acid sequences linked together in a way that does not occur naturally or does not occur naturally in a host cell, which fusion protein can function as a receptor when present on a surface of a cell.
- CARs of the present disclosure include an extracellular portion comprising an antigen-binding domain (e.g ., obtained or derived from an antigen-binding domain (e.g ., obtained or derived from an antigen-binding domain).
- immunoglobulin or immunoglobulin-like molecule such as a scFv or scTCR derived from an antibody or TCR specific for a cancer antigen, or an antigen-binding domain derived or obtained from a killer immunoreceptor from an NK cell, or from another protein (natural, recombinant, or synthetic) that has, or is engineered to possess, the ability to specifically bind to an antigen) linked to a transmembrane domain and one or more intracellular signaling domains (optionally containing co-stimulatory domain(s)) (see, e.g., Sadelain et al, Cancer Discov., 3(4):388 (2013); see also Harris and Kranz, Trends Pharmacol.
- a binding protein comprises a CAR comprising an antigen-specific TCR binding domain (see, e.g., Walseng et al.,
- variable region refers to the domain of a TCR a-chain or b-chain (or g-chain and d-chain for gd TCRs), or of an antibody heavy or light chain, that is involved in binding to antigen (i.e., contains amino acids and/or other structures that contact antigen and result in binding).
- the variable domains of the a- chain and b-chain (Va and nb, respectively) of a native TCR generally have similar structures, with each domain comprising four generally conserved framework regions (FRs) and three CDRs.
- Variable domains of antibody heavy (VH) and light (VL) chains each also generally comprise four generally conserved framework regions (FRs) and three CDRs.
- framework regions separate CDRs and CDRs are situated between framework regions (i.e., in primary structure).
- CDR complementarity determining region
- HVR hypervariable region
- framework amino acids can also contribute to binding, e.g, may also contact the antigen or antigen-containing molecule.
- there are three CDRs in each variable region i.e., three CDRs in each of the TCRa-chain and b-chain variable regions; 3 CDRs in each of the antibody heavy chain and light chain variable regions).
- CDR3 is thought to be the main CDR responsible for recognizing processed antigen.
- CDR1 and CDR2 mainly interact with the MHC.
- Variable domain sequences can be aligned to a numbering scheme (e.g ., Rabat, EU, International Immunogenetics Information System (IMGT) and Aho), which can allow equivalent residue positions to be annotated and for different molecules to be compared using Antigen receptor Numbering And Receptor
- IMGT International Immunogenetics Information System
- Aho Antigen receptor Numbering And Receptor
- Antigen refers to an immunogenic molecule that provokes an immune response. This immune response may involve antibody production, activation of specific immunologically-competent cells (e.g., T cells), or both.
- An antigen immunologically-competent cell
- An antigen immunologically-competent molecule
- An antigen immunologically-competent molecule
- An antigen immunologically-competent molecule
- An antigen immunologically-competent cells
- glycopeptide polypeptide, glycopolypeptide, polynucleotide, polysaccharide, lipid or the like. It is readily apparent that an antigen can be synthesized, produced
- exemplary biological samples that can contain one or more antigens include tissue samples, tumor samples, cells, biological fluids, or combinations thereof.
- Antigens can be produced by cells that have been modified or genetically engineered to express an antigen.
- epitope includes any molecule, structure, amino acid sequence or protein determinant that is recognized and specifically bound by a cognate binding molecule, such as an immunoglobulin, T cell receptor (TCR), chimeric antigen receptor, or other binding molecule, domain or protein.
- a cognate binding molecule such as an immunoglobulin, T cell receptor (TCR), chimeric antigen receptor, or other binding molecule, domain or protein.
- Epitopic determinants generally contain chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three dimensional structural characteristics, as well as specific charge characteristics.
- Treatment refers to medical management of a disease, disorder, or condition of a subject (e.g, a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat).
- a subject e.g, a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat.
- an appropriate dose or treatment regimen comprising a host cell expressing a fusion protein of the present disclosure, and optionally an adjuvant, is administered in an amount sufficient to elicit a therapeutic or prophylactic benefit.
- Therapeutic or prophylactic/preventive benefit includes improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease; stabilization of disease state; delay of disease progression; remission; survival; prolonged survival; or any
- a “therapeutically effective amount” or “effective amount” of a fusion protein or host cell expressing a fusion protein of this disclosure refers to an amount of fusion proteins or host cells sufficient to result in a therapeutic effect, including improved clinical outcome; lessening or alleviation of symptoms associated with a disease;
- a therapeutically effective amount refers to the effects of that ingredient or cell expressing that ingredient alone.
- a therapeutically effective amount refers to the combined amounts of active ingredients or combined adjunctive active ingredient with a cell expressing an active ingredient that results in a therapeutic effect, whether administered serially or simultaneously.
- a combination may also be a cell expressing more than one active ingredient, such as two different fusion proteins (e.g ., CARs) that specifically bind a an antigen, or a fusion protein of the present disclosure.
- pharmaceutically acceptable excipient or carrier or “physiologically acceptable excipient or carrier” refer to biologically compatible vehicles, e.g., physiological saline, which are described in greater detail herein, that are suitable for administration to a human or other non-human mammalian subject and generally recognized as safe or not causing a serious adverse event.
- statically significant refers to a p-value of 0.050 or less when calculated using the Student’s t-test and indicates that it is unlikely that a particular event or result being measured has arisen by chance.
- adjuvant immune therapy or "adoptive immune therapy
- immunotherapy refers to administration of naturally occurring or genetically engineered, disease-antigen-specific immune cells (e.g ., T cells).
- Adoptive cellular immunotherapy may be autologous (immune cells are from the recipient), allogeneic (immune cells are from a donor of the same species) or syngeneic (immune cells are from a donor genetically identical to the recipient).
- the present disclosure provides fusion proteins, comprising: (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain; and (c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof; (ii) an ITAM from CD3y, or a functional variant thereof;(iii) an ITAM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or OI)3z, or a functional variant thereof; or (vi) any combination of (i)-(v), wherein: (1) the extracellular domain does not comprise a TCR extracellular domain, preferably does not
- a fusion protein of the present disclosure when expressed by a T cell or a cell that otherwise expresses TCR complex proteins, does not associate with or form a TCR complex (i.e., does not form or associate with a TCR complex comprising a TCR, a dimer comprising two OI)3z chains, a dimer comprising a CD35 chain and a CDe chain, and a dimer comprising a CD3y chain and a CDe chain, any one or more of which components may be endogenous or heterologous to the T cell).
- Whether two or more proteins form a complex can be determined by any suitable technique, such as, for example, imaging a T cell that expresses a detectably labeled (e.g., fluorescently labeled or bound by a labeled antibody) fusion protein of this disclosure and a fluorescently labeled TCR, co-precipitating a fusion protein and a TCR, or the like.
- a fusion protein of the present disclosure does not comprise an ectodomain and/or a transmembrane domain from CDe, from CD3y, from CD35, or any combination thereof.
- a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e.
- a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD35. In certain embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3y.
- a fusion protein of the present disclosure comprises:
- an extracellular component comprising a binding domain that specifically binds to an antigen
- a transmembrane domain comprising an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof; (ii) an ITAM from CD3y, or a functional variant thereof; (iii) an ITAM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or O ⁇ 3z, or a functional variant thereof; or (vi) any combination of (i)-(v), and does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD35, and/or CD3
- ITAM Intracellular
- the effector domain or functional portion thereof comprises an ITAM from CD3e, or a functional variant thereof, and a PRS from CD3e, or a functional variant thereof.
- the fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
- the effector domain or functional fragment thereof comprises an amino acid sequence having at least 75% (z.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 8.
- the effector domain or functional fragment thereof comprises one, two, or three, four, or more of the amino acids of SEQ ID NO: 5 or SEQ ID NO: 111 that are immediately amino-terminal to and/or comprises one, two, or three, four, or more of the amino acids of SEQ ID NO: 5 or SEQ ID NO: 111 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 8.
- the effector domain comprises a BRS from CD3e, or a functional variant thereof.
- the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:5 or 111.
- the effector domain comprises: an IT AM from CD3y, or a functional variant thereof; and/or comprises an ITAM from CD35, or a functional variant thereof.
- the effector domain comprises: (i) an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 11, optionally wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO:l 1 is not a leucine, and is preferably an alanine or a glycine; and/or (ii) an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 11, optionally
- the effector domain or functional fragment thereof comprises the amino acid sequence set forth in SEQ ID NO: 12 and further comprises one, two, or three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 10 or 11 that are immediately amino-terminal to and/or comprises one, two, or three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 10 or 11 that are immediately carboxy-terminal to the amino acid sequence of SEQ ID NO: 12.
- the effector domain or functional fragment thereof comprises the amino acid sequence set forth in SEQ ID NO: 15 and further comprises one, two, three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 14 that are immediately amino-terminal to and/or comprises one, two, or three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 14 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 15.
- the effector domain further comprises an IT AM from O ⁇ 3z, or a functional portion or variant thereof. In further embodiments, the effector domain further comprises two or three of IT AMs (a), (b), and (c) from O ⁇ 3z, or functional portions or variants thereof.
- the effector domain comprises SEQ ID NO: 18, SEQ ID NO: 19, and/or SEQ ID NO:20, and further comprises one, two, three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 17 that are immediately amino-terminal to the amino acid sequence of SEQ ID NO: 18, 19, or 20, respectively, and/or comprises one, two, or three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 17 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 18, 19, or 20, respectively.
- the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: l7.
- a fusion protein can comprise an ITAM motif, a Lck-binding motif, a PRS, a BRS, or sequence comprising the same, having or comprising the amino acid sequence as set forth in any one of SEQ ID NOS: 1-9, 11, 12, 14, 15, 18-24, 27-32, or 111, or a functional variant or fragment thereof, or any combination thereof.
- binding domain refers to a molecule or portion thereof (e.g ., peptide, oligopeptide, polypeptide, protein (e.g., a fusion protein)) that possesses the ability to specifically and non-covalently associate, unite, or combine with a target.
- a binding domain includes any naturally occurring, synthetic, semi -synthetic, or recombinantly produced binding partner for a biological molecule, a molecular complex (i.e., complex comprising two or more biological molecules), or other target of interest.
- binding domains include single chain immunoglobulin variable regions (e.g, scTCR, scFv, Fab, TCR variable regions), receptor ectodomains, ligands (e.g, cytokines, chemokines), or synthetic polypeptides selected for their specific ability to bind to a biological molecule, a molecular complex or other target of interest.
- the binding domain is a scFv, scTCR, or ligand.
- the binding domain is chimeric, human, or humanized.
- the binding domain is a scFv comprising a VH domain, a VL domain, and a peptide linker.
- a scFv comprises a VH domain joined to a VL domain by a peptide linker, which can be in a VH-linker-VL orientation or in a VL-linker-VH orientation.
- Any scFv of the present disclosure may be engineered so that the C-terminal end of the VL domain is linked by a short peptide sequence to the N-terminal end of the VH domain, or vice versa (i.e., (N)VL(C)-linker-(N)VH(C) or (N)VH(C)-linker-(N)VL(C).
- any scTCR of the present disclosure may be engineered so that the C-terminal end of the Va domain is linked by a short peptide sequence to the N- terminal end of the nb domain, or vice versa (i.e., (N)Va(C)-linker-(N)Vb(C) or (N)nb (C)-linker-(N) V a(C)) .
- binding protein e.g a T cell receptor or a chimeric antigen receptor
- binding domain or fusion protein comprising a binding domain
- K a i.e., an equilibrium association constant of a particular binding interaction with units of l/M
- 10 5 M 1 which equals the ratio of the on-rate [K 0n ] to the off rate [K 0ff ] for this association reaction
- Binding proteins or binding domains may be classified as “high-affinity” binding proteins or binding domains (or fusion proteins thereof) or as “low-affinity” binding proteins or binding domains (or fusion proteins thereof).
- "High-affinity" binding proteins or binding domains refer to those binding proteins or binding domains having a K a of at least l0 7 M _1 , at least 10 8 M 1 , at least 10 9 M l , at least 10 10 M 1 , at least 10 11 M 1 , at least l0 12 M _1 , or at least 10 13 M 1 .
- Bind- affinity binding proteins or binding domains refer to those binding proteins or binding domains having a K a of up to 10 7 M 1 , up to 10 6 M 1 , or up to 10 5 M 1 .
- affinity may be defined as an equilibrium dissociation constant (KD) of a particular binding interaction with units of M ( e.g ., 10 5 M to 10 13 M).
- a fusion protein of the instant disclosure specifically binds to a target antigen (e.g., a cancer antigen such as, for example, a CD 19, CD20, CD22, ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7,
- a target antigen e.g., a cancer antigen such as, for example, a CD 19, CD20, CD22, ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7,
- binding domains specific for these antigens are known in the art.
- Exemplary binding domains specific for ROR1 and CD 19 antigens, including CDRs thereof, are disclosed SEQ ID NOs:55-l02.
- a fusion protein of the present disclosure can, in certain embodiments, comprise a variable domain and/or one or more CDRs (e.g. , three heavy chain CDRs and three light chain CDRs) according to any one of these exemplary binding domain sequences (e.g, from an anti-RORl or anti-CD 19 scFv, or Rl l antibody, R12 antibody, Y31 antibody, 2A2 antibody, or FMC63 antibody), or can comprise a functional variant sequence thereof.
- a fusion protein of the instant disclosure is expressed by a host cell (e.g, an immune system cell such as, for example, a T cell) and the host cell specifically recognizes (i.e., comprising specific binding) and initiates an immune response to a target cell expressing a reduced (e.g., as compared to a reference baseline level of expression of the same or a different antigen (e.g, as compared to an average level among subjects or tumors having a same disease or disease state), or to a prior level of expression by a disease site, such as a tumor, in the subject) or low or intermediate level of the antigen).
- a host cell e.g, an immune system cell such as, for example, a T cell
- the host cell specifically recognizes (i.e., comprising specific binding) and initiates an immune response to a target cell expressing a reduced (e.g., as compared to a reference baseline level of expression of the same or a different antigen (e.g, as compared to an average level
- a reduced level of expression comprises at a reduction of at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, as compared to a reference baseline or previous subject level.
- a reduced level of expression is a reduction of 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or lOO-fold, or more, as compared to a prior or reference level of expression.
- An expression level of an antigen can be determined using any art-accepted methodology, including, for example, use of labeled antibodies, Western Blot, RNA-Seq, or the like.
- a low antigen density comprises less than about 10,000, less than about 9,000, less than about 8,000, less than about 7,000, less than about 6,000, less than about 5,000, less than about 4,000, less than about 3,000, less than about 2,000, less than about 1,000, less than about 500, less than about 200, less than about 190, less than about 180, less than about 170, less than about 160, less than about 150, less than about 140, less than about 130, less than about 120, less than about 110, about 100, less than about 90, less than about 80, less than about 70, less than about 60, less than about 50, less than about 40, less than about 30, less than about 20, or less than about 10 molecules of the antigen expressed on the surface of a target cell.
- an intermediate antigen density comprises about 10,000 to about 20,000 molecules of antigen expressed on the surface of a target cell.
- a high antigen density comprises about 20,000 molecules or more of antigen expressed on the surface of a target cell.
- a receptor or binding domain may have "enhanced affinity," which refers to selected or engineered receptors or binding domains with stronger binding to a target antigen than a wild type (or parent) binding domain.
- enhanced affinity may be due to a K a (equilibrium association constant) for the target antigen that is higher than the wild type binding domain, due to a Kd
- binding domains of the present disclosure that specifically bind a particular target, as well as determining binding domain or fusion protein affinities, such as Western blot, ELISA, analytical
- apparent KD of a fusion protein is measured using 2-fold dilutions of labeled tetramers at a range of concentrations, followed by determination of binding curves by non-linear regression, apparent KD being determined as the concentration of ligand that yielded half-maximal binding.
- an effector domain is an intracellular portion or domain of a fusion protein or receptor that can directly or indirectly promote a biological or physiological response (e.g ., an immune response) in a cell when receiving an appropriate signal.
- an effector domain is from a protein or portion thereof or protein complex that receives a signal when bound to a target or cognate molecule, or when the protein or portion thereof or protein complex binds directly to a target or cognate molecule and triggers a signal from the effector domain.
- An effector domain may directly promote a cellular response (e.g., immune response) when it contains one or more signaling domains or motifs, such as an
- ITAM Intracellular Tyrosine-based Activation Motif
- ITAMs are important for T cell activation following ligand (e.g, antigen) engagement by a T cell receptor or by a fusion protein comprising a T cell effector domain.
- the intracellular component or functional portion thereof comprises an ITAM.
- effector domains include those from CD3e, CD35, OI)3z, CD25, CD79A, CD79B, CARD11, DAP 10, FcRa, FcRp, FcRy, Fyn, HVEM, ICOS, Lck, LAG3, LAT, LRP, NKG2D, NOTCH1, NOTCH2, NOTCH3, NOTCH4, Wnt, ROR2, Ryk, SLAMF1, Slp76, pTa, TCRa, TCRp, TRIM, Zap70, PTCH2, or any combination thereof.
- an effector domain comprises a lymphocyte receptor signaling domain (e.g, E ⁇ 3z or a functional portion or variant thereof).
- the intracellular component of the fusion protein further comprises a costimulatory domain or a functional portion thereof selected from CD27, CD28, 4-1BB (CD137), 0X40 (CD134), CD2, CD5, ICAM-l (CD54), LFA-l
- the intracellular component comprises a CD28 costimulatory domain or a functional portion or variant thereof (which may optionally include a LL- GG mutation at positions 186-187 of the native CD28 protein (see Nguyen el al, Blood 702:4320, 2003)), a 4-1BB costimulatory domain or a functional portion or variant thereof, or both.
- a costimulatory domain or functional portion or variant thereof comprises or consists of an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to any one of SEQ ID NOs:25 and 47-49.
- an effector domain comprises a O ⁇ 3z endodomain or a functional ( e.g ., signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a CD27 endodomain or a functional (e.g., signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a CD28 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a 4-1BB endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises an 0X40 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a CD2 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a CD5 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises an ICAM-l endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises a LFA-l endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof.
- an effector domain comprises an ICOS endodomain or a functional (e.g ., signaling) portion thereof, or a functional variant thereof.
- the intracellular domain of a fusion protein according to the present disclosure comprises a costimulatory domain, an endodomain or effector domain from CD3z or a functional portion or variant thereof, and an effector domain from CD3e or a functional portion or variant thereof, wherein the effector domain from CD3e or functional portion or variant thereof optionally comprises or consists essentially of a PRS and an IT AM from CD3e.
- the effector domain from CD3e or functional portion or variant thereof is disposed between the costimulatory domain or functional portion or variant thereof and the endodomain or effector domain from CD3z or functional portion or variant thereof.
- the costimulatory domain or functional portion or variant thereof is from 4-1BB.
- the intracellular component of the fusion protein comprises, in amino-terminal to carboxy-terminal direction: (i) the costimulatory domain or functional portion or variant thereof; (ii) the effector domain from CD3e or functional portion or variant thereof; and (iii) the endodomain or effector domain from CD3z or functional portion or variant thereof.
- the endodomain or effector domain from CD3z or functional portion or variant thereof is disposed between the costimulatory domain and the effector domain from CD3e or functional portion or variant thereof.
- the costimulatory domain is from 4-1BB.
- the intracellular component of the fusion protein comprises, in amino-terminal to carboxy- terminal direction: (i) the costimulatory domain or functional portion or variant thereof; (ii) the endodomain or effector domain from O ⁇ 3z or functional portion or variant thereof; and (iii) the effector domain from CD3e or functional portion or variant thereof.
- transmembrane domain is a portion of a transmembrane protein that can insert into or span a cell membrane.
- Transmembrane domains have a three-dimensional structure that is thermodynamically stable in a cell membrane and generally range in length from about 15 amino acids to about 30 amino acids.
- the structure of a transmembrane domain may comprise an alpha helix, a beta barrel, a beta sheet, a beta helix, or any combination thereof.
- the transmembrane domain comprises or is derived from a known transmembrane protein (e.g ., a CD4 transmembrane domain, a CD8 transmembrane domain, a CD27 transmembrane domain, a CD28 transmembrane domain, or any combination thereof).
- a known transmembrane protein e.g ., a CD4 transmembrane domain, a CD8 transmembrane domain, a CD27 transmembrane domain, a CD28 transmembrane domain, or any combination thereof.
- An exemplary CD28 transmembrane domain amino acid sequence is provided in SEQ ID NO:26.
- a transmembrane domain comprises or consists of an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity to SEQ ID NO:26.
- the extracellular component of the fusion protein further comprises a linker disposed between the binding domain and the transmembrane domain.
- a linker may be an amino acid sequence having from about two amino acids to about 500 amino acids, which can provide flexibility and room for conformational movement between two regions, domains, motifs, fragments, or modules connected by the linker.
- a linker of the present disclosure can position the binding domain away from the surface of a host cell expressing the fusion protein to enable proper contact between the host cell and a target cell, antigen binding, and activation (Patel et al, Gene Therapy 6: 412-419, 1999).
- Linker length may be varied to maximize antigen recognition based on the selected target molecule, selected binding epitope, or antigen binding domain size and affinity (see, e.g., Guest et al., J. Immunother. 28: 203-11, 2005; PCT Publication No. WO 2014/031687).
- Exemplary linkers include those having a glycine-serine amino acid chain having from one to about ten repeats of Gly x Ser y , wherein x and y are each independently an integer from 0 to 10, provided that x and y are not both 0 (e.g, (Gly 4 Ser)2; (Gly3Ser) 2 ; GlyiSer; or a combination thereof, such as (Gly3Ser)2Gly2Ser).
- the extracellular domain comprises a glycine-serine linker that is not comprised in the binding domain; e.g., is disposed between the transmembrane domain and the binding domain.
- a fusion protein comprises an extracellular domain comprising a first glycine-serine linker disposed between the transmembrane domain and the binding domain, and the binding domain may comprise a scFv or an scTCR that comprises a second glycine-serine linker, wherein the first and second glycine-serine linkers may be a same or a different glycine- serine linker and may be of a same or a different length.
- linker amino acid sequences of the present disclosure are provided in SEQ ID NOs: 103-110.
- Linkers of the present disclosure also include immunoglobulin constant regions (i.e., CH1, CH2, CH3, or CL, of any isotype) and portions and variants thereof.
- the linker comprises a CH3 domain, a CH2 domain, or both.
- the linker comprises a CH2 domain and a CH3 domain.
- the CH2 domain and the CH3 domain are each a same isotype.
- the CH2 domain and the CH3 domain are an IgG4 or IgGl isotype.
- the CH2 domain and the CH3 domain are each a different isotype.
- the CH2 comprises a N297Q mutation.
- the linker comprises a human immunoglobulin constant region or a portion thereof.
- the linker comprises an extracellular domain from CD4, or a portion thereof.
- the linker comprises an extracellular domain from CD8, or a portion thereof.
- a linker may comprise a hinge region or a portion thereof.
- An exemplary hinge sequence of the present disclosure is provided in SEQ ID NO:33.
- Hinge regions are flexible amino acid polymers of variable length and sequence (typically rich in proline and cysteine amino acids) and connect typically larger and less-flexible regions of immunoglobulin proteins.
- hinge regions connect the Fc and Fab regions of antibodies and connect the constant and transmembrane regions of TCRs.
- the linker comprises an immunoglobulin constant region or a portion thereof and a hinge region or a portion thereof.
- the linker comprises a glycine-serine linker as described herein.
- one or more of the extracellular component, the binding domain, the linker, the transmembrane domain, the intracellular component, the effector domain, or the costimulatory domain further comprise one or more junction amino acids.
- junction amino acids or “junction amino acid residues” refer to one or more ( e.g ., about 2-20) amino acid residues between two adjacent domains, motifs, regions, modules, or fragments of a protein, such as between a binding domain and an adjacent linker, between a transmembrane domain and an adjacent extracellular or intracellular domain, or on one or both ends of a linker that links two domains, motifs, regions, modules, or fragments (e.g., between a linker and an adjacent binding domain or between a linker and an adjacent hinge).
- Junction amino acids may result from the construct design of a fusion protein (e.g, amino acid residues resulting from the use of a restriction enzyme site or self-cleaving peptide sequences during the construction of a polynucleotide encoding a fusion protein).
- a transmembrane domain of a fusion protein may have one or more junction amino acids at the amino-terminal end, carboxy -terminal end, or both.
- Protein tags are unique peptide sequences that are affixed or genetically fused to, or are a part of, a protein of interest and can be recognized or bound by, for example, a heterologous or non-endogenous cognate binding molecule or a substrate (e.g, receptor, ligand, antibody, carbohydrate, or metal matrix) or a fusion protein of this disclosure. Protein tags can be useful for detecting, identifying, isolating, tracking, purifying, enriching for, targeting, or biologically or chemically modifying tagged proteins of interest, particularly when a tagged protein is part of a heterogeneous population of cell proteins or cells (e.g, a biological sample like peripheral blood).
- a heterologous or non-endogenous cognate binding molecule or a substrate e.g, receptor, ligand, antibody, carbohydrate, or metal matrix
- Protein tags can be useful for detecting, identifying, isolating, tracking, purifying, enriching for, targeting, or biologically or chemically modifying
- a protein tag of a fusion protein of this disclosure comprises a Myc tag, His tag, Flag tag, Xpress tag, Avi tag, Calmodulin tag, Polyglutamate tag, HA tag, Nus tag, S tag, X tag, SBP tag, Softag, V5 tag, CBP, GST, MBP, GFP, Thioredoxin tag, Strep tags (e.g, Strep-Tag; Strep-Tag II; and variants thereof, including those disclosed in, for example, Schmidt and Skerra, Nature Protocols, 2: 1528-1535 (2007), U.S. Patent No. 7,981,632; and PCT Publication No.
- a fusion protein can be or can comprise a CAR or a TCR.
- Methods for making fusion proteins, including CARs are described, for example, in U.S. Patent No. 6,410,319; U.S. Patent No. 7,446,191; U.S. Patent Publication No. 2010/065818; U.S. Patent No. 8,822,647; PCT Publication No. WO 2014/031687; U.S. Patent No. 7,514,537; Brentjens et al., 2007, Clin. Cancer Res. 13:5426, and Walseng et al., Scientific Reports 7:10713, 2017, the techniques of which are herein incorporated by reference.
- the antigen-binding fragment of the TCR comprises a single chain TCR (scTCR), which comprises both the TCR Va and nb domains TCR, but only a single TCR constant domain (Ca or Ob).
- scTCR single chain TCR
- the antigen-binding fragment of the TCR, or chimeric antigen receptor is chimeric ( e.g ., comprises amino acid residues or motifs from more than one donor or species), humanized (e.g., comprises residues from a non-human organism that are altered or substituted so as to reduce the risk of immunogenicity in a human), or human.
- Methods useful for isolating and purifying recombinantly produced soluble fusion proteins may include obtaining supernatants from suitable host cell/vector systems that secrete the recombinant soluble fusion protein into culture media and then concentrating the media using a commercially available filter.
- the concentrate may be applied to a single suitable solvent
- purification matrix or to a series of suitable matrices, such as an affinity matrix or an ion exchange resin.
- One or more reverse phase HPLC steps may be employed to further purify a recombinant polypeptide.
- These purification methods may also be employed when isolating an immunogen from its natural environment.
- Methods for large scale production of one or more of the isolated/recombinant soluble fusion protein described herein include batch cell culture, which is monitored and controlled to maintain appropriate culture conditions. Purification of the soluble fusion protein may be performed according to methods described herein and known in the art and that comport with laws and guidelines of domestic and foreign regulatory agencies. Fusion proteins as described herein may be functionally characterized according to any of a large number of art-accepted methodologies for assaying host cell (e.g .,
- T cell activity including determination of T cell binding, activation or induction and also including determination of T cell responses that are antigen-specific. Examples include determination of intracellular calcium, T cell proliferation, T cell cytokine release, antigen-specific T cell stimulation, MHC-restricted T cell stimulation, CTL activity (e.g., by detecting 51 Cr or Europium release from pre-loaded target cells), changes in T cell phenotypic marker expression, phosphorylation of certain T cell proteins, and other measures of T-cell functions. Procedures for performing these and similar assays are described herein and/or may be found, for example, in Lefkovits (Immunology Methods Manual: The Comprehensive Sourcebook of Techniques, 1998). See, also, Current Protocols in Immunology, Weir, Handbook of Experimental
- cytokines may be determined according to methods described herein and practiced in the art, including for example, ELISA, ELISPOT, intracellular cytokine staining, and flow cytometry and combinations thereof (e.g, intracellular cytokine staining and flow cytometry).
- Assays for determining intracellular calcium are known and include, for example, fluorescence microscopy using the Ca 2+ -sensitive dye Fluo-4 AM (BD PharmingenTM).
- Immune cell proliferation and clonal expansion resulting from an antigen-specific elicitation or stimulation of an immune response may be determined by isolating lymphocytes, such as circulating lymphocytes in samples of peripheral blood cells or cells from lymph nodes, stimulating the cells with antigen, and measuring cytokine production, cell proliferation and/or cell viability, such as by incorporation of tritiated thymidine or non-radioactive assays, such as MTT assays and the like.
- lymphocytes such as circulating lymphocytes in samples of peripheral blood cells or cells from lymph nodes
- stimulating the cells with antigen and measuring cytokine production, cell proliferation and/or cell viability, such as by incorporation of tritiated thymidine or non-radioactive assays, such as MTT assays and the like.
- Thl cytokines such as IFN-g, IL-12, IL-2, and TNF-b
- Type 2 cytokines such as IL-4, IL-5, IL-9, IL-10, and IL-13.
- a fusion protein when expressed by a host cell, which optionally is an immune system cell such as a T cell, provides for or promotes: (i) improved cell signaling, and/or activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased and/or sustained cytokine production and/or release, and/or phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as LAT, PLC-g I , SLP-76, or any combination thereof; (ii) improved cell activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased mobilization of intracellular calcium , killing activity, proliferation, earlier activation in response to antigen, or any combination thereof; (iii) improved cell signaling and/or activity, relative to a host cell expressing a reference fusion protein, upon binding to a target antigen that is
- the intracellular component of the fusion protein comprises a costimulatory domain, or a functional portion or variant thereof, from 4- 1BB.
- the reference protein comprises an intracellular domain comprising a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
- the fusion protein and the reference protein each comprise an endodomain or effector domain from CD3z or a functional portion or variant thereof.
- the host cell expressing the fusion protein and the host cell expressing the reference fusion protein are each an immune system cell, optionally a T cell, optionally a CD8 T cell, a CD4 T cell, or both.
- nucleic acid molecules are provided that encode any one or more of the fusion proteins as described herein. In certain embodiments, a
- polynucleotide encoding a fusion protein comprises, or consists of, a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence set forth in any one of SEQ ID NOs.:34-46.
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD3e intracellular sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:34.
- 70% i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD3e_PRS_ITAM sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:35.
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a O03z intracellular sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:36.
- a fusion- protein encoding polynucleotide comprises a polynucleotide that encodes a 4-1BB signaling sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:37.
- a fusion-protein encoding polynucleotide comprises a
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a hinge sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:39.
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB signal_CD3e_PRS_ITAM E ⁇ 3z sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:40.
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB
- 8 ⁇ ⁇ M ⁇ _E ⁇ 3e_E03z sequence has at least 70% (i.e., at least 70%, 75%, 80%, 85%,
- a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB 8 ⁇ M ⁇ _EO3z_E03e sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:42.
- a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:43.
- 70% i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more
- a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%,
- a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:45.
- a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:46.
- a polynucleotide encoding a fusion protein further comprises a polynucleotide encoding a marker.
- markers include green fluorescent protein, an extracellular domain of human CD2, a truncated human EGFR (huEGFRt, (see Wang et al, Blood 118: 1255, 2011), a truncated human CD19
- an encoded marker comprises EGFRt (e.g., SEQ ID NO:54), CDl9t, CD34t, or NGFRt.
- a fusion protein-encoding polynucleotide can further comprise a polynucleotide that encodes a marker and a polynucleotide that encodes a self-cleaving polypeptide, wherein the polynucleotide encoding the self-cleaving polypeptide is located between the polynucleotide encoding the fusion protein and the polynucleotide encoding the marker.
- the fusion- protein encoding polynucleotide, marker-encoding polynucleotide, and self-cleaving polypeptide are expressed by a host cell, the fusion protein and the marker will be present on the host cell surface as separate molecules.
- a self cleaving polypeptide comprises a 2A peptide from porcine teschovirus-l (P2A, Thoseaasigna virus (T2A, equine rhinitis A virus (E2A), or foot-and-mouth disease virus (F2A)) (see, e.g., SEQ ID NOs.:50-53).
- P2A porcine teschovirus-l
- T2A Thoseaasigna virus
- E2A equine rhinitis A virus
- F2A foot-and-mouth disease virus
- a self-cleaving polypeptide encoded by a chimeric polynucleotide of this disclosure encodes a P2A, a T2A, an E2A, or a F2A.
- a polynucleotide of the present disclosure may be codon-optimized for a host cell containing the polynucleotide (see, e.g, Scholten et al, Clin. Immunol. 779:135-145 (2006). Codon optimization can be performed using, e.g., the GenScript® Optimum GeneTM tool. Codon-optimized sequences include sequences that are partially codon-optimized (i.e., one or more of the codons is optimized for expression in the host cell) and those that are fully codon-optimized.
- a polynucleotide encoding a desired fusion protein of this disclosure can be inserted into an appropriate vector (e.g, viral vector or non-viral plasmid vector) for introduction into a host cell of interest (e.g, an immune cell, such as a T cell).
- an appropriate vector e.g, viral vector or non-viral plasmid vector
- a host cell of interest e.g, an immune cell, such as a T cell.
- expression constructs are provided, wherein the expression constructs comprise a polynucleotide of the present disclosure (e.g, a fusion protein encoding polynucleotide or a polynucleotide encoding a tagged marker) operably linked to an expression control sequence (e.g, a promoter).
- the expression construct is comprised in a vector.
- An exemplary vector may comprise a polynucleotide capable of transporting another polynucleotide to which it has been linked, or which is capable of replication in a host organism.
- Some examples of vectors include plasmids, viral vectors, cosmids, and others.
- Some vectors may be capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors), whereas other vectors may be integrated into the genome of a host cell or promote integration of the polynucleotide insert upon introduction into the host cell and thereby replicate along with the host genome (e.g, lentiviral vector, retroviral vector).
- bacterial vectors having a bacterial origin of replication and episomal mammalian vectors e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors
- other vectors may be integrated into the genome of a host cell or promote integration of the polynucleotide insert upon introduction into the host cell and thereby replicate along with the host genome (e.g, lentiviral vector, retroviral vector).
- vectors are capable of directing the expression of genes to which they are operatively linked (these vectors may be referred to as "expression vectors").
- expression vectors e.g., polynucleotides encoding fusion proteins as described herein
- agents e.g., polynucleotides encoding fusion proteins as described herein
- each agent may reside in separate or the same vectors, and multiple vectors (each containing a different agent or the same agent) may be introduced to a cell or cell population or administered to a subject.
- polynucleotides of the present disclosure may be operatively linked to certain elements of a vector.
- polynucleotide sequences that are needed to effect the expression and processing of coding sequences to which they are ligated may be operatively linked.
- Expression control sequences may include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion.
- Expression control sequences may be operatively linked if they are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
- the vector comprises a plasmid vector or a viral vector (e.g, a vector selected from lentiviral vector or a g-retroviral vector).
- Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as ortho-myxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g., measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).
- herpesvirus e
- viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
- retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields et al ., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
- “Retroviruses” are viruses having an RNA genome, which is reverse-transcribed into DNA using a reverse transcriptase enzyme, the reverse-transcribed DNA is then incorporated into the host cell genome.
- “Gammaretrovirus” refers to a genus of the retroviridae family. Examples of gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses.
- Lentiviral vector means HIV-based lentiviral vectors for gene delivery, which can be integrative or non-integrative, have relatively large packaging capacity, and can transduce a range of different cell types. Lentiviral vectors are usually generated following transient transfection of three (packaging, envelope and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the cell surface. On entry, the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral integration into the DNA of infected cells.
- the viral vector can be a gammaretrovirus, e.g. , Moloney murine leukemia virus (MLV)-derived vectors.
- the viral vector can be a more complex retrovirus-derived vector, e.g. , a lentivirus-derived vector. HIV- 1 -derived vectors belong to this category.
- Other examples include lentivirus vectors derived from HIV-2, FIV, equine infectious anemia virus, SIV, and Maedi-Visna virus (ovine lentivirus).
- Retroviral and lentiviral vector constructs and expression systems are also commercially available.
- Other viral vectors also can be used for polynucleotide delivery including DNA viral vectors, including, for example adenovirus-based vectors and adeno-associated virus (AAV)-based vectors; vectors derived from herpes simplex viruses (HSVs), including amplicon vectors, replication-defective HSV and attenuated HSV (Krisky et al., Gene Ther. 5: 1517, 1998).
- HSVs herpes simplex viruses
- vectors developed for gene therapy uses can also be used with the compositions and methods of this disclosure.
- Such vectors include those derived from baculoviruses and a- viruses. (Jolly, D J. 1999. Emerging Viral Vectors pp 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plasmid vectors (such as sleeping beauty or other transposon vectors).
- the viral vector may also comprise additional sequences between the two (or more) transcripts allowing for bicistronic or multi cistronic expression.
- additional sequences used in viral vectors include internal ribosome entry sites (IRES), furin cleavage sites, viral 2A peptide, or any combination thereof.
- a polynucleotide in each recombinant expression construct includes at least one appropriate expression control sequence (also called a regulatory sequence), such as a leader sequence and particularly a promoter operably (i.e., operatively) linked to the nucleotide sequence encoding the immunogen.
- a regulatory sequence also called a regulatory sequence
- polynucleotides of the present disclosure are used to transfect/transduce a host cell (e.g ., a T cell) for use in adoptive transfer therapy (e.g, targeting a cancer antigen).
- a host cell e.g ., a T cell
- adoptive transfer therapy e.g, targeting a cancer antigen.
- T cells of desired target-specificity e.g ., Schmitt et al., Hum. Gen. 20: 1240, 2009; Dossett et al., Mol. Ther. 77:742, 2009; Till et al. , Blood 772:2261, 2008; Wang et al.
- the host cell is a hematopoietic progenitor cell or a human immune system cell.
- a "hematopoietic progenitor cell”, as referred to herein, is a cell that can be derived from hematopoietic stem cells or fetal tissue and is capable of further differentiation into mature cells types (e.g., immune system cells).
- Exemplary hematopoietic progenitor cells include those with a CD24 Lo Lin- CD117 + phenotype or those found in the thymus (referred to as progenitor thymocytes).
- an "immune system cell” means any cell of the immune system that originates from a hematopoietic stem cell in the bone marrow, which gives rise to two major lineages, a myeloid progenitor cell (which give rise to myeloid cells such as monocytes, macrophages, dendritic cells, megakaryocytes and granulocytes) and a lymphoid progenitor cell (which give rise to lymphoid cells such as T cells, B cells, natural killer (NK) cells, and NK-T cells).
- a myeloid progenitor cell which give rise to myeloid cells such as monocytes, macrophages, dendritic cells, megakaryocytes and granulocytes
- lymphoid progenitor cell which give rise to lymphoid cells such as T cells, B cells, natural killer (NK) cells, and NK-T cells.
- Exemplary immune system cells include a CD4 + T cell, a CD8 + T cell, a CD4 CD8 double negative T cell, a gd T cell, a regulatory T cell, a stem cell memory T cell, a natural killer cell (e.g, aNK cell or a NK-T cell), a B cell, and a dendritic cell.
- Macrophages and dendritic cells may be referred to as "antigen presenting cells" or "APCs,” which are specialized cells that can activate T cells when a major histocompatibility complex (MHC) receptor on the surface of the APC complexed with a peptide interacts with a TCR on the surface of a T cell.
- MHC major histocompatibility complex
- T cell or "T lymphocyte” is an immune system cell that matures in the thymus and produces T cell receptors (TCRs).
- T cells can be naive (not exposed to antigen; increased expression of CD62L, CCR7, CD28, CD3, CD 127, and CD45RA, and decreased expression of CD45RO as compared to TCM), memory T cells (TM) (antigen-experienced and long-lived), and effector cells (antigen-experienced, cytotoxic).
- TM can be further divided into subsets of central memory T cells (TCM, increased expression of CD62L, CCR7, CD28, CD 127, CD45RO, and CD95, and decreased expression of CD54RA as compared to naive T cells) and effector memory T cells (TEM, decreased expression of CD62L, CCR7, CD28, CD45RA, and increased expression of CD127 as compared to naive T cells or TCM).
- TCM central memory T cells
- TEM effector memory T cells
- Effector T cells refers to antigen-experienced CD8 + cytotoxic T
- helper T cells are CD4 + cells that influence the activity of other immune cells by releasing cytokines.
- CD4 + T cells can activate and suppress an adaptive immune response, and which of those two functions is induced will depend on presence of other cells and signals.
- T cells can be collected using known techniques, and the various subpopulations or combinations thereof can be enriched or depleted by known techniques, such as by affinity binding to antibodies, flow cytometry, or immunomagnetic selection.
- Other exemplary T cells include regulatory T cells, such as CD4 + CD25 + (Foxp3 + ) regulatory T cells and Tregl7 cells, as well as Trl, Th3, CD8 + CD28 , and Qa-l restricted T cells.
- Cells of T cell lineage refer to cells that show at least one phenotypic characteristic of a T cell, or a precursor or progenitor thereof that distinguishes the cells from other lymphoid cells, and cells of the erythroid or myeloid lineages.
- Such phenotypic characteristics can include expression of one or more proteins specific for T cells (e.g ., CD3 + , CD4 + , CD8 + ), or a physiological, morphological, functional, or immunological feature specific for a T cell.
- cells of the T cell lineage may be progenitor or precursor cells committed to the T cell lineage; CD25 + immature and inactivated T cells; cells that have undergone CD4 or CD8 linage commitment; thymocyte progenitor cells that are CD4 + CD8 + double positive; single positive CD4 + or CD8 + ; TCRa.p or TCR gd; or mature and functional or activated T cells.
- the immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell (e.g., NK cell or NK- T cell), a dendritic cell, a B cell, or any combination thereof.
- the T cell is a naive T cell, a central memory T cell, an effector memory T cell, a stem cell memory T cell, or any combination thereof.
- a host cell may include any individual cell or cell culture which may receive a vector or the incorporation of nucleic acids or express proteins. The term also encompasses progeny of the host cell, whether genetically or phenotypically the same or different.
- Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate the vector or other material by use of a viral vector, transformation via calcium phosphate precipitation, DEAE-dextran,
- a host cell that comprises a heterologous polynucleotide encoding a fusion protein is an immune cell which is modified to reduce or eliminate expression of one or more endogenous genes that encode a polypeptide product selected from PD-l, LAG-3, CTLA4, TIM3, TIGIT, an HLA molecule, a TCR molecule, or any component or combination thereof.
- certain endogenously expressed immune cell proteins may downregulate the immune activity of a modified immune host cell (e.g ., PD-l, LAG-3, CTLA4, TIGIT), or may compete with a heterologous fusion protein of the present disclosure for expression by the host cell, or may interfere with the binding activity of a heterologously expressed fusion protein of the present disclosure and interfere with the immune host cell binding to a target cell that expresses an antigen , or any combination thereof.
- a modified immune host cell e.g PD-l, LAG-3, CTLA4, TIGIT
- endogenous proteins e.g., immune host cell proteins, such as an HLA
- endogenous proteins expressed on a donor immune cell to be used in a cell transfer therapy may be recognized as foreign by an allogeneic recipient, which may result in elimination or suppression of the donor immune cell by the allogeneic recipient.
- endogenous genes or proteins can improve the activity, tolerance, and persistence of the host cells in an autologous or allogeneic host setting, and allows universal
- a modified host immune cell is a donor cell (e.g., allogeneic) or an autologous cell.
- a modified immune host cell of this disclosure comprises a chromosomal gene knockout of one or more of a gene that encodes PD-l, LAG-3, CTLA4, TIM3, TIGIT, an HLA component (e.g., a gene that encodes an al macroglobulin, an a2 macroglobulin, an a3 macroglobulin, a b ⁇ microglobulin, or a b2 microglobulin), or a TCR component (e.g., a gene that encodes a TCR variable region or a TCR constant region) (see, e.g., Torikai el al., Nature Sci.
- chromosomal gene knockout refers to a genetic alteration in a host cell that prevents production, by the host cell, of a functionally active endogenous polypeptide product. Alterations resulting in a chromosomal gene knockout can include, for example, introduced nonsense mutations (including the formation of premature stop codons), missense mutations, gene deletion, and strand breaks, as well as the heterologous expression of inhibitory nucleic acid molecules that inhibit endogenous gene expression in the host cell.
- a chromosomal gene knock-out or gene knock-in is made by chromosomal editing of a host cell.
- Chromosomal editing can be performed using, for example, endonucleases.
- endonucleases refers to an enzyme capable of catalyzing cleavage of a phosphodiester bond within a polynucleotide chain.
- an endonuclease is capable of cleaving a targeted gene thereby inactivating or "knocking out" the targeted gene.
- An endonuclease may be a naturally occurring, recombinant, genetically modified, or fusion endonuclease.
- the nucleic acid strand breaks caused by the endonuclease are commonly repaired through the distinct mechanisms of homologous recombination or non-homologous end joining (NHEJ).
- NHEJ non-homologous end joining
- a donor nucleic acid molecule may be used for a donor gene "knock-in”, for target gene "knock-out”, and optionally to inactivate a target gene through a donor gene knock in or target gene knock out event.
- NHEJ is an error- prone repair process that often results in changes to the DNA sequence at the site of the cleavage, e.g., a substitution, deletion, or addition of at least one nucleotide.
- NHEJ may be used to "knock-out" a target gene.
- Examples of endonucleases include zinc finger nucleases, TALE-nucleases, CRISPR-Cas nucleases, meganucleases, and megaTALs.
- a "zinc finger nuclease” refers to a fusion protein comprising a zinc finger DNA-binding domain fused to a non-specific DNA cleavage domain, such as a Fokl endonuclease.
- ZFN zinc finger nuclease
- Each zinc finger motif of about 30 amino acids binds to about 3 base pairs of DNA, and amino acids at certain residues can be changed to alter triplet sequence specificity (see, e.g., Desjarlais et al., Proc. Natl. Acad. Sci.
- ZFNs mediate genome editing by catalyzing the formation of a site-specific DNA double strand break (DSB) in the genome, and targeted integration of a transgene comprising flanking sequences homologous to the genome at the site of DSB is facilitated by homology directed repair.
- DSB DNA double strand break
- a DSB generated by a ZFN can result in knock out of target gene via repair by non-homologous end joining (NHEJ), which is an error-prone cellular repair pathway that results in the insertion or deletion of nucleotides at the cleavage site.
- NHEJ non-homologous end joining
- a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, made using a ZFN molecule.
- TALEN transcription activator-like effector nuclease
- a "TALE DNA binding domain” or “TALE” is composed of one or more TALE repeat domains/units, each generally having a highly conserved 33-35 amino acid sequence with divergent l2th and l3th amino acids.
- the TALE repeat domains are involved in binding of the TALE to a target DNA sequence.
- the divergent amino acid residues referred to as the Repeat Variable Diresidue (RVD), correlate with specific nucleotide recognition.
- RVD Repeat Variable Diresidue
- the natural (canonical) code for DNA recognition of these TALEs has been determined such that an HD (histine-aspartic acid) sequence at positions 12 and 13 of the TALE leads to the TALE binding to cytosine (C), NG (asparagine-glycine) binds to a T nucleotide, NI (asparagine-isoleucine) to A, NN (asparagine-asparagine) binds to a G or A nucleotide, and NG (asparagine-glycine) binds to a T nucleotide.
- Non-canonical (atypical) RVDs are also known (see, e.g., U.S. Patent Publication No.
- TALENs can be used to direct site-specific double-strand breaks (DSB) in the genome of T cells.
- Non- homologous end joining (NHEJ) ligates DNA from both sides of a double-strand break in which there is little or no sequence overlap for annealing, thereby introducing errors that knock out gene expression.
- homology directed repair can introduce a transgene at the site of DSB providing homologous flanking sequences are present in the transgene.
- a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, and made using a TALEN molecule.
- CRISPR/Cas nuclease system refers to a system that employs a CRISPR RNA (crRNA)-guided Cas nuclease to recognize target sites within a genome (known as protospacers) via base-pairing complementarity and then to cleave the DNA if a short, conserved protospacer associated motif (PAM) immediately follows 3’ of the complementary target sequence.
- CRISPR/Cas systems are classified into three types (i.e., type I, type II, and type III) based on the sequence and structure of the Cas nucleases.
- the crRNA-guided surveillance complexes in types I and III need multiple Cas subunits.
- Type II system the most studied, comprises at least three components: an RNA-guided Cas9 nuclease, a crRNA, and a trans-acting crRNA (tracrRNA).
- the tracrRNA comprises a duplex forming region.
- a crRNA and a tracrRNA form a duplex that is capable of interacting with a Cas9 nuclease and guiding the
- Cas9/crRNA:tracrRNA complex to a specific site on the target DNA via Watson-Crick base-pairing between the spacer on the crRNA and the protospacer on the target DNA upstream from a PAM.
- Cas9 nuclease cleaves a double-stranded break within a region defined by the crRNA spacer. Repair by NHEJ results in insertions and/or deletions which disrupt expression of the targeted locus.
- a transgene with homologous flanking sequences can be introduced at the site of DSB via homology directed repair.
- the crRNA and tracrRNA can be engineered into a single guide RNA (sgRNA or gRNA) (see, e.g., Jinek et al., Science 337:816-21, 2012). Further, the region of the guide RNA complementary to the target site can be altered or programed to target a desired sequence (Xie et al. , PLOS One 9:el00448, 2014; U.S. Pat. Appl. Pub. No. US 2014/0068797, U.S. Pat. Appl. Pub. No. US 2014/0186843; U.S. Pat. No. 8,697,359, and PCT Publication No. WO 2015/071474; each of which is incorporated by reference).
- a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, and made using a CRISPR/Cas nuclease system.
- Exemplary gRNA sequences and methods of using the same to knock out endogenous genes that encode immune cell proteins include those described in Ren et al., Clin. Cancer Res. 23(9):2255-2266 (2017), the gRNAs, CAS9 DNAs, vectors, and gene knockout techniques of which are hereby incorporated by reference in their entirety.
- Exemplary meganucleases include I-Scel, I-Ceul, PI-PspI, RI-Sce, 1-SceIV, I-Csml, I-Panl, I-Scell, I-Ppol, I-SceIII, I-Crel, I- TevI, I-TevII and I-TevIII, whose recognition sequences are known (see, e.g., U.S. Patent Nos. 5,420,032 and 6,833,252; Belfort et al., Nucleic Acids Res. 25: 3379-3388, 1997; Dujon et al ., Gene 82: 115-118, 1989; Perler et al., Nucleic Acids Res. 22:1125- 1127, 1994; Jasin, Trends Genet. 72:224-228, 1996; Gimble et al., J. Mol. Biol.
- naturally-occurring meganucleases may be used to promote site-specific genome modification of a target selected from PD-l, LAG3,
- TIM3, CTLA4, TIGIT an HLA-encoding gene, or a TCR component-encoding gene.
- an engineered meganuclease having a novel binding specificity for a target gene is used for site-specific genome modification (see, e.g., Porteus et al, Nat. Biotechnol. 23:967-73, 2005; Sussman et al, J. Mol. Biol. 342: 31-41, 2004; Epinat et al, Nucleic Acids Res. 37:2952-62, 2003; Chevalier et al, Molec. Cell 70:895-905, 2002; Ashworth et al, Nature 441:656-659, 2006; Paques et al, Curr. Gene Ther. 7:49- 66, 2007; U.S. Patent Publication Nos.
- a chromosomal gene knockout is generated using a homing endonuclease that has been modified with modular DNA binding domains of TALENs to make a fusion protein known as a megaTAL.
- MegaTALs can be utilized to not only knock-out one or more target genes, but to also introduce (knock in) heterologous or exogenous
- polynucleotides when used in combination with an exogenous donor template encoding a polypeptide of interest.
- a chromosomal gene knockout comprises an inhibitory nucleic acid molecule that is introduced into a host cell (e.g ., an immune cell) comprising a heterologous polynucleotide encoding an antigen-specific receptor that specifically binds to a tumor associated antigen, wherein the inhibitory nucleic acid molecule encodes a target-specific inhibitor and wherein the encoded target-specific inhibitor inhibits endogenous gene expression (i.e., of PD-l, TIM3, LAG3, CTLA4, TIGIT, an HLA component, or a TCR component, or any combination thereof) in the host immune cell.
- a host cell e.g ., an immune cell
- a heterologous polynucleotide encoding an antigen-specific receptor that specifically binds to a tumor associated antigen
- the inhibitory nucleic acid molecule encodes a target-specific inhibitor and wherein the encoded target-specific inhibitor inhibits endogenous gene expression (i.e., of
- a chromosomal gene knockout can be confirmed directly by DNA sequencing of the host immune cell following use of the knockout procedure or agent.
- Chromosomal gene knockouts can also be inferred from the absence of gene expression (e.g., the absence of an mRNA or polypeptide product encoded by the gene) following the knockout.
- a host cell e.g, immune cell
- a host cell of the present disclosure is engineered so that expression of a presently disclosed fusion protein by the host cell is modulated (e.g, controlled) by binding of the host cell to an antigen that is not the same antigen as the antigen to which the fusion protein specifically binds.
- a host cell can comprise (i) a polynucleotide encoding an engineered (i.e., synthetic) Notch receptor comprising (a) an extracellular component comprising a binding domain that binds to an antigen, which is a different antigen than the antigen to which the fusion protein binds, (b) a Notch core domain, or a functional portion or variant thereof; and (c) an intracellular component comprising a
- transcriptional factor i.e., a polypeptide capable of activating or increasing, or inhibiting, repressing or reducing, transcription of a target nucleotide sequence (e.g., a gene) or set of target nucleotide sequences); and (ii) the heterologous polynucleotide encoding a fusion protein as disclosed herein and comprising an expression control sequence that can be recognized or bound by the transcriptional factor, wherein binding of the engineered Notch receptor to antigen leads to release of the transcriptional factor from the engineered Notch receptor ( e.g ., by protease-driven cleavage), which can, in turn, drive transcription of the fusion protein.
- a target nucleotide sequence e.g., a gene
- Such "logic-gated" expression systems may be useful to modulate expression of a fusion protein of this disclosure so that the expression occurs only, or preferentially, when the host cell encounters a first antigen (i.e ., that can be bound by the synthetic Notch receptor) that is only expressed by, or is principally expressed by, or has a higher expression level on cancer cells as compared to healthy cells.
- a first antigen i.e ., that can be bound by the synthetic Notch receptor
- Such embodiments may reduce "on-target off-tissue" recognition by a fusion protein in circumstances where the antigen recognized by the fusion protein is expressed by healthy cells.
- kits comprising (a) a vector or an expression construct as described herein and (b) reagents for transducing the vector or the expression construct into a host cell.
- the present disclosure also provides methods for treating a disease or condition, wherein the methods comprise administering to a subject in need thereof an effective amount of a host cell, composition, or unit dose of the present disclosure, wherein the disease or condition expresses or is otherwise associated with the antigen that is specifically bound by the fusion protein.
- the disease or condition is a hyperproliferative or proliferative disease, such as a cancer, an autoimmune disease, or an infectious disease (e.g, viral, bacterial, fungal, or parasitic).
- hyperproliferative disorder refers to excessive growth or proliferation as compared to a normal or undiseased cell.
- exemplary hyperproliferative disorders include tumors, cancers, neoplastic tissue, carcinoma, sarcoma, malignant cells, pre-malignant cells, as well as non-neoplastic or non-malignant hyperproliferative disorders (e.g, adenoma, fibroma, lipoma, leiomyoma, hemangioma, fibrosis, restenosis, as well as autoimmune diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, inflammatory bowel disease, or the like).
- proliferative diseases include certain tumors, cancers, neoplastic tissue, carcinoma, sarcoma, malignant cells, pre malignant cells, as well as non-neoplastic or non-malignant disorders.
- cancer may refer to any accelerated proliferation of cells, including solid tumors, ascites tumors, blood or lymph or other malignancies;
- connective tissue malignancies connective tissue malignancies; metastatic disease; minimal residual disease following transplantation of organs or stem cells; multi-drug resistant cancers, primary or secondary malignancies, angiogenesis related to malignancy, or other forms of cancer.
- a cancer treatable according to the presently disclosed methods and uses comprises a carcinoma, a sarcoma, a glioma, a lymphoma, a leukemia, a myeloma, or any combination thereof.
- cancer comprises a cancer of the head or neck, melanoma, pancreatic cancer,
- cholangiocarcinoma hepatocellular cancer
- breast cancer including triple-negative breast cancer (TNBC)
- gastric cancer non-small-cell lung cancer
- prostate cancer esophageal cancer
- mesothelioma small-cell lung cancer
- colorectal cancer colorectal cancer
- a cancer comprises Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, PNET, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans (DFSP), desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma,
- GIST gastrointestinal stromal tumor
- hemangiopericytoma hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, linitis plastic, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, renal cell carcinoma, Grawitz tumor, ependymoma, astrocytoma, oligodendroglioma, brainstem glioma, optice nerve glioma, a mixed gli
- the cancer comprises a solid tumor.
- the solid tumor is a sarcoma or a carcinoma.
- the solid tumor is selected from: chondrosarcoma; fibrosarcoma (fibroblastic sarcoma); Dermatofibrosarcoma protuberans (DFSP); osteosarcoma; rhabdomyosarcoma; Ewing’s sarcoma; a gastrointestinal stromal tumor; Leiomyosarcoma; angiosarcoma (vascular sarcoma); Kaposi’s sarcoma; liposarcoma; pleomorphic sarcoma; or synovial sarcoma.
- the solid tumor is selected from a lung carcinoma (e.g., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular carcinoma in situ (non-invasive), Invasive Ductal carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular carcinoma in situ (non-invasive), Invasive Ductal
- a lung carcinoma e.g., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcino
- Carcinoma Invasive lobular carcinoma, Non-invasive Carcinoma
- a liver carcinoma e.g., Hepatocellular Carcinoma, Cholangiocarcinomas or Bile Duct Cancer
- Large-cell undifferentiated carcinoma Bronchioalveolar carcinoma
- an ovarian carcinoma e.g., Surface epithelial-stromal tumor (Adenocarcinoma) or ovarian epithelial carcinoma (which includes serous tumor, endometrioid tumor and mucinous cystadenocarcinoma), Epidermoid (Squamous cell carcinoma), Embryonal carcinoma and choriocarcinoma (germ cell tumors)
- a kidney carcinoma e.g., Renal adenocarcinoma, hypernephroma, Transitional cell carcinoma (renal pelvis), Squamous cell carcinoma, Bellini duct carcinoma, Clear cell adenocarcinoma, Transitional cell carcinoma, Carcinoid tumor of the renal pelvis
- the solid tumor is an ovarian carcinoma, an ovarian epithelial carcinoma, a cervical adenocarcinoma or small cell carcinoma, a pancreatic carcinoma, a colorectal carcinoma (e.g., an adenocarcinoma or squamous cell carcinoma), a lung carcinoma, a breast ductal carcinoma, or an adenocarcinoma of the prostate.
- the host cell is an allogeneic cell, a syngeneic cell, or an autologous cell.
- Subjects that can be treated by the present invention are, in general, human and other primate subjects, such as monkeys and apes for veterinary medicine purposes.
- the subject may be a human subject.
- the subjects can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects.
- Cells according to the present disclosure may be administered in a manner appropriate to the disease, condition, or disorder to be treated as determined by persons skilled in the medical art.
- a cell comprising a fusion protein as described herein is administered intravenously, intraperitoneally, intratumorally, into the bone marrow, into a lymph node, or into the cerebrospinal fluid so as to encounter the target antigen or cells.
- An appropriate dose, suitable duration, and frequency of administration of the compositions will be determined by such factors as a condition of the patient; size, type, and severity of the disease, condition, or disorder; the undesired type or level or activity of the tagged cells, the particular form of the active ingredient; and the method of
- methods of the present disclosure comprise administering a host cell expressing a fusion protein of the present disclosure, or a composition comprising the host cell.
- the amount of cells in a composition is at least one cell (for example, one fusion protein-modified CD8 + T cell subpopulation; one fusion protein-modified CD4 + T cell subpopulation) or is more typically greater than 10 2 cells, for example, up to 10 6 , up to 10 7 , up to 10 8 cells, up to 10 9 cells, or 10 10 cells or more, such as about 10 11 cells/m 2 .
- the cells are administered in a range from about 10 5 to about 10 11 cells/m 2 , preferably in a range of about 10 5 or about 10 6 to about 10 9 or about 10 10 cells/m 2 .
- the number of cells will depend upon the ultimate use for which the composition is intended as well the type of cells included therein.
- cells modified to contain a fusion protein specific for a particular antigen will comprise a cell population containing at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of such cells.
- cells are generally in a volume of a liter or less, 500 mls or less,
- the density of the desired cells is typically greater than 10 4 cells/ml and generally is greater than 10 7 cells/ml, generally 10 8 cells/ml or greater.
- the cells may be administered as a single infusion or in multiple infusions over a range of time. A clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , or 10 11 cells.
- Unit doses are also provided herein which comprise a host cell (e.g ., a modified immune cell comprising a polynucleotide of the present disclosure) or host cell composition of this disclosure.
- a unit dose comprises (i) a composition comprising at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% modified CD4 + T cells, combined with (ii) a composition comprising at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells (i.e., has less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about
- a unit dose comprises (i) a composition comprising at least about 50% modified CD4 + T cells, combined with (ii) a composition comprising at least about 50% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises (i) a composition comprising at least about 60% modified CD4 + T cells, combined with (ii) a composition comprising at least about 60% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises (i) a composition comprising at least about 70% modified CD4 + T cells, combined with (ii) a composition comprising at least about 70% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises (i) a composition comprising at least about 80% modified CD4 + T cells, combined with (ii) a composition comprising at least about 80% modified CD8 + T cells, in about a 1 :1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises (i) a composition comprising at least about 85% modified CD4 + T cells, combined with (ii) a composition comprising at least about 85% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises (i) a composition comprising at least about 90% modified CD4 + T cells, combined with (ii) a composition comprising at least about 90% modified CD8 + T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
- a unit dose comprises equal, or approximately equal numbers of engineered CD45RA CD3 + CD8 + and engineered CD45RA- CD3 + CD4 + TM cells.
- compositions that comprise fusion proteins or cells expressing the fusion proteins as disclosed herein and a
- compositions comprising fusion proteins or host cells as disclosed herein further comprise a suitable infusion media.
- suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), 5% dextrose in water, Ringer's lactate can be utilized.
- An infusion medium can be supplemented with human serum albumin or other human serum components.
- compositions may be administered in a manner appropriate to the disease or condition to be treated (or prevented) as determined by persons skilled in the medical art.
- An appropriate dose and a suitable duration and frequency of administration of the compositions will be determined by such factors as the health condition of the patient, size of the patient (i.e., weight, mass, or body area), the type and severity of the patient's condition, the undesired type or level or activity of the tagged cells, the particular form of the active ingredient, and the method of
- an appropriate dose and treatment regimen provide the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (such as described herein, including an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity).
- a dose should be sufficient to prevent, delay the onset of, or diminish the severity of a disease associated with disease or disorder. Prophylactic benefit of the immunogenic compositions
- administered according to the methods described herein can be determined by performing pre-clinical (including in vitro and in vivo animal studies) and clinical studies and analyzing data obtained therefrom by appropriate statistical, biological, and clinical methods and techniques, all of which can readily be practiced by a person skilled in the art.
- Certain methods of treatment or prevention contemplated herein include administering a host cell (which may be autologous, allogeneic or syngeneic) comprising a desired polynucleotide as described herein that is stably integrated into the chromosome of the cell.
- a host cell which may be autologous, allogeneic or syngeneic
- a cellular composition may be generated ex vivo using autologous, allogeneic or syngeneic immune system cells (e.g T cells, antigen-presenting cells, natural killer cells) in order to administer a desired, fusion protein-expressing T-cell composition to a subject as an adoptive immunotherapy.
- the host cell is a hematopoietic progenitor cell or a human immune cell.
- the immune system cell is a CD4 + T cell, a CD8 + T cell, a CD4 CD8 double-negative T cell, a gd T cell, a natural killer cell, a dendritic cell, or any combination thereof.
- the immune system cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
- the cell is a CD4 + T cell.
- the cell is a CD8 + T cell.
- administration of a composition refers to delivering the same to a subject, regardless of the route or mode of delivery. Administration may be effected continuously or intermittently, and parenterally. Administration may be for treating a subject already confirmed as having a recognized condition, disease or disease state, or for treating a subject susceptible to or at risk of developing such a condition, disease or disease state.
- Co-administration with an adjunctive therapy may include simultaneous and/or sequential delivery of multiple agents in any order and on any dosing schedule (e.g ., fusion protein-expressing recombinant (i.e., engineered) host cells with one or more cytokines; immunosuppressive therapy such as calcineurin inhibitors,
- corticosteroids corticosteroids, microtubule inhibitors, low dose of a mycophenolic acid prodrug, or any combination thereof.
- a plurality of doses of a recombinant host cell as described herein is administered to the subject, which may be administered at intervals between administrations of about two to about four weeks.
- the subject being treated is further receiving immunosuppressive therapy, such as calcineurin inhibitors, corticosteroids, microtubule inhibitors, low dose of a mycophenolic acid prodrug, or any combination thereof.
- immunosuppressive therapy such as calcineurin inhibitors, corticosteroids, microtubule inhibitors, low dose of a mycophenolic acid prodrug, or any combination thereof.
- the subject being treated has received a non-myeloablative or a myeloablative hematopoietic cell transplant, wherein the treatment may be administered at least two to at least three months after the non-myeloablative hematopoietic cell transplant.
- An effective amount of a pharmaceutical composition refers to an amount sufficient, at dosages and for periods of time needed, to achieve the desired clinical results or beneficial treatment, as described herein.
- An effective amount may be delivered in one or more
- the term "therapeutic amount” may be used in reference to treatment, whereas “prophylactically effective amount” may be used to describe administrating an effective amount to a subject that is susceptible or at risk of developing a disease or disease-state (e.g ., recurrence) as a preventative course.
- the level of a CTL immune response may be determined by any one of numerous immunological methods described herein and routinely practiced in the art.
- the level of a CTL immune response may be determined prior to and following administration of any one of the herein described fusion proteins expressed by, for example, a T cell.
- Cytotoxicity assays for determining CTL activity may be performed using any one of several techniques and methods routinely practiced in the art (see, e.g., Henkart et ah, "Cytotoxic T-Lymphocytes" in Fundamental Immunology, Paul (ed.) (2003 Lippincott Williams & Wilkins, Philadelphia, PA), pages 1127-50, and references cited therein).
- Antigen-specific T cell responses are typically determined by comparisons of observed T cell responses according to any of the herein described T cell functional parameters (e.g, proliferation, cytokine release, CTL activity, altered cell surface marker phenotype, etc.) that may be made between T cells that are exposed to a cognate antigen in an appropriate context (e.g., the antigen used to prime or activate the T cells, when presented by immunocompatible antigen-presenting cells) and T cells from the same source population that are exposed instead to a structurally distinct or irrelevant control antigen.
- a cognate antigen e.g., the antigen used to prime or activate the T cells, when presented by immunocompatible antigen-presenting cells
- a response to the cognate antigen that is greater, with statistical significance, than the response to the control antigen signifies antigen-specificity.
- a biological sample may be obtained from a subject for determining the presence and level of an immune response to a tagged protein or cell as described herein.
- a "biological sample” as used herein may be a blood sample (from which serum or plasma may be prepared), biopsy specimen, body fluids (e.g, lung lavage, ascites, mucosal washings, synovial fluid), bone marrow, lymph nodes, tissue explant, organ culture, or any other tissue or cell preparation from the subject or a biological source.
- Biological samples may also be obtained from the subject prior to receiving any immunogenic composition, which biological sample is useful as a control for establishing baseline (i.e., pre-immunization) data.
- compositions described herein may be presented in unit- dose or multi-dose containers, such as sealed ampoules or vials. Such containers may be frozen to preserve the stability of the formulation until.
- a unit dose comprises a recombinant host cell as described herein at a dose of about 10 7 cells/m 2 to about 10 11 cells/m 2 .
- the composition may also include sterile aqueous or oleaginous solution or suspension.
- suitable non-toxic parenterally acceptable diluents or solvents include water, Ringer’s solution, isotonic salt solution, l,3-butanediol, ethanol, propylene glycol or polythethylene glycols in mixtures with water.
- Aqueous solutions or suspensions may further comprise one or more buffering agents, such as sodium acetate, sodium citrate, sodium borate or sodium tartrate.
- any material used in preparing any dosage unit formulation should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compounds may be incorporated into sustained-release preparation and formulations.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit may contain a predetermined quantity of recombinant cells or active compound calculated to produce the desired effect in association with an appropriate pharmaceutical carrier.
- an appropriate dosage and treatment regimen provides the active molecules or cells in an amount sufficient to provide therapeutic or prophylactic benefit.
- a response can be monitored by establishing an improved clinical outcome (e.g, more frequent remissions, complete or partial, or longer disease-free survival) in treated subjects as compared to non-treated subjects.
- Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome.
- Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which are routine in the art and may be performed using samples obtained from a subject before and after treatment.
- kits are provided that comprise (a) a host cell, (b) a composition, or (c) a unit dose as described herein.
- Methods according to this disclosure may further include administering one or more additional agents to treat the disease or disorder in a combination therapy.
- a combination therapy comprises administering a fusion protein (or an engineered host cell expressing the same) with (concurrently, simultaneously, or sequentially) an immune checkpoint inhibitor.
- a combination therapy comprises administering fusion protein of the present disclosure (or an engineered host cell expressing the same) with an agonist of a stimulatory immune checkpoint agent.
- a combination therapy comprises administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with a secondary therapy, such as chemotherapeutic agent, a radiation therapy, a surgery, an antibody, or any combination thereof.
- immune suppression agent refers to one or more cells, proteins, molecules, compounds or complexes providing inhibitory signals to assist in controlling or suppressing an immune response.
- immune suppression agents include those molecules that partially or totally block immune stimulation; decrease, prevent or delay immune activation; or increase, activate, or up regulate immune suppression.
- immunosuppression agents to target include PD-l, PD-L1, PD- L2, LAG3, CTLA4, B7-H3, B7-H4, CD244/2B4, HVEM, BTLA, CD160, TIM3, GAL9, KIR, PVR1G (CD112R), PVRL2, adenosine, A2aR, immunosuppressive cytokines (e.g., IL-10, IL-4, IL-1RA, IL-35), IDO, arginase, VISTA, TIGIT, LAIR1, CEACAM-l, CEACAM-3, CEACAM-5, Treg cells, or any combination thereof.
- immunosuppression agents to target include PD-l, PD-L1, PD- L2, LAG3, CTLA4, B7-H3, B7-H4, CD244/2B4, HVEM, BTLA, CD160, TIM3, GAL9, KIR, PVR1G (CD112R), PVRL2, adenosine
- An immune suppression agent inhibitor may be a compound, an antibody, an antibody fragment or fusion polypeptide (e.g., Fc fusion, such as CTLA4-Fc or LAG3-Fc), an antisense molecule, a ribozyme or RNAi molecule, or a low molecular weight organic molecule.
- a method may comprise administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with one or more inhibitor of any one of the following immune suppression components, singly or in any combination.
- a fusion protein is used in combination with a PD-l inhibitor, for example a PD-l -specific antibody or binding fragment thereof, such as pidilizumab, nivolumab (Keytruda, formerly MDX-1106), pembrolizumab (Opdivo, formerly MK-3475), MEDI0680 (formerly AMP-514), AMP-224, BMS-936558 or any combination thereof.
- a PD-l inhibitor for example a PD-l -specific antibody or binding fragment thereof, such as pidilizumab, nivolumab (Keytruda, formerly MDX-1106), pembrolizumab (Opdivo, formerly MK-3475), MEDI0680 (formerly AMP-514), AMP-224, BMS-936558 or any combination thereof.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a PD-L1 specific antibody or binding fragment thereof, such as BMS-936559, durvalumab (MEDI4736), atezolizumab (RG7446), avelumab (MSB0010718C), MPDL3280A, or any combination thereof.
- a PD-L1 specific antibody or binding fragment thereof such as BMS-936559, durvalumab (MEDI4736), atezolizumab (RG7446), avelumab (MSB0010718C), MPDL3280A, or any combination thereof.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a LAG3 inhibitor, such as LAG525, IMP321, IMP701, 9H12, BMS-986016, or any combination thereof.
- a LAG3 inhibitor such as LAG525, IMP321, IMP701, 9H12, BMS-986016, or any combination thereof.
- a fusion protein is used in combination with an inhibitor of CTLA4.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a CTLA4 specific antibody or binding fragment thereof, such as ipilimumab, tremelimumab, CTLA4-Ig fusion proteins (e.g., abatacept, belatacept), or any combination thereof.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a B7-H3 specific antibody or binding fragment thereof, such as enoblituzumab (MGA271), 376.96, or both.
- a B7-H4 antibody binding fragment may be a scFv or fusion protein thereof, as described in, for example, Dangaj et al, Cancer Res. 73:4820, 2013, as well as those described in U.S. Patent No. 9,574,000 and PCT Patent Publication Nos.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of CD244. In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of BLTA, HVEM, CD 160, or any combination thereof.
- Anti CD- 160 antibodies are described in, for example, PCT Publication No. WO 2010/084158.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of TIM3.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of Gal 9.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of adenosine signaling, such as a decoy adenosine receptor.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of A2aR.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of KIR, such as lirilumab (BMS-986015).
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of an inhibitory cytokine (typically, a cytokine other than TGFP) or Treg development or activity.
- an inhibitory cytokine typically, a cytokine other than TGFP
- Treg development or activity typically, a cytokine other than TGFP
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an IDO inhibitor, such as levo-l-methyl tryptophan, epacadostat (INCB024360; Liu et al ., Blood
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an arginase inhibitor, such as N(omega)-Nitro-L-arginine methyl ester (L-NAME), N-omega- hydroxy-nor-l-arginine (nor-NOHA), L-NOHA, 2(S)-amino-6-boronohexanoic acid (ABH), S-(2-boronoethyl)-L-cysteine (BEC), or any combination thereof.
- an arginase inhibitor such as N(omega)-Nitro-L-arginine methyl ester (L-NAME), N-omega- hydroxy-nor-l-arginine (nor-NOHA), L-NOHA, 2(S)-amino-6-boronohexanoic acid (ABH), S-(2-boronoethyl)-L-cysteine (BEC),
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of VISTA, such as CA-170 (Curis, Lexington, Mass.).
- an inhibitor of VISTA such as CA-170 (Curis, Lexington, Mass.).
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of TIGIT such as, for example, COM902 (Compugen, Toronto, Ontario Canada), an inhibitor of CD155, such as, for example, COM701 (Compugen), or both.
- an inhibitor of TIGIT such as, for example, COM902 (Compugen, Toronto, Ontario Canada)
- CD155 such as, for example, COM701 (Compugen)
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of PVRIG, PVRL2, or both.
- Anti-PVRIG antibodies are described in, for example, PCT Publication No. WO 2016/134333.
- Anti-PVRL2 antibodies are described in, for example, PCT Publication No. WO 2017/021526.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a LAIR1 inhibitor.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of CEACAM-l, CEACAM-3, CEACAM-5, or any combination thereof.
- a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an agent that increases the activity (i.e., is an agonist) of a stimulatory immune checkpoint molecule.
- an agent that increases the activity i.e., is an agonist
- a fusionprotein of the present disclosure (or an engineered host cell expressing the same) can be used in combination with a CD137 (4-1BB) agonist (such as, for example, urelumab), a CD 134 (OX-40) agonist (such as, for example,
- MEDI6469, MEDI6383, or MEDI0562 lenalidomide, pomalidomide, a CD27 agonist (such as, for example, CDX-l 127), a CD28 agonist (such as, for example, TGN1412, CD80, or CD86), a CD40 agonist (such as, for example, CP-870,893, rhuCD40L, or SGN-40), a CD122 agonist (such as, for example, IL-2) an agonist of GITR (such as, for example, humanized monoclonal antibodies described in PCT Patent Publication No. WO 2016/054638), an agonist of ICOS (CD278) (such as, for example,
- a method may comprise administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with one or more agonist of a stimulatory immune checkpoint molecule, including any of the foregoing, singly or in any combination.
- a combination therapy comprises a fusion protein of the present disclosure (or an engineered host cell expressing the same) and a secondary therapy comprising one or more of: an antibody or antigen binding-fragment thereof that is specific for a cancer antigen expressed by the non-inflamed solid tumor, a radiation treatment, a surgery, a chemotherapeutic agent, a cytokine, RNAi, or any combination thereof.
- a combination therapy method comprises administering a fusion protein and further administering a radiation treatment or a surgery.
- Radiation therapy is well-known in the art and includes X-ray therapies, such as gamma- irradiation, and radiopharmaceutical therapies.
- Surgeries and surgical techniques appropriate to treating a given cancer or non-inflamed solid tumor in a subject are well- known to those of ordinary skill in the art.
- a combination therapy method comprises administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) and further administering a chemotherapeutic agent.
- a chemotherapeutic agent includes, but is not limited to, an inhibitor of chromatin function, a topoisomerase inhibitor, a microtubule inhibiting drug, a DNA damaging agent, an antimetabolite (such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs), a DNA synthesis inhibitor, a DNA interactive agent (such as an intercalating agent), and a DNA repair inhibitor.
- chemotherapeutic agents include, without limitation, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors
- anti-metabolites/anti-cancer agents such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors
- antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin,
- fibrinolytic agents such as tissue plasminogen activator, streptokinase and urokinase
- aspirin dipyridamole
- ticlopidine clopidogrel
- abciximab antimigratory agents
- antisecretory agents cowveldin; immunosuppressives (cyclosporine, tacrolimus (FK- 506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (TNP470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies
- trastuzumab rituximab
- chimeric antigen receptors cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors
- doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-l l) and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylpednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers, toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin disruptors.
- toxins such as Cholera toxin, ricin
- Cytokines are used to manipulate host immune response towards anticancer activity. See, e.g., Floros & Tarhini, Semin. Oncol. 42 ⁇ 4):539-548, 2015. Cytokines useful for promoting immune anticancer or antitumor response include, for example, IFN-a, IL-2, IL-3, IL-4, IL-10, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-21, IL-24, and GM-CSF, singly or in any combination with the binding proteins or cells expressing the same of this disclosure.
- the present disclosure also includes the following exemplary embodiments.
- a fusion protein comprising:
- an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion or variant thereof comprises:
- an Intracellular Tyrosine-based Activation Motif (i) from CD3e, or a functional portion or variant thereof;
- the extracellular domain does not comprise a TCR ectodomain
- the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
- a fusion protein comprising:
- an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises:
- IAM Intracellular Tyrosine-based Activation Motif
- CD3e does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD35, and/or CD3y.
- Embodiment 3 The fusion protein of embodiment 1 or 2, wherein the effector domain or functional portion thereof comprises an IT AM from CD3e, or a functional variant thereof, and a PRS from CD3e, or a functional variant thereof.
- Embodiment 4 The fusion protein of any one of embodiments 1-3, wherein the fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
- Embodiment 5 The fusion protein of any one of embodiments 1-4, wherein the effector domain or functional fragment thereof comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:8.
- Embodiment 6 The fusion protein of any one of embodiments 1-3 or 5, wherein the effector domain comprises a BRS from CD3e, or a functional variant thereof.
- Embodiment 7 The fusion protein of any one of embodiments 1-6, wherein the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:5 or 111.
- Embodiment 8 The fusion protein of any one of embodiments 1-7, wherein the effector domain comprises: an IT AM from CD3y, or a functional variant thereof; and/or comprises an ITAM from CD35, or a functional variant thereof.
- Embodiment 9 The fusion protein of embodiment 8, wherein the effector domain comprises:
- an amino acid sequence having at least 75% i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity to the amino acid sequence shown in SEQ ID NO: 11, wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO: 11 is optionally not a leucine, and is preferably an alanine or a glycine; and/or
- SEQ ID NO: 14 optionally is not a leucine, and is preferably an alanine or a glycine.
- Embodiment 10 The fusion protein of embodiment 8 or 9, wherein the effector domain comprises a BRS from CD3e, or a functional portion or variant thereof.
- Embodiment 11 The fusion protein of any one of embodiments 1-10, wherein the effector domain further comprises an IT AM from O ⁇ 3z, or a functional portion or variant thereof.
- Embodiment 12 The fusion protein of embodiment 11, wherein the effector domain further comprises two or three of IT AMs (a), (b), and (c) from E03z, or functional portions or variants thereof.
- Embodiment 13 The fusion protein of embodiment 11 or 12, wherein the effector domain comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 17.
- Embodiment 14 The fusion protein of any one of embodiments 1-13, further comprising a costimulatory domain or a functional portion or variant thereof.
- Embodiment 15 The fusion protein of embodiment 14, wherein the costimulatory domain or functional portion or variant thereof is from 4-1BB, CD28, 0X40, CD27, CD2, CD5, ICAM-l (CD54), LFA-l (CD 11 a/CD 18), ICOS (CD278), GITR, CD30, CD40, BAFF-R, HVEM, LIGHT, MKG2C, SLAMF7, NKp80, CD 160, B7-H3, a ligand that specifically binds with CD83, or any combination thereof.
- Embodiment 16 The fusion protein of embodiment 15, wherein the costimulatory domain comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
- Embodiment 17 The fusion protein of any one of embodiments 14-16, wherein the intracellular domain comprises a costimulatory domain, an endodomain or effector domain from O ⁇ 3z or a functional portion or variant thereof, and an effector domain from CD3e or a functional portion or variant thereof, wherein the effector domain from CD3e or functional portion or variant thereof optionally comprises or consists essentially of a PRS and an IT AM from CD3e.
- Embodiment 18 The fusion protein of embodiment 17, wherein the effector domain from CD3e or functional portion or variant thereof is disposed between the costimulatory domain and the endodomain or effector domain from O ⁇ 3z or functional portion or variant thereof.
- Embodiment 19 The fusion protein of embodiment 17, wherein the endodomain or effector domain from O ⁇ 3z or functional portion or variant thereof is disposed between the costimulatory domain and the effector domain from CD3e or functional portion or variant thereof.
- Embodiment 20 The fusion protein of any one of embodiments 1-19, wherein the transmembrane domain comprises or is a CD28 transmembrane domain, a CD27 transmembrane domain, a CD4 transmembrane domain, a CD8 transmembrane domain, or any combination thereof.
- Embodiment 21 The fusion protein of any one of embodiments 1-20, wherein the extracellular domain comprises a CH1, a CH2, a CH3, a CL, a CD8 extracellular domain, a CD28 extracellular domain, a CD4 extracellular domain, an IgG hinge, a glycine-serine linker comprising from about one to about ten repeats of Gly x Ser y (SEQ ID NO: 108), a linker having an amino acid sequence as set forth in any one of SEQ ID NOs.: 103-107, 109, or 110, or a functional variant or portion thereof, or a combination thereof.
- Embodiment 22 The fusion protein of any one of embodiments 1-21, wherein the extracellular domain comprises a linker disposed between the binding domain and the transmembrane domain.
- Embodiment 23 The fusion protein of embodiment 22, wherein the linker comprises a hinge region or a portion thereof.
- Embodiment 24 The fusion protein of any one of embodiments 1-23, wherein the binding domain comprises or consists of a scFv, a Fab, a scTCR, or a ligand.
- Embodiment 25 The fusion protein of embodiment 23, wherein the binding domain comprises a scFv.
- Embodiment 26 The fusion protein of any one of embodiments 1-25, wherein the binding domain is chimeric, human, or humanized.
- Embodiment 27 The fusion protein of any one of embodiments 1-26, wherein the binding domain specifically binds to an antigen that is expressed by or is associated with a cancer.
- Embodiment 28 The fusion protein of embodiment 27, wherein the cancer comprises a solid tumor.
- Embodiment 29 The fusion protein of any one of embodiments 1-28, wherein the antigen is selected from a ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7, Her2, Ll-CAM, Lewis A, Lewis Y, MUC1, MUC16, PSCA, PSMA, CD 19, CD20, CD22, CD56, CD23, CD24, CD30, CD33, CD37, CD44v7/8, CD38, CD56, CD123, CA125, c-MET, FcRH5, WT1, folate receptor a, VEGF-a, VEGFR1, VEGFR2, IL-l3Ra2, IL-l lRa, MAGE-A1, PSA, ephrin A2, ephrin B2, NKG2D, NY-ESO-l, TAG-72, mesothe
- Embodiment 30 The fusion protein of embodiment 29, wherein the antigen is a ROR1 antigen.
- Embodiment 31 The fusion protein of any one of embodiments 1-30, further comprising a protein tag.
- Embodiment 32 The fusion protein of any one of embodiments 1-31, wherein the fusion protein, when expressed by a host cell, optionally an immune system cell, provides for or promotes:
- improved cell signaling and/or activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased and/or sustained cytokine production and/or release, and/or phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as LAT, PLC-g I , SLP-76, or any combination thereof;
- improved cell activity in response to antigen relative to a host cell expressing a reference fusion protein wherein improved cell signaling optionally comprises increased mobilization of intracellular calcium , killing activity, proliferation, earlier activation in response to antigen, or any combination thereof;
- Embodiment 33 The fusion protein of embodiment 32, wherein the intracellular component comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
- Embodiment 34 The fusion protein of embodiment 32 or 33, wherein the reference protein comprises an intracellular domain comprising a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
- Embodiment 35 The fusion protein of any one of embodiments 32-34, wherein the fusion protein and the reference protein each comprise an endodomain or effector domain from OI)3z or a functional portion or variant thereof.
- Embodiment 36 The fusion protein of any one of embodiments 32-35, wherein the host cell expressing the fusion protein and the host cell expressing the reference fusion protein are each a T cell, optionally a CD8+ T cell.
- Embodiment 37 An isolated polynucleotide, encoding the fusion protein of any one of embodiments 1-36.
- Embodiment 38 The isolated polynucleotide of embodiment 37, further comprising a polynucleotide encoding a transduction marker.
- Embodiment 39 The isolated polynucleotide of embodiment 38, wherein the encoded transduction marker comprises EGFRt, CDl9t, CD34t, or NGFRt.
- Embodiment 40 The isolated polynucleotide of any one of embodiments 38 or 39, further comprising a polynucleotide encoding a self-cleaving polypeptide.
- Embodiment 41 The isolated polynucleotide of embodiment 40, wherein the fusion protein-encoding polynucleotide is separated from the transduction marker encoding polynucleotide by the polynucleotide encoding a self-cleaving polypeptide.
- Embodiment 42 The isolated polynucleotide of embodiment 40 or 41, wherein the encoded self-cleaving polypeptide comprises a P2A, an F2A, a T2A, an E2A, or a variant thereof.
- Embodiment 43 The isolated polynucleotide of any one of embodiments 37-42, wherein the polynucleotide is codon optimized for expression in a host cell.
- Embodiment 44 The isolated polynucleotide of any one of embodiments 37-43, wherein the polynucleotide comprises a polynucleotide having at least 70% identity to the nucleotide sequence set forth in any one of SEQ ID NOs.:34-46.
- Embodiment 45 An expression vector, comprising the isolated
- polynucleotide of any one of embodiments 37-44 operably linked to an expression control sequence operably linked to an expression control sequence.
- Embodiment 46 The expression vector of embodiment 45, wherein the vector is capable of delivering the polynucleotide to a host cell.
- Embodiment 47 The expression vector of embodiment 46, wherein the host cell is a hematopoietic progenitor cell or a human immune system cell.
- Embodiment 48 The expression vector of embodiment 47, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
- Embodiment 49 The expression vector of embodiment 47 or 48, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
- Embodiment 50 The expression vector of any one of embodiments 45-49, wherein the vector is a viral vector.
- Embodiment 51 The expression vector of embodiment 50, wherein the viral vector is a lentiviral vector or a g-retroviral vector.
- Embodiment 52 A host cell, comprising the polynucleotide of any one of embodiments 37-44.
- Embodiment 53. A host cell, expressing at its cell surface the fusion protein of any one of embodiments 1-36.
- Embodiment 54 The host cell of embodiment 53, further expressing a transduction marker at its cell surface.
- Embodiment 55 The host cell of any one of embodiments 52-54, wherein the host cell is a hematopoietic progenitor cell or a human immune system cell.
- Embodiment 56 The host cell of embodiment 55, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
- Embodiment 57 The host cell of embodiment 55 or 56, wherein the host cell comprises a T cell.
- Embodiment 58 The host cell of embodiment 56 or 57, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
- Embodiment 59 The host cell of any one of embodiments 52-58, comprising a chromosomal gene knockout or a mutation of a PD-l gene; a LAG3 gene; a TIM3 gene; a CTLA4 gene; an HLA component gene; a TCR component gene, or any combination thereof.
- Embodiment 60 A composition, comprising a fusion protein of any one of embodiments 1-36 and a pharmaceutically acceptable carrier, excipient, or diluent.
- Embodiment 61 A composition, comprising a host cell of any one of embodiments 52-59, and a pharmaceutically acceptable carrier, excipient, or diluent.
- Embodiment 62 A unit dose, comprising an effective amount of the host cell of any one of embodiments 52-59, or of the host cell composition of embodiment 61.
- Embodiment 63 The unit dose of embodiment 62, comprising (i) a composition comprising at least about 30% CD4+ T host cells, combined with (ii) a composition comprising at least about 30% CD8+ T host cells, in about a 1 : 1 ratio.
- Embodiment 64 A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of the host cell of any one of embodiments 52-59, the composition of embodiment 60 or 61, or the unit dose of embodiment 62 or 63, wherein the disease or condition is characterized by the presence of the antigen.
- Embodiment 65 A method of eliciting an immune response against an antigen that is specifically bound by the fusion protein of any one of embodiments 1-36, the method comprising administering to a subject comprising or expressing the antigen an effective amount of the host cell of any one of embodiments 52-59, the composition of embodiment 60 or 61, or the unit dose of embodiment 62 or 63.
- Embodiment 66 The method of embodiment 64, wherein the disease or condition comprises a hyperproliferative disease or a proliferative disease.
- Embodiment 67 The method of embodiment 64 or 66, wherein the disease or condition is a cancer.
- Embodiment 68 The method of embodiment 67, wherein the cancer comprises a carcinoma, a sarcoma, a glioma, a lymphoma, a leukemia, a myeloma, or any combination thereof.
- Embodiment 69 The method of embodiment 67 or 68, wherein the cancer comprises a cancer of the head or neck, melanoma, pancreatic cancer,
- cholangiocarcinoma hepatocellular cancer
- breast cancer including triple-negative breast cancer (TNBC)
- gastric cancer non-small-cell lung cancer
- prostate cancer esophageal cancer
- mesothelioma small-cell lung cancer
- colorectal cancer colorectal cancer
- glioblastoma or any combination thereof.
- Embodiment 70 The method of any one of embodiments 67-69, wherein the cancer comprises Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, PNET, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans (DFSP), desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal
- DFSP dermatofibrosarcoma protuberans
- osteosarcoma osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST),
- hemangiopericytoma hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, linitis plastic, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, renal cell carcinoma, Grawitz tumor, ependymoma, astrocytoma, oligodendroglioma, brainstem glioma, optice nerve glioma, a mixed glioma, Hodgkin’s
- lymphoplasmacytic lymphoma splenic marginal zone lymphoma, extra-nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, adult T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, enteropathy-associated T-cell lymphoma,
- hepatosplenic T-cell lymphoma blastic NK cell lymphoma, Sezary syndrome, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, or any combination thereof.
- Embodiment 71 The method of any one of embodiments 67-70, wherein the cancer comprises a solid tumor.
- Embodiment 72 The method of embodiment 71, wherein the solid tumor is a sarcoma or a carcinoma.
- Embodiment 73 The method of embodiment 72, wherein the solid tumor is selected from: chondrosarcoma; fibrosarcoma (fibroblastic sarcoma);
- DFSP Dermatofibrosarcoma protuberans
- osteosarcoma rhabdomyosarcoma
- Ewing sarcoma
- a gastrointestinal stromal tumor Leiomyosarcoma
- angiosarcoma vascular sarcoma
- Kaposi s sarcoma
- liposarcoma pleomorphic sarcoma
- synovial sarcoma Dermatofibrosarcoma protuberans
- Embodiment 74 The method of embodiment 72 or 73, wherein the solid tumor is selected from a lung carcinoma (e.g ., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular carcinoma in situ (non-invasive), Invasive Ductal Carcinoma, Invasive lobular carcinoma, Non-invasive Carcinoma); a liver carcinoma (e.g ., Hepatocellular
- a lung carcinoma e.g ., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma
- Carcinoma Cholangiocarcinomas or Bile Duct Cancer); Large-cell undifferentiated carcinoma, Bronchioalveolar carcinoma); an ovarian carcinoma (e.g., Surface epithelial-stromal tumor (Adenocarcinoma) or ovarian epithelial carcinoma (which includes serous tumor, endometrioid tumor and mucinous cystadenocarcinoma), Epidermoid (Squamous cell carcinoma), Embryonal carcinoma and choriocarcinoma (germ cell tumors)); a kidney carcinoma (e.g., Renal adenocarcinoma, hypernephroma, Transitional cell carcinoma (renal pelvis), Squamous cell carcinoma, Bellini duct carcinoma, Clear cell adenocarcinoma, Transitional cell carcinoma, Carcinoid tumor of the renal pelvis); an adrenal carcinoma (e.g., Adrenocortical carcinoma), a carcinoma of the testis (e.g., Germ cell carcinoma (Seminom
- Adenocarcinoma an intestinal carcinoma (e.g., Adenocarcinoma of the duodenum); a colorectal carcinoma; or a skin carcinoma (e.g., Basal cell carcinoma, Squamous cell carcinoma).
- Embodiment 75 The method of embodiment 72 or 73, wherein the solid tumor is an ovarian carcinoma, an ovarian epithelial carcinoma, a cervical
- adenocarcinoma or small cell carcinoma a pancreatic carcinoma, a colorectal carcinoma (e.g., an adenocarcinoma or squamous cell carcinoma), a lung carcinoma, a breast ductal carcinoma, or an adenocarcinoma of the prostate.
- Embodiment 76 The method of any one of embodiments 64-75, wherein the host cell is an allogeneic cell, a syngeneic cell, or an autologous cell.
- Embodiment 77 The method of any one of embodiments 64-76, wherein the method comprises administering a plurality of unit doses to the subject.
- Embodiment 78 The method of embodiment 77, wherein the plurality of unit doses are administered at intervals between administrations of about two, three, four, five, six, seven, eight, or more weeks.
- Embodiment 79 The method according to any one of embodiments 64-78, wherein the unit dose comprises about 10 5 cells/m 2 to about 10 11 cells/m 2 .
- Embodiment 80 The method of any one of embodiments 57-79, wherein the subject is receiving, has received, or will receive one or more of:
- Embodiment 81 ETse of the polynucleotide of any one of embodiments 37- 44, or the expression vector of any one of embodiments 45-51, the host cell of any one of embodiments 52-59, or the composition of any one of embodiments 60 or 61, in the manufacture of a medicament for the treatment of a disease; e.g ., a disease
- Embodiment 82 ETse of the polynucleotide of any one of embodiments 37- 44, or the expression vector of any one of embodiments 45-51, the host cell of any one of embodiments 52-59, or the composition of any one of embodiments 60 or 61, in the treatment of a disease; e.g. , a disease characterized by or associated with expression of an antigen that is specifically bound by the fusion protein of any one of embodiments 1-
- Embodiment 83 The use according to embodiment 81 or 82, wherein the disease is a cancer.
- a fusion protein comprising:
- an Intracellular Tyrosine-based Activation Motif (i) from CD3e, or a functional portion or variant thereof;
- the extracellular domain does not comprise a TCR ectodomain
- the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
- a fusion protein comprising:
- an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises:
- an Intracellular Tyrosine-based Activation Motif (i) from CD3e, or a functional portion or variant thereof;
- Embodiment 86 The fusion protein of embodiment 84 or 85, wherein the intracellular component comprises an ITAM from CD3e and a PRS from CD3e, and further comprises an endodomain or effector domain from E03z or functional portion or variant thereof.
- Embodiment 87 The fusion protein of embodiment 86, wherein the ITAM from CD3e comprises or consists of the amino acid sequence set forth in SEQ ID NO:6.
- Embodiment 88. The fusion protein of embodiment 86 or 87, wherein the PRS from CD3e comprises or consists of the amino acid sequence set forth in SEQ ID NO:7 or 8.
- Embodiment 89 The fusion protein of any one of embodiments 85-88, wherein the intracellular component further comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
- Embodiment 90 The fusion protein of embodiment 89, wherein the intracellular component comprises or consists of any amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to the amino acid sequence set forth in any one of SEQ ID NOs:6-8, 24, 25, or 27-32.
- Embodiment 91 An isolated polynucleotide encoding the fusion protein of any one of embodiments 85-90.
- Embodiment 92 A host cell, comprising the polynucleotide of embodiment 91, wherein the host cell is optionally an immune system cell, further optionally a T cell.
- CD 19-specific CAR T cells are FDA-approved therapy for individuals with relapsed or refractory B cell malignancies. Generally, greater than 70% of acute lymphocytic leukemia patients who are treated with CAR T cells achieve a complete response (Majzner & Mackall, Cancer Discov. 5: 1219-1226 (2018)). However, a significant proportion relapse with leukemia blasts expressing little to no detectable CD19 (see, e.g. , Turtle el ah, Sci. Transl. Med. 5:355ral 16 (2016); Park et ah, N. Engl. J. Med. 378: 449-459 (2016); Maude et al, N. Engl.
- TCRs can detect peptide antigens presented by MHC molecules with high sensitivity. It has been reported that as few as one to ten agonist pMHC complexes in a sea of thousands of self-pMHC can trigger T cell activation through the TCR (e.g, Sykulev et al., Immunity 7:565-571 (1996); Huang et al. , Immunity 39:846-857 (2013)). In contrast, it has been reported that CARs require at least 200 molecules of antigen on the target cell to initiate CAR T cell cytotoxicity and thousands of molecules to elicit full effector function (e.g., Watanabe et al, J. Immunol. 797:911-920 (2015); Walker et al., Mol. Ther. 25:2189-2201 (2017); Fried an et al, Hum. Gene Ther. 29:585-601 (2016)). Whether these requirements for increased antigen density apply to all CARs or can be improved upon is an open question.
- TCRs are thought to form complexes with multiple CD3 proteins following binding to
- CARs generally contain only a O ⁇ 3z signaling endodomain in a single molecule comprising a binding domain, a transmembrane domain, and a costimulatory domain from CD28, 4- 1BB, or ICOS.
- variation in the stoichiometric ratios of signaling molecules or the absence of certain signaling components at the immunological synapse may alter antigen sensitivity and signal intensity. Indeed, initial images of CAR immunological synapses were distinct from those formed by TCRs (see James & Vale, Nature 757:64-69 (2012)).
- Bi-specific T cells were engineered that endogenously express an EBV- specific TCR and were transduced to express a RORl-specific CAR ( Figure 1 A).
- Bi-specific T cells offer the advantages of: 1) comparing TCR and CAR function in one cell population with a single culture history and phenotype, and 2) utilizing the endogenous TCR, which negates potential effects of reduced TCR expression or TCRa and TCRP chain mispairing after transduction of an engineered TCR.
- CD8 + CD45RO + memory T cells from HLA-B8 + EBV seropositive donors were stimulated with autologous irradiated and EBV peptide-pulsed peripheral blood mononuclear cells. Dividing cells were then transduced with a lentiviral vector encoding a RORl-specific E028/E ⁇ 3z CAR. Bi-specific T cells that bound to an HLA-B8/EBV-RAK tetramer and expressed the CAR transduction marker, tCDl9, were purified by fluorescence-activated cell sorting (FACS) and expanded ( Figure 1B).
- FACS fluorescence-activated cell sorting
- EBV/ROR1 bi-specific T cells with tumor cells expressing TCR or CAR antigens was an attractive strategy to initiate phosphoprotein signaling, but antigen-presenting cells contaminated the cellular lysate and were not amenable for MS analysis (data not shown). Therefore, microbeads coated with recombinant single chain timers (SCT) of EBV RAKFKQLL peptide, HLA-B8, and b2 microglobulin, or recombinant ROR1 ectodomain were formulated and used to initiate cell signaling ( Figure 1C) (see Yu et al. , ./. Immunol. 168:3145-3149 (2002)).
- SCT single chain timers
- SCT or ROR1 beads activated T cell signaling and the amount of protein coated on the beads was titrated down (Figure 1D), as was as the bead to cell ratio (Figure 1E) to levels that reduced reagent costs while still saturating P0 4 of the CAR, TCR, and PLC-gE
- a CD28 mAh was also added to SCT beads so that TCR bead-based stimulation delivered 'signal G and 'signal 2' and would be functionally equivalent to E ⁇ 28L2 ⁇ 3z CAR stimulation.
- SCT/CD28 beads increased PLC-yl Tyr 783 P0 4 and T cell proliferation after stimulation compared to SCT beads ( Figures 1F, 1G).
- T cell effector functions and signaling profiles initiated by beads or cells were compared. Expanded bi-specific T cells were incubated with either SCT/CD28 or ROR1 microbeads, or K562 cells expressing HLA- B8 alongside endogenously processed EBV peptides or full-length human ROR1. TCR stimulation using either SCT/CD28 beads or K562/B8/EBV cells elicited greater cell division than CAR stimulation using either ROR1 beads or K562/B8/ROR1 cells ( Figure 1H).
- Fluorescence microscopy using the Ca 2+ -sensitive dye Fluo-4 AM was also used to measure Ca 2+ flux after antigen engagement and provide an index of the relative antigen sensitivity of the TCR and CAR.
- Recombinant SCT and ROR1 ectodomain were biotinylated and coated onto a supported lipid bilayer via biotin/streptavidin linkage.
- the responses of hundreds of individual T cells to TCR or CAR stimulation were compared using the fraction of cells exhibiting high intracellular calcium as a metric of the response amplitude.
- antigen density was modulated by incorporating a small mole fraction ( ⁇ l%) of biotinylated PE into the supported bilayer, followed by sequential labeling with excess concentrations of streptavidin and biotinylated SCT or ROR1.
- a greater fraction of bi- specific T cells was triggered by TCR stimulation than by CAR stimulation ( Figure 1N).
- the TCR response appeared nearly saturated because similar frequencies of T cells responded over time.
- the fraction of triggered T cells diminished as R0R1 density was reduced. Because TCR and CAR triggering were quantified at identical SCT and R0R1 densities, these results demonstrated that TCRs possessed increased antigen sensitivity as compared to a 0028/003z CAR.
- MS identifies common protein phosphorylation events after TCR or CAR stimulation.
- EBV/ROR1 bi-specific T cells were incubated with SCT/CD28, ROR1, or uncoated (control) magnetic beads for 10, 45, or 90 minutes prior to cell lysis ( Figure 2A).
- Bi-specific T cells generated from two different donors were used in two experiments; a third experiment utilized bi-specific T cells independently derived from one of the two donors.
- Phosphorylation events mediated by TCRs and CARs differ in kinetics and magnitude Statistical analysis (limma in the R statistical computing framework) was performed to identify PO4 sites that were up- or down-modulated by TCR or CAR stimulation.
- a PO4 site was determined to be CAR stimulation-responsive if it was detected in at least two of the three experiments, displayed an average
- FDR false discovery rate
- TCR stimulation induced greater fold changes in protein PO4 at the 10 minute time point compared to CAR stimulation. These differences became less apparent after 45 and 90 minutes of stimulation ( Figures 2G and 2H, respectively).
- Network analysis of stimulation-responsive P0 4 sites revealed that both TCR and CAR stimulation altered the P0 4 of proteins in the KEGG T cell receptor signaling, RNA transport, and actin cytoskeleton regulatory pathways (data not shown).
- E03z and CD28 proteins in bi-specific T cells are encoded by both the endogenous genes and the CAR transgene, and LC-MS/MS cannot differentiate identical peptides in trypsin digested lysates that are derived from distinct sources.
- CAR protein is larger than endogenous E03z
- Western blot analysis was performed on analyzed undigested whole cell lysates.
- CD3e and CD3y remained more intensely phosphorylated by TCR and CAR stimulation, and preferential PO4 of TAGAP, SOS1, STAT3, STAT5A/B, and NR4A1 was detected after TCR, but not CAR, stimulation.
- Plotting individual sites across time further demonstrated that signaling adaptors known to be critical for TCR signaling were less intensely phosphorylated by CAR stimulation than TCR stimulation ( Figures 3E-3H). These differences were consistent with the weaker SLP-76 and PLC- g ⁇ P0 4 measured after CAR stimulation by Western blot ( Figure 2M), and indicated that CARs may not recapitulate all TCR-induced signaling events.
- CD 3e sequences improve CAR T cell recognition o/RORP 0 tumor cells
- the relatively weaker PO4 of key TCR signaling adaptors after CAR stimulation may be responsible for increased antigen density requirements.
- additional IT AMs and/or protein recruitment domains were considered for inclusion in the CAR backbone.
- the CD3e endodomain was chosen for incorporation into an existing 4- 1 BBL2 ⁇ 3z CAR backbone because cross-linking endogenous CD3e is sufficient for T cell activation and 4-1BBL3 ⁇ 3z CAR signaling appears less likely to promote T cell exhaustion in vivo than E028L/S)3z CAR signaling (Salter et ah, Sci. Signal. 11 :eaat6753 (2016);
- the CD3e endodomain includes three known signaling motifs.
- a basic residue-rich sequence (BRS) lies adjacent the membrane at the N-terminal portion of the endodomain and is known to bind Lck (see Li et l., PNAS U.S.A. 774:E589l-5899 (2017)).
- a proline-rich sequence (PRS) resides further within the endodomain, and may enhance TCR sensitivity to certain antigens by interacting with Nckl (see Tailor et al, J. Immunol. 757:243-255 (2008); Mingueneau et al, Nat. Immunol.
- CD3e endodomain was placed either before or after the OI)3z domain in CDl9-specific or RORl-specific 4-1BB/OI)3z CARs ( Figure 4A). T cells expressing these constructs were examined to determine whether the CAR could augment recognition of low-density antigens.
- CARs contained an STII sequence to allow measurement of cell surface expression.
- the addition of full-length CD3s either before or after CD3z resulted in lower CAR surface expression, however the CAR containing only the CD3s PRS and ITAM domains was expressed at similar levels to a 4-1BB/OI)3z CAR on the cell surface ( Figures 4B and 4C).
- CD 19-specific CARs including the full length endodomain of CD3e or the PRS ITAM domain of CD3e efficiently activated T cells after STII microbead crosslinking, although placing the entire CD3e endodomain between the 4-1BB and CD3z domains surprisingly led to relatively weaker SLP-76 Ser 376 and PLC-g! Tyr 783 P0 4 after stimulation (Figure 4D).
- CDl9-specific CD3e CAR T cell variants were then co-cultured with K562/CD19 cells that were previously sorted for high or lower CD 19 expression ( Figure 4E). The addition of all or a signaling portion of the CD3e endodomain did not enhance CAR T cell cytokine production at either antigen density ( Figures 4F and 4G).
- 4- lBB/CD3cPRS_FrAMAiTl ⁇ CAR T cells proliferated to a greater extent upon co- culture with RORl int MDA-MB-231 and ROR1 10 NCI-H358 cells ( Figures 4J and 4K).
- Antigen sensitivity of the highly expressed 4-1BBL2O3erk5_itAM/O03z was compared to a conventional 4-1BB/O ⁇ 3z CAR. Fluorescence microscopy
- CD3e sequences enhance CAR antitumor function in antigen 1 TM settings
- 4-1 BB/CD3CPRS p ⁇ M ⁇ Oz CAR T cells displayed improved in vivo antitumor function in a xenograft tumor model of RORl mt MDA-MB-23 l breast adenocarcinoma ( Figure 4M, Figure 5).
- 4- 1 BB/CD3CPRS p-AM ⁇ 03z CAR T cells better controlled tumor at both early and late time points compared to 4-1 BBL7 ⁇ 3z CAR T cells ( Figures 4M, 4N (left)).
- the improved tumor control occurred despite similar intratumor CAR T cell frequencies that did not meet statistical significance (Figure 4N (right)).
- novel CARs informed by the results comparing signaling with TCRs, more efficiently convert CAR GOS z P0 4 into downstream PO4 of signaling intermediates.
- O ⁇ 28/O ⁇ 3z CAR T cells are less effective than 4-1BB/O ⁇ 3z CAR T cells at low doses for treating lymphoma and leukemia xenografts in NSG mice due to the rapid development of O ⁇ 28/O ⁇ 3z CAR T cell exhaustion (see Salter el al. (supra), Cherkassky el al. (supra), Feucht el al, Nat. Med. 545: 423 (2016)).
- CD4 + and CD8 + T cells were isolated using the EasySep Human CD4 + and CD8 + T Cell Isolation Kits (StemCell Technologies). For the three shotgun mass spectrometry experiments, CD8+CD45RO+ T cells were enriched by EasySep Human Memory CD8+ T Cell Enrichment Kit (StemCell Technologies). Isolations were performed in accordance with manufacturer’s instructions.
- LentiX cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum, lmM L-glutamine (Gibco), 25mM HEPES (Gibco), and lOOU/mL penicillin/streptomycin (Gibco).
- K562 CL-243
- NCI-H358 CL-5807
- MDA-MB-231 HMB-26
- Raji CL-86 cells were obtained from American Type Culture Collection and cultured in RPMI-1640 (Gibco) supplemented with 5% fetal bovine serum, lmM L-glutamine, 25mM HEPES, and lOOU/mL
- K562/CD19 and K562/ROR1 cells The generation of K562/CD19 and K562/ROR1 cells was previously described (Salter:20l8ft).
- Primary human T cells were cultured in CTL medium consisting of RPMI-1640 supplemented with 10% human serum, 2mM L- glutamine, 25mM HEPES, lOOU/mL penicillin/streptomycin, 50mM b-mercaptoethanol (Sigma), and 50 U/mL IL-2 (Prometheus). All cells were cultured at 37°C and 5% C02, and tested bi-monthly for the absence of mycoplasma using MycoAlert
- CARs chimeric antigen receptors
- CDl9-specific and RORl-specific 4-lBB/CD3C and CD28/CD3C CAR constructs with an R12 scFv and IgG4 hinge have been previously described
- CD3e CARs were constructed by inserting a single Strep-tag II sequence and two G4S linkers between the FMC63 or R12 single chain variable fragment and IgG4 hinge (Liu:20l6hy). These were linked to the 27- amino acid transmembrane domain of human CD28 (UniProt: P 10747), a signaling module comprising the 42 amino acid cytoplasmic domain of human 4-1BB (UniProt: Q07011), and the 1 l2-amino acid cytoplasmic domain of isoform 3 of human O03z (UniProt: P20963-3).
- CD3e endodomain (UniProt: P07766) or a truncated endodomain (amino acids 179-207) containing PRS and IT AM components was inserted either immediately before or after the O03z endodomain.
- All CAR constructs were linked by T2A sequence to a truncated CD 19 (CDl9t) or epidermal growth factor receptor (EGFRt), codon-optimized, and cloned into a HIV7 lentiviral vector. All cloning was performed by PCR, enzyme digest, and/or Gibson assembly. Plasmids were verified by capillary sequencing and restriction digest.
- Lentivirus was generated by transient transfection of LentiX cells using psPAX2, pMD2.G, and a CAR encoding lentiviral vector.
- Primary human T cells were activated and transduced as described in Salter et al. ⁇ supra).
- K562 cells expressing HLA-B8 LentiX cells were transiently transfected with psPAX2, pMD2.G, and a HIV7 lentiviral vector encoding HLA-B8.
- LentiX cells were transiently transfected with MLV g/p, 10A1, and a mp7l retroviral vector encoding GFP and an EBV peptide minigene, or human ROR1.
- the mp7l retroviral vector was a gift of Dr. Wolfgang Uckert, Max Delbruck Center for Molecular Medicine.
- Raji/ffluc cells LentiX cells were transiently transfected with psPAX2, pMD2.G, and an HIV7 lentiviral vector encoding GFP and firefly luciferase.
- FACS-sorted CD8+tetramer+CDl9t+ or CD8+EGFRt+ cells were expanded over a single stimulation cycle prior to MS and/or functional analyses.
- Bi-specific and ROR1 -specific CAR T cells were expanded using a rapid expansion protocol containing purified OKT3, irradiated LCL, and irradiated PBMC, and assayed 11 days after stimulation.
- CDl9-specific CAR T cells were expanded by co-culture with irradiated CD19+ lymphoblastoid cell lines (LCL) in a 1 :7 (T celfLCL) ratio and assayed 8 days after stimulation. During expansion, cultures were fed with fresh CTL media containing 50 IU/mL IL-2 every 2-3 days.
- T cells were stained with a 1 : 100 dilution of fluorophore-conjugated monoclonal antibodies specific for human CD4 (RPA-T4), CD8 (SK1), CD 19 (HIB19), CD28 (CD28.2), CD45 (HI30), CD45RO (UCHL1), CD62L (DREG56) or CD279 (eBioJl05) purchased from BD Biosciences, ThermoFisher, or Biolegend. T cells were also stained with isotype control fluorophore-conjugated antibodies when appropriate.
- Cetuximab anti-EGFR, Bristol Myers Squibb was biotinylated using the EZ-Link Sulfo-NHS-Biotin kit (ThermoFisher) followed by cleanup with a Zeba Spin Desalting Column (ThermoFisher) and used to stain T cells in conjunction with Streptavidin-APC (ThermoFisher).
- DNA content staining was performed by fixing T cells with 70% ice- cold ethanol, permeabilizing cells with 1% Triton-X (Sigma), degrading RNA with l00Dg/mL RNAse A (ThermoFisher), and staining DNA with 20pg/mL Propidium Iodide (ThermoFisher). All data was collected on a FACSCanto II or FACSAria II (BD Biosciences).
- SCT single chain turner
- human RORl Recombinant single chain turner
- PBS+P/S penicillin/streptomycin
- SCT and RORl microbeads were prepared by resuspending beads in lmL PBS+P/S and then slowly adding recombinant protein while vortexing the solution. Protein was added at the indicated molar ratios according to manufacturer’s predetermined molar binding capacities.
- SCT/CD28 microbeads were prepared by resuspending beads in lmL PBS+P/S and then slowly adding recombinant SCT protein and biotinylated CD28 mAb (CD28.2, ThermoFisher) at a 3 : 1 molar ratio.
- STII microbeads were prepared by resuspending beads in lmL PBS+P/S and then slowly adding l6.67pg anti-STII biotin mAb (GenScript) while vortexing the bead solution.
- microbeads were incubated overnight at 4°C on a 3D orbital shaker, washed three times with excess PBS+P/S using a benchtop magnet, and resuspended in 4mL PBS+P/S for STII microbeads or lmL PBS+P/S for control, SCT, SCT/CD28 and ROR1 beads.
- lmL Streptavidin-Coated Magnetic Particles was washed once using a benchtop magnet and the bead pellet was resuspended in lmL PBS+P/S. All beads were stored at 4°C.
- CAR T cells were washed and resuspended in warm CTL medium. T cells were brought to a concentration of 2xl0 7 cells per mL and incubated with control, SCT, SCT/CD28, ROR1, or STII microbeads in a 37°C water bath. After the allotted time, cells were quickly washed twice using ice-cold PBS, then lysed in a 6M Urea, 25mM Tris (pH 8.0), lmM EDTA, lmM EGTA solution supplemented with protease (Sigma) and phosphatase inhibitors (Sigma) at a 1 : 100 dilution, hereon referred to as lysis buffer. Lysates were sonicated for 15 seconds prior to centrifuging at l0,000xg and 4°C for 10 minutes. Beads were removed during lysate clearing.
- Protein was quantified in lysates by Micro BCA Assay (Therm oFisher), and lysates were diluted to 2mg/mL using lysis buffer. Lysates were reduced in 24mM TCEP (ThermoFisher) for 30 minutes at 37°C with shaking, followed by alkylation with 48mM iodoacetamide (Sigma) in the dark at room temperature for 30 minutes. Lysates were then diluted with 200mM Tris (pH 8.0), to a urea concentration of 2M.
- Lys-C (Wako) was dissolved in 25mM Tris (pH 8.0) at 200ug/mL and added to lysates at 1 : 100 (enzyme: protein) ratio by mass and incubated for 2 hours at 37°C with shaking. Samples were further diluted with 200mM Tris (pH 8.0) to a urea
- TMT labeling (ThermoFisher) desalted peptides were resuspended in 50 mM HEPES at lmg/mL based on starting protein mass. TMT reagents were resuspended in 257pL MeCN and transferred to the peptide sample. Samples were incubated at room temperature for 1 hour with mixing. Labeling reactions were quenched by the addition of 50pL of 5% hydroxyl Amine (Sigma) and incubated for 15 minutes at room temperature with mixing. The independent labeling reactions were then pooled together and lyophilized.
- the labeled peptides were desalted as above and then lyophilized and stored at -80°C.
- Immunoprecipitation of pTyr peptides was performed using the PTMScan P-Tyr-l000 Kit (Cell Signaling).
- the enriched pTyr peptide fraction was purified using a C18 Spin Tip (ThermoFisher), lyophilized, and stored at -80°C until analysis.
- the flow-through fraction was desalted, lyophilized, and stored at -80°C.
- the desalted and pTyr peptide-depleted flow-through was fractionated by high- pH reverse phase (RP) liquid chromatography. 4 mg of the protein digest was loaded onto a LC system consisting of an Agilent 1200 HPLC with mobile phases of 5mM NH4HC03 (pH 10) (A) and 5mM NH4HC03 in 90% MeCN (pH 10) (B).
- the peptides were separated by a 4.6 mm x 250 mm Zorbax Extend-Cl8, 3.5pm, column (Agilent) over 96 minutes at a flow rate of l.OmL/min by the following timetable: hold 0% B for 9 minutes, gradient from 0 to 10% B for 4 minutes, 10 to 28.5% B for 50 minutes, 28.5 to 34% B for 5.5 minutes, 34 to 60% B for 13 minutes, hold at 60% B for 8.5 minutes, 60 to 0% B for 1 minute, re-equilibrate at 0% B for 5 minutes.
- 1 minute fractions were collected from 0-96 minutes by the shortest path by row in a 1 mL deep well plate (ThermoFisher).
- the high pH RP fractions were concatenated into 24 samples by every other plate column starting at minute 15 (e.g ., sample 1 contained fractions from wells B10, D10, F10, etc). The remaining fractions were combined such that fractions from 12 to 14 minutes were added to sample 1, all fractions after 86 minutes were added to sample 24, and all fractions from 0 to 11 minutes were combined into sample‘A’. 95% of every l2th fraction of the 24 samples was combined (1,13; 2,14; ...) to generate 12 more samples, which were dried down and stored at -80°C prior to phosphopeptide enrichment by immobilized metal affinity chromatography.
- Immobilized metal affinity chromatography IMAC
- IMAC enrichment was performed using Ni-NTA-agarose beads (Qiagen) stripped with EDTA and incubated in a lOmM FeCl3 solution to prepare Fe3+-NTA- agarose beads.
- Fractionated lysate was reconstituted in 200pL of 0.1% TFA in 80% MeCN and incubated for 30 minutes with lOOpL of the 5% bead suspension while mixing at room temperature. After incubation, beads were washed 3 times with 300pL of 0.1% TFA in 80% MeCN.
- Phosphorylated peptides were eluted from the beads using 200pL of 70% ACN, 1% Ammonium Hydroxide for 1 minute with agitation at room temperature. Samples were transferred into a fresh tube containing 60pL of 10% FA, dried down and re-suspended in 0.1% FA, 3% MeCN. Samples were frozen at - 80°C until analysis.
- Phosphopeptide-enriched samples were analyzed by LC-MS/MS on an Easy- nLC 1000 (ThermoFisher) coupled to an LTQ-Orbitrap Fusion mass spectrometer (ThermoFisher) operated in positive ion mode.
- the LC system configured in a vented format consisted of a fused-silica nanospray needle (PicoTip emitter, 50pm ID x 20cm, New Objective) packed in-house with ReproSil-Pur C18-AQ, 3pm and a trap
- a spray voltage of 2000 V was applied to the nanospray tip.
- MS/MS analysis occurred over a 3 second cycle time consisting of 1 full scan MS from 350-1500 m/z at resolution 120,000 followed by data dependent MS/MS scans using HCD activation with 27% normalized collision energy of the most abundant ions. Selected ions were dynamically excluded for 45 seconds after a repeat count of 1.
- anti-CD247 (8D3, BD Biosciences), anti-CD247 pTyr 142 (K25-407.69, BD Biosciences), anti-SLP- 76 (polyclonal, Cell Signaling), anti-SLP-76 pSer 376 (D9D6E, Cell Signaling), anti- PLC-yl (D9H10, Cell Signaling), anti-PLC-g 1 pTyr 783 (D6M9S, Cell Signaling), anti mouse horseradish peroxidase (HRP) (polyclonal, Cell Signaling), and anti-rabbit HRP (polyclonal, Cell Signaling).
- Typical antibody dilutions ranged from 1 : 10,000 to 1 :2500.
- CAR T cells were co-cultured with tumor cells at a T cell to tumor cell ratio of 2: 1 or beads at a ratio of 7.5pL beads per lxlO 6 cells. Intracellular cytokine staining was performed by incubating T cells with tumor cells or beads and GolgiStop (BD Biosciences) for 5 hours. Cells were fixed and permeabilized using
- mice Six- to eight- week-old male or female NSG mice were obtained from the Jackson Laboratory or bred in-house. Mice were engrafted via tail vein with 5x 10 5 Raji/ffluc, MDA-MB-23 l/ffluc, or Jeko/ffluc cells and, 7 days later, injected intravenously with a defined product of CAR T cells.
- Raji experiments CD8 + and CD4 + CAR T cells were mixed together in a 1 : 1 ratio.
- MDA-MB-231 and Jeko experiments CD8 + T cells were infused. Bioluminescence imaging was performed as described and mice were followed for survival. Mice handlers were blinded to group allocation. The Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee approved all experimental procedures.
- MaxQuant/ Andromeda search engine version 1.6.0.1 (Cox:2008ir). The search was performed with a tryptic enzyme constraint for up to two missed cleavages. Variable modifications were oxidized methionine, phosphorylated serine, phosphorylated threonine, and phosphorylated tyrosine. Carbamidomethylated cysteine was set as a static modification. Peptide MH+ mass tolerances were set at 20 ppm. The overall FDR was set at ⁇ 1% using a reverse database target decoy approach.
- phosphopeptide site localization was determined by MaxQuant and converted to phosphorylation sites using Perseus version 1.6.0.7 (Tyanova:20l6ds). At this step, reverse hits and potential contaminants were excluded from further analysis. Data normalization was performed by scaling each TMT channel to the channel median, followed by a log2transformation. Stimulation vs. control ratios were calculated by subtracting the appropriate control channels from stimulated channels. Due to incomplete MS sampling, some phosphorylation sites (features) were only found in one or two replicate experiments, and a much smaller minority ( ⁇ 1%) of sites were not found in every TMT channel.
Abstract
The present disclosure provides fusion proteins with improved signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular antigen-binding domain, a transmembrane domain, and an intracellular component comprising one or more domain or motif from a CD3ε, γ, or δ protein, and have improved signaling in response to antigen-binding, including of antigens with reduced, low, or intermediate levels of expression on a target cell, such as a solid tumor cell. Recombinant host cells expressing the fusion proteins are also provided, as well as compositions and methods comprising the same.
Description
CHIMERIC RECEPTOR PROTEINS AND USES THEREOF
STATEMENT OF GOVERNMENT INTEREST
This invention was made with government support under CA136551 and CA114536 awarded by the National Institutes of Health. The government has certain rights in the invention.
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the
specification. The name of the text file containing the Sequence Listing is
360056_465WO_SEQUENCE_LISTING.txt. The text file is 72.4 KB, was created on September 23, 2019, and is being submitted electronically via EFS-Web.
BACKGROUND
Adoptive transfer of genetically modified T cells has emerged as a potent therapy for various malignancies. The most widely employed strategy has been infusion of patient-derived T cells expressing chimeric antigen receptors (CARs) targeting tumor associated antigens. This approach has numerous theoretical advantages, including the ability to target T cells to any cell surface antigen, circumvent loss of major histocompatibility complex as a tumor escape mechanism, and employ a single vector construct to treat any patient, regardless of human leukocyte antigen haplotype. For example, CAR clinical trials for B-cell non-Hodgkin’s lymphoma (NHL) have, to date, targeted CD 19, CD20, or CD22 antigens that are expressed on malignant lymphoid cells as well as on normal B cells (Brentjens et al, Sci Transl Med 20l3;5(l77): l77ra38; Haso et al, Blood 2013; 121(7): 1165-74; James et al., J Immunol 2008;l80(l0):7028-38; Kalos et al., Sci Transl Med 201 l;3(95):95ra73; Kochenderfer et al, J Clin Oncol 20l5;33(6):540-9; Lee et al, Lancet 2015;385(9967):517-28; Porter et al, Sci Transl 25 M¾/20l5;7(303):303ral39; Savoldo et al, J Clin Invest
2011; 121(5): 1822-6; Till et al, Blood2008 \ 12(6):2261-71; Till et al, Blood
2012;119(17):3940-50; Coiffier et al, N Engl J Med 2002;346(4):235-42).
However, adoptive cell therapies are still developing, and new strategies are needed, for example, to improve CAR functionality when targeting antigens in vivo , including in the context of solid tumors. The presently disclosed embodiments address these needs and provide other related advantages.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Figures 1A-1N show design and testing of bi-specific T cells for selective analysis of TCR- and CAR-induced signaling and effector functions in a single-cell- type population. (A) Schematic of bi-specific T cells that express an endogenous EBV- specific T cell receptor (TCR) and were transduced to express a ROR1 -specific chimeric antigen receptor (CAR). (B) Flow cytometry analysis of EBV-tetramer binding and CDl9t expression in expanded T cells. FACS plot shows stained (black) and isotype (grey) CD8+ singlet lymphocytes. (C) Schematic of magnetic beads coated with HLA-B8/EBV-RAK single chain trimer (SCT), ROR1 ectodomain, or SCT and CD28 mAh. (D) Western blot analysis for Oϋ3z, Oϋ3z pTyr142, and PLC-yl pTyr783 in lysates from T cells incubated for 45 minutes with microbeads coated with various molar ratios of SCT or ROR1. 30pL beads were used per million cells. (E) Western blot analysis for Oϋ3z, Oϋ3z pTyr142, and PLC-yl pTyr783 in lysates from T cells incubated for 45 minutes with various amounts SCT or ROR1 microbeads (molar ratio = 0.5). (F) Western blot analysis for Oϋ3z, Oϋ3z pTyr142, and PLC-yl pTyr783 in lysates from T cells incubated for 45 minutes with uncoated (0), SCT, or SCT/CD28 microbeads. 7.5pL beads were used per million cells. (G) Flow cytometry analysis of T cell proliferation as measured by CFSE dye dilution at 72 hours after microbead stimulation. Histogram plot of CD8+ lymphocytes treated with uncoated (dash-dot),
SCT (dashed line) or SCT/CD28 (solid line) microbeads. (H) Flow cytometry analysis of T cell proliferation as measured by CFSE dye dilution at 72 hours after co-culture with: K562/B8 cells or control beads; K562/B8/EBV cells or SCT/CD28 beads; or K562/B8/RORl+ cells or RORl-coated beads. Histogram plots show CD8+
lymphocytes and are representative of 2-3 independent experiments. (I)-(L) Flow cytometry analysis showing IFN-g, IL-2, and TNF-a production 5 hours after co-culture of bi-specific T cells with: K562/B8 cells; K562/B8/EBV cells; K562/B8/ROR1+ cells; control beads; SCT/CD28 beads; or ROR1 -coated beads. (I, K) FACS plots show CD45+ singlet lymphocytes. The frequency of IFN-y+IL-2+TNFa+ cells is shown in (I). Data are means ± standard deviation (SD) of 2-3 independent experiments. The indicated P values were calculated by unpaired two-tailed t test. Cytokine production is quantified in Figures 1 J and 1L. (M) Western blot analysis for CD3 z, Oϋ3z pTyr142, SLP-76 pSer376, and PLC-g I pTyr783 in T cell lysates after stimulation with beads or cells for 45 minutes. (N) Ca2+ mobilization in populations of cells stimulated by ROR1- or SCT-containing bilayers was measured by Fluo-4 AM intensity of individual cell responses for 15 min after exposure to bilayers. Traces represent the fraction of cells above an activation threshold at any given time. Antigen density was modulated by the mole fraction of biotinylated lipids in the supported lipid bilayer - .005% or .01%.
Figures 2A-2M relate to experiments identifying protein phosphorylation events by mass spectrometry (MS) following TCR or CAR stimulation. (A) Schematic of experimental design stimulating bi-specific T cells with microbeads coated with TCR (SCT/CD28) or CAR (ROR1) antigens. (B) Flow cytometry analysis of T cell markers in the three experiments. (C) Venn diagram of the overlap among phosphorylation sites. (D) Histogram of the SD of the fold-change (log2FC) values across all tandem MS/MS experiments. (E) Total number of pSer, pThr and pTyr peptides identified by MS/MS. (F)-(H) Volcano plots of log2FC and false discovery rate (FDR) for phosphorylation sites identified by tandem MS/MS at the indicated timepoints after stimulation. Dots in the upper right portion indicate sites with increased
phosphorylation, and dots in the upper left portion indicate sites with decreased phosphorylation after stimulation in at least two experiments. (I)-(L) Fold change of the indicated P04 sites identified by tandem MS/MS (H03z P04; CD28 P04; ZAP-70 P04; PLC-g I P04). Data are means from 2 or 3 experiments. (M) Western blot analysis for E03z, E03z pTyr142, SLP-76 pSer376, and PLC-g! pTyr783 in bi-specific T cell
lysates at the indicated times after stimulation. Bi-specific T cells expressed a
0028L2ϋ3z CAR (M). Blots are representative of all tandem MS/MS experiments.
Figures 3A-3H provide data from MS/MS experiments showing that CAR stimulation induces less intense P04 of CD3 chains and signaling adaptors as compared to TCR stimulation. (A)-(C) Comparison of the log2FC of P04 sites identified by tandem MS/MS at the indicated timepoints after TCR or CAR stimulation. Dots above and below dashed lines specify sites that possessed mean log2FC values differing by >
1 between TCR- and CAR-stimulated samples in at least 2 tandem MS/MS
experiments. Dots above and below dashed lines specify sites that possessed mean log2FC values differing by > 1 between TCR- and CAR-stimulated samples. (D) Heat map shows mean log2FC values of select genes identified in (A) at the lO-minute time point. Data are means from 2 or 3 experiments. (E)-(H) Mean log2FC of P04 sites identified by tandem MS/MS after TCR or CAR stimulation. Blots are representative of 2 independent experiments. Data are means from all experiments.
Figures 4A-4R show that T cells expressing CARs that incorporate CD3e ITAM and protein recruitment sequences display improved recognition of tumor cells with low antigen density. (A) Schematic of CD3e-containing CAR designs that included (not shown) a CD 19-specific scFv derived from FMC63 or (shown) a ROR1- specific scFv derived from R12 antibody. (B) Western blot analysis for E03z in the indicated CAR T cell lysates. Blots are representative of 2 independent experiments. (C) Flow cytometric analysis of EGFRt and STII (CAR) expression on sort purified and expanded CD8+EGFRt+ T cells. (D) Western blot analysis for PLC-g I pTyr783, SLP-76 pSer376, and CAR and TCR E03z in the indicated CAR T cell lysates following stimulation ("+") or not ("-"). (E) Flow cytometry analysis of CD 19 expression on K562 cells with low ("K562/CD1910") or high ("K562/E019M") expression. FACS plot shows isotype (dash-dot), K562/CD1910 (dashed line), and K562/E019M (solid line) singlets. (F, G) ELISA analysis of cytokine production 24 hours after co-culture of the indicated CD 19-specific CAR T cells and tumor cells having expressing antigen as indicated. Data are means from two independent experiments. (H) Mean + SEM fold- change in cytokine production in cellular supernatant 24 hours after co-culture of CAR T cells with K562/ROR1 tumor cell lines. In (F)-(H), fold change is relative to a
control CAR containing the same scFv as the tested CAR, a 4-1BB costimulatory domain, and a CD3z domain, but not a CD3e domain. N = 4 healthy T cell donors. (I) ELISA analysis of cytokine production by the indicated ROR1 -specific CAR T cells 24 hours after co-culture with tumor cells having medium surface expression of ROR1. Data are means from one experiment. (J), (K) Flow cytometry analysis of CAR T cell proliferation as measured by CFSE dye dilution at 72 hours after co-culture with the indicated tumor cells having medium (MRORlmed NCI-H358") or low ("RORlloMDA- MB-231") surface expression of ROR1. Histogram plots show 4- 1 BB/Eϋ3z (solid line) and 4-lBB/CD3ePRS_ITAMAHI^ (dashed line) CD8+ lymphocytes and are representative of one experiment. (L) Fluo-4 Ca2+ mobilization measurements for cells stimulated on ROR1 -labeled bilayers. (Left) traces represent the fraction of cells with high levels of intracellular Ca2+ across time after exposure to bilayers. Data from 4 independent experiments are accumulated for each trace, and fill represents the SD between experiments. (Right) Fraction of cells responding at 20 min after exposure to bilayer for a range of ROR1 densities, determined by the mol% of biotinylated lipids in the bilayer. Each data point represents 3-4 independent experiments. Error bars are SEM. (M) Mean ± SEM radiance of luciferase-expressing RORllow MDA-MB-231 tumors over time. (N) (left) Mean ± SEM tumor radiance at day 27 post-tumor infection and (right) CAR T cell frequency in tumors at day 20. n = 7 mice per group. (O) Western blot analysis for E03z, E03z pTyr142, LAT pTyr191, SLP-76 pSer376, and
PLC-gI pTyr783 in T cell lysates at after 10 minutes of stimulation. Data are
representative of n = 3 independent experiments. (P) Survival curves of NSG mice that were injected with Raji/ffluc cells and, 7 days following engraftment, received with a single infusion of the indicated CAR T cells. Data were pooled from two independent experiments, with 6 or 10 mice per treatment group. (Q) Survival curves of NSG mice injected with RORlmt Jeko-l cells and administered CD28/CD3^ 4- 1 BB/Eϋ3z, or 4- 1 BB/CD3CPRS P AM/Eϋ3z CAR T cells. N = 8 mice per group. (R) ROR1 expression (solid line) by MDA-MB-231 breast adenocarcinoma and NCI-H358 lung
adenocarcinoma cell lines.
Figure 5 shows characterization of ROR1 expression on various tumor cell lines. Flow cytometry analysis of ROR1 expression on the indicated tumor lines. Histograms show stained (solid line) and isotype (dashed line) singlets.
DETAILED DESCRIPTION
The present disclosure provides chimeric receptor proteins with improved signaling properties and/or activities over existing immunoreceptor proteins ( e.g ., chimeric antigen receptors (CARs), T cell receptors (TCRs), or the like), which improved properties include, in certain embodiments, initiating, generating, propagating, and/or amplifying a signal in a host cell (e.g., an immune cell such as a T cell) expressing the fusion protein when the fusion protein binds to an antigen. In certain embodiments, the antigen bound by the fusion protein is expressed at a low level, or at an intermediate level, or in some embodiments, at a high level, by a target antigen-expressing cell, such as, for example, a cancer cell. Exemplary fusion proteins of this disclosure comprise (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain (e.g, connecting the extracellular component and intracellular component); and (c) an intracellular component comprising an effector domain or a functional portion or variant thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (IT AM) from CD3e, or a functional portion or variant thereof ; (ii) an ITAM from CD3y, or a functional portion or variant thereof; (iii) an ITAM from CD35, or a functional portion or variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or E03z, or a functional portion or variant thereof; or (vi) any combination of (i)-(v).
In certain embodiments, a fusion protein is provided that comprises: (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain; and (c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof (i.e., a functional variant of
the IT AM); (ii) an ITAM from CD3y, or a functional variant thereof; (iii) an IT AM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or 0)3z, or a functional variant thereof; or (vi) any combination of (i)-(v), and does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD3y and/or CD35.
In certain embodiments, an effector domain or a functional portion or variant thereof from a CD3e is not a full-length CD3e and is not an endodomain (also referred to herein as a cytoplasmic domain) from CD3e.
In certain embodiments, an intracellular component of a fusion protein comprises a PRS and an ITAM from CD3e.
In some embodiments, a fusion protein does not comprise a BRS from CD3e, or a functional variant thereof. In other embodiments, the effector domain of the fusion protein comprises a BRS from CD3e, or a functional variant thereof (i.e., of the BRS).
In certain embodiments, the intracellular component further comprises an ITAM from CD3z, or a functional variant thereof (i.e., of the ITAM). In some embodiments, the intracellular component comprises a cytoplasmic domain (also referred to as an endodomain) from a human 003z, or a functional portion or variant thereof.
In certain embodiments, the intracellular component further comprises a costimulatory domain or a functional portion or variant thereof ( e.g ., from 4-1BB).
In some embodiments, the intracellular component comprises a costimulatory domain, an endodomain or effector domain from CD3 z, or a functional portion or variant thereof, and an effector domain from CD3e, or a functional portion or variant thereof. In further embodiments, the effector domain from CD3e (or functional portion or variant of an effector domain from CD3e) is disposed between the costimulatory domain (or functional portion or variant of the costimulatory domain) and the endodomain or effector domain from Oϋ3z (or functional portion or variant of the endodomain or effector domain from 003z). In other embodiments, the endodomain or effector domain from Oϋ3z or functional portion or variant thereof is disposed between the costimulatory domain and the effector domain from CD3e or functional portion or variant thereof.
In certain embodiments, a fusion protein of the present disclosure does not comprise a TCR extracellular domain, preferably does not comprise a TCR ectodomain.
In certain embodiments, a fusion protein of the present disclosure, when expressed by a T cell, does not associate with or form a TCR complex ( e.g ., a TCR complex as described herein, which can include one or more endogenous or
heterologous components).
In certain embodiments, the extracellular component comprises a CH1, a CH2, a CH3, a CL (i.e., from an immunoglobulin), or comprises an amino acid sequence derived therefrom, a CD8 extracellular domain, a CD4 extracellular domain, a CD28 extracellular domain (e.g., amino acids 19-152 of the CD28 amino acid sequence provided in UniProt entry P 10747) or a functional variant or portion thereof, or comprises a combination thereof.
The presently disclosed fusion proteins can be useful in cellular
immunotherapies comprising host cells (e.g, an immune system cell such as, for example, a T cell, NK cell, or NK-T cell, or a hematopoietic progenitor cell) that express the fusion proteins and specifically bind to antigens that are expressed by or are otherwise associated with a disease or condition, such as, for example, a cancer. In certain aspects, a host cell expressing a fusion protein of the instant disclosure has improved (e.g, increased and/or sustained) cell signaling (e.g, cytokine production and/or release (for example, IFN-g, TNFa, IL-2), phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as phosphorylation of LAT, PLC-g I , SLP-76, or any combination thereof) and/or activity (e.g, mobilization of intracellular calcium, killing activity, secretion of a cytokine, proliferation, earlier activation following stimulation, or the like) in response to antigen relative to a host cell expressing a reference fusion protein that does not comprise in an intracellular component a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein. In some embodiments, a host cell expressing a fusion protein of this disclosure has improved (e.g, earlier and/or stronger, relative to a host cell expressing a reference fusion protein) cell signaling and/or activity upon binding to a target antigen that is expressed at a low level or an intermediate level on a target cell
(e.g., solid tumor cell) surface, and/or in certain embodiments, upon binding to a target antigen that is expressed at a high level on a target cell surface.
In certain embodiments, a host cell expressing a fusion protein of the present disclosure is capable, when administered to a subject having a tumor comprising cells that expresses an antigen that is specifically bound or recognized by the fusion protein, of reducing or suppressing growth, area, volume, and/or spread of the tumor, of killing tumor cells, and/or of increasing survival of the subject to a greater degree and/or for a longer period of time as compared to a reference subject administered a cell therapy wherein the cells do not comprise a fusion protein as provided herein (e.g, comprise a reference fusion protein that has a similar structure to the fusion protein of the present disclosure but does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein).
In certain embodiments, a host cell expressing a fusion protein of the present disclosure is capable of greater antitumor activity as compared to a reference host cell expressing a fusion protein that does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein; e.g, host cells expressing a fusion protein of the present disclosure may infiltrate a tumor in a number that is statistically not significantly different as compared to the number of reference host cells infiltrating a reference tumor, but the host cell expressing a fusion protein of the present disclosure has improved antitumor activity (e.g, causes slower growth or stops growth of the tumor, or reduces tumor size, or spread, or the like) versus the reference host cell.
In certain embodiments, a fusion protein of the present disclosure can, following stimulation with antigen, promote (i.e., directly or indirectly) phosphorylation of LAT, SLP-76, and/or PLC-g I more efficiently than a reference fusion protein that does not comprise a sequence or motif from a CD3e, CD3y, and/or CD35 protein, as disclosed herein. By way of illustration, in certain embodiments, a fusion protein of the present disclosure is expressed in a host cell (e.g, an immune cell such as, for example, a T cell) and comprises (i) a sequence or motif from a CD3e, CD3y, and/or CD35 protein and (ii) a Oϋ3z IT AM or endodomain, and binding of the fusion protein to antigen results in decreased phosphorylation of the Oϋ3z ITAM or endodomain as compared to binding of a reference fusion protein comprising a CD3z ITAM or endodomain to
antigen, but results in a similar or increased phosphorylation of a downstream cell signaling protein, such as, for example, LAT, PLC-g I , or both.
In certain embodiments, a host cell ( e.g ., an immune cell such as a T cell) expressing a fusion protein of the present disclosure has improved sensitivity to antigen as compared to a host cell expressing a reference fusion protein that does not contain a sequence or motif from a CD3e, CD3y, and/or CD35 protein, but does not produce more, or does not produce substantially more, of a pro-inflammatory cytokine (e.g., IFN-g, IL-2, TNF-a) as compared to the host cell expressing the reference fusion protein. Without wishing to be bound by theory, marked increases in production of pro- inflammatory cytokines may cause toxicities. Accordingly, presently disclosed fusion proteins and host cells expressing the same have, in certain embodiments, improved sensitivity for antigen (i.e., at a low, intermediate, and/or high level of antigen expression) but do not increase, or do not substantially increase, a risk of an
inflammatory cytokine-associated toxicity.
In certain embodiments, a fusion protein according to the present disclosure comprises a sequence or motif from a CD3e, CD3y, and/or CD35 protein and further comprises a 4-1BB costimulatory domain. In certain embodiments, a reference fusion protein comprises a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein.
Additional definitions are set forth throughout this disclosure.
In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Also, any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, is to be understood to include any integer within the recited range, unless otherwise indicated. As used herein, the term "about" means ± 20% of the indicated range, value, or structure, unless otherwise indicated. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any
combination of the alternatives. As used herein, the terms "include," "have," and "comprise" are used synonymously, which terms and variants thereof are intended to be construed as non-limiting.
"Optional" or "optionally" means that the subsequently described element, component, event, or circumstance may or may not occur, and that the description includes instances in which the element, component, event, or circumstance occurs and instances in which they do not.
In addition, it should be understood that the individual constructs, or groups of constructs, derived from the various combinations of the structures and subunits described herein, are disclosed by the present application to the same extent as if each construct or group of constructs was set forth individually. Thus, selection of particular structures or particular subunits is within the scope of the present disclosure.
The term "consisting essentially of is not equivalent to "comprising" and refers to the specified materials or steps of a claim, or to those that do not materially affect the basic characteristics of a claimed subject matter. For example, a protein domain, region, or module ( e.g ., a binding domain, hinge region, or linker) or a protein (which may have one or more domains, regions, or modules) "consists essentially of a particular amino acid sequence when the amino acid sequence of a domain, region, module, or protein includes extensions, deletions, mutations, or a combination thereof (e.g., amino acids at the amino- or carboxy -terminus or between domains) that, in combination, contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1%) of the length of a domain, region, module, or protein and do not
substantially affect (i.e., do not reduce the activity by more than 50%, such as no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) the activity of the domain(s), region(s), module(s), or protein (e.g, the target binding affinity of a binding protein).
As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g, hydroxyproline, g-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring
amino acid, i.e., an a-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g ., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a naturally occurring amino acid.
As used herein, "mutation" refers to a change in the sequence of a nucleic acid molecule or polypeptide molecule as compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. A mutation can result in several different types of change in sequence, including substitution, insertion or deletion of nucleotide(s) or amino acid(s).
A "conservative substitution" refers to amino acid substitutions that do not significantly affect or alter binding characteristics of a particular protein. Generally, conservative substitutions are ones in which a substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include a substitution found in one of the following groups: Group 1 : Alanine (Ala or A), Glycine (Gly or G), Serine (Ser or S), Threonine (Thr or T); Group 2: Aspartic acid (Asp or D), Glutamic acid (Glu or Z); Group 3 : Asparagine (Asn or N), Glutamine (Gln or Q); Group 4: Arginine (Arg or R), Lysine (Lys or K), Histidine (His or H); Group 5: Isoleucine (Ile or I), Leucine (Leu or L), Methionine (Met or M), Valine (Val or V); and Group 6: Phenylalanine (Phe or F), Tyrosine (Tyr or Y), Tryptophan (Trp or W).
Additionally or alternatively, amino acids can be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g, acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, an aliphatic grouping may include, for purposes of substitution, Gly, Ala, Val, Leu, and Ile. Other conservative substitutions groups include: sulfur-containing: Met and Cysteine (Cys or C); acidic: Asp, Glu, Asn, and Gln; small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gln; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp.
Additional information can be found in Creighton (1984) Proteins. W.H. Freeman and Company. Variant proteins, peptides, polypeptides, and amino acid sequences of the present disclosure can, in certain embodiments, comprise one or more conservative substitutions relative to a reference amino acid sequence.
As used herein, "protein" or "polypeptide" refers to a polymer of amino acid residues. Proteins apply to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid and non-naturally occurring amino acid polymers.
As used herein, "fusion protein" refers to a protein that, in a single chain, has at least two distinct domains or motifs, wherein the domains or motifs are not naturally found together ( e.g ., in the specified arrangement, order, or number, or at all) in a protein. In certain embodiments, a fusion protein comprises at least two distinct domains or motifs that are not naturally found together in a single peptide or polypeptide. A polynucleotide encoding a fusion protein may be constructed using PCR, recombinantly engineered, or the like, or such fusion proteins can be synthesized. A fusion protein may further contain other components, such as a tag, a linker, or a transduction marker. In certain embodiments, a fusion protein expressed or produced by a host cell (e.g., a T cell) locates to the cell surface, where the fusion protein is anchored to the cell membrane (e.g, via a transmembrane domain) and comprises an extracellular portion or component (e.g, containing a binding domain and, in certain embodiments, a linker, a spacer, or both) and an intracellular portion or component (e.g, containing a sequence or motif from a CD3 protein as provided herein).
"Nucleic acid molecule" or "polynucleotide" refers to a polymeric compound including covalently linked nucleotides, which can be made up of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine ring). Purine bases include adenine, guanine, hypoxanthine, and xanthine, and pyrimidine bases include uracil, thymine, and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA), polydeoxyribonucleic acid (DNA), which includes cDNA, genomic DNA, and synthetic DNA, either of which may be single or double-stranded. If single- stranded, the nucleic acid molecule may be the coding strand or non-coding (anti-sense
strand). A nucleic acid molecule encoding an amino acid sequence includes all nucleotide sequences that encode the same amino acid sequence. Some versions of the nucleotide sequences may also include intron(s) to the extent that the intron(s) would be removed through co- or post-transcriptional mechanisms. In other words, different nucleotide sequences may encode the same amino acid sequence as the result of the redundancy or degeneracy of the genetic code, or by splicing.
Variants of nucleic acid molecules of this disclosure are also contemplated. Variant nucleic acid molecules are at least 70%, 75%, 80%, 85%, 90%, and are preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical a nucleic acid molecule of a defined or reference polynucleotide as described herein, or that hybridize to a polynucleotide under stringent hybridization conditions of 0.015M sodium chloride, 0.0015M sodium citrate at about 65-68°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at about 42°C. Nucleic acid molecule variants retain the capacity to encode a fusion protein or a binding domain thereof having a functionality described herein, such as specifically binding a target molecule.
"Percent sequence identity" refers to a relationship between two or more sequences, as determined by comparing the sequences. Preferred methods to determine sequence identity are designed to give the best match between the sequences being compared. For example, the sequences are aligned for optimal comparison purposes e.g ., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment). Further, non-homologous sequences may be disregarded for comparison purposes. The percent sequence identity referenced herein is calculated over the length of the reference sequence, unless indicated otherwise. Methods to determine sequence identity and similarity can be found in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using a BLAST program (e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX). The mathematical algorithm used in the BLAST programs can be found in Altschul et al ., Nucleic Acids Res. 25: 3389-3402, 1997. Within the context of this disclosure, it will be understood that where sequence analysis software is used for analysis, the results of the analysis are based on the "default values" of the program
referenced. "Default values" mean any set of values or parameters which originally load with the software when first initialized.
The term "isolated" means that the material is removed from its original environment ( e.g ., the natural environment if it is naturally occurring). For example, a naturally occurring nucleic acid or polypeptide present in a living animal is not isolated, but the same nucleic acid or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such nucleic acid could be part of a vector and/or such nucleic acid or polypeptide could be part of a composition (e.g., a cell lysate), and still be isolated in that such vector or composition is not part of the natural environment for the nucleic acid or polypeptide. The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region ("leader and trailer") as well as intervening sequences (introns) between individual coding segments (exons).
A "functional variant" refers to a polypeptide or polynucleotide that is structurally similar or substantially structurally similar to a parent or reference compound of this disclosure, but differs, in some contexts slightly, in composition (e.g., one base, atom or functional group is different, added, or removed; or one or more amino acids are mutated, inserted, or deleted), such that the polypeptide or encoded polypeptide is capable of performing at least one function of the encoded parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide. In other words, a functional variant of a polypeptide or encoded polypeptide of this disclosure has "similar binding," "similar affinity" or "similar activity" when the functional variant displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide, such as an assay for measuring binding affinity (e.g, Biacore® or tetramer staining measuring an association (Ka) or a dissociation (KD) constant) or avidity; or an assay measuring phosphorylation or activation of, or by, an immune cell protein such as, for example, Lck, ZAP70, Fyn, PLOy-l, SLP-76, LAT, or the like, including the assays described herein. The ability of a polypeptide or encoded polypeptide of this disclosure (or a functional variant of the same) to initiate, continue, participate in, propagate, or
amplify a cell signaling event or events ( e.g ., T cell signaling in response to antigen binding) may be determined by examining the activity, structure, chemical state (e.g., phosphorylation), or interactions of or between the variant polypeptide and an immune cell protein that directly acts (e.g. , binds to) therewith, or by examining the activity, localization, structure, expression, secretion, chemical state (e.g, phosphorylation), or interactions of or between other biomolecules known or thought to participate in or be affected by the cell signaling event or events. The ability of a polypeptide or encoded polypeptide of this disclosure (or a functional variant of the same) to initiate, continue, participate in, propagate, or amplify a cell signaling event or events may also be determined by using functional assays of host cell activity, including those described herein for measuring the ability of a host cell to release cytokines, proliferate, selectively kill target cells, or treat a subject having a disease or condition expressing or otherwise associated with an antigen bound by a fusion protein of this disclosure.
As used herein, a "functional portion" or "functional fragment" refers to a polypeptide or polynucleotide that comprises only a domain, motif, portion or fragment of a parent or reference compound, and the polypeptide or encoded polypeptide retains at least 50% activity associated with the domain, portion or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% level of activity of the parent polypeptide, or provides a biological benefit (e.g, effector function). A "functional portion" or "functional fragment" of a polypeptide or encoded polypeptide of this disclosure has "similar binding" or "similar activity" when the functional portion or fragment displays no more than a 50% reduction in performance in a selected assay as compared to the parent or reference polypeptide (preferably no more than 20% or 10%, or no more than a log difference as compared to the parent or reference with regard to affinity), such as an assay for measuring binding affinity or measuring effector function (e.g, cytokine release). In certain embodiments, a functional portion refers to a "signaling portion" of an effector molecule, effector domain, costimulatory molecule, or costimulatory domain.
As used herein, "heterologous" or "non-endogenous" or "exogenous" refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a
host cell or a subject, or any gene, protein, compound, nucleic acid molecule, or activity native to a host cell or a subject that has been altered. Heterologous, non-endogenous, or exogenous includes genes, proteins, compounds, or nucleic acid molecules that have been mutated or otherwise altered such that the structure, activity, or both is different as between the native and altered genes, proteins, compounds, or nucleic acid molecules.
In certain embodiments, heterologous, non-endogenous, or exogenous genes, proteins, or nucleic acid molecules ( e.g ., receptors, ligands, etc.) may not be endogenous to a host cell or a subject, but instead nucleic acids encoding such genes, proteins, or nucleic acid molecules may have been added to a host cell by conjugation, transformation, transfection, electroporation, or the like, wherein the added nucleic acid molecule may integrate into a host cell genome or can exist as extra-chromosomal genetic material (e.g., as a plasmid or other self-replicating vector). It will be appreciated that in the case of a host cell that comprises a heterologous polynucleotide, the polynucleotide is "heterologous" to progeny of the host cell, whether or not the progeny were themselves manipulated (e.g, transduced) to contain the polynucleotide.
The term "homologous" or "homolog" refers to a gene, protein, compound, nucleic acid molecule, or activity found in or derived from a host cell, species, or strain. For example, a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure, sequence, expression level, or any combination thereof. A non- endogenous polynucleotide or gene, as well as the encoded polypeptide or activity, may be from the same species, a different species, or a combination thereof.
As used herein, the term "endogenous" or "native" refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or a subject.
The term "expression", as used herein, refers to the process by which a polypeptide is produced based on the encoding sequence of a nucleic acid molecule, such as a gene. The process may include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post- translational modification, or any combination thereof. An expressed nucleic acid
molecule is typically operably linked to an expression control sequence ( e.g ., a promoter).
The term "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Unlinked" means that the associated genetic elements are not closely associated with one another and the function of one does not affect the other.
As used herein, "expression vector" refers to a DNA construct containing a nucleic acid molecule that is operably linked to a suitable control sequence capable of effecting the expression of the nucleic acid molecule in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid," "expression plasmid," "virus" and "vector" are often used interchangeably.
The term "introduced" in the context of inserting a nucleic acid molecule into a cell, means "transfection", or "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell wherein the nucleic acid molecule may be incorporated into the genome of a cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA). As used herein, the term "engineered," "recombinant" or "non-natural" refers to an organism, microorganism, cell, nucleic acid molecule, or vector that includes at least one genetic alteration or has been modified by introduction of an exogenous nucleic acid molecule, wherein such alterations or modifications are introduced by genetic engineering (i.e., human intervention). Genetic alterations include, for example, modifications introducing
expressible nucleic acid molecules encoding proteins, fusion proteins or enzymes, or other nucleic acid molecule additions, deletions, substitutions or other functional disruption of a cell’s genetic material. Additional modifications include, for example, non-coding regulatory regions in which the modifications alter expression of a polynucleotide, gene or operon.
As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as separate nucleic acid molecules, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof. When two or more heterologous nucleic acid molecules are introduced into a host cell, it is understood that the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule ( e.g ., on a single vector), on separate vectors, integrated into the host chromosome at a single site or multiple sites, or any
combination thereof. The number of referenced heterologous nucleic acid molecules or protein activities refers to the number of encoding nucleic acid molecules or the number of protein activities, not the number of separate nucleic acid molecules introduced into a host cell.
The term "construct" refers to any polynucleotide that contains a recombinant nucleic acid molecule. A construct may be present in a vector (e.g., a bacterial vector, a viral vector) or may be integrated into a genome. A "vector" is a nucleic acid molecule that is capable of transporting another nucleic acid molecule. Vectors may be, for example, plasmids, cosmids, viruses, a RNA vector or a linear or circular DNA or RNA molecule that may include chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acid molecules. Vectors of the present disclosure also include transposon systems (e.g, Sleeping Beauty, see, e.g, Geurts et al., Mol. Ther. 5: 108, 2003: Mates el al, Nat. Genet. 41:153, 2009). Exemplary vectors are those capable of autonomous replication (episomal vector), capable of delivering a polynucleotide to a cell genome (e.g, viral vector), or capable of expressing nucleic acid molecules to which they are linked (expression vectors).
As used herein, the term "host" refers to a cell (e.g., T cell) or microorganism targeted for genetic modification with a heterologous nucleic acid molecule to produce
a polypeptide of interest ( e.g ., a fusion protein of the present disclosure). In certain embodiments, a host cell may optionally already possess or be modified to include other genetic modifications that confer desired properties related or unrelated to, e.g., biosynthesis of the heterologous protein (e.g, inclusion of a detectable marker; deleted, altered or truncated endogenous TCR; or increased co-stimulatory factor expression).
As used herein, "enriched" or "depleted" with respect to amounts of cell types in a mixture refers to an increase in the number of the "enriched" type, a decrease in the number of the "depleted" cells, or both, in a mixture of cells resulting from one or more enriching or depleting processes or steps. Thus, depending upon the source of an original population of cells subjected to an enriching process, a mixture or composition may contain 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more (in number or count) of the "enriched" cells. Cells subjected to a depleting process can result in a mixture or composition containing 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% percent or less (in number or count) of the "depleted" cells. In certain embodiments, amounts of a certain cell type in a mixture will be enriched and amounts of a different cell type will be depleted, such as enriching for CD4+ cells while depleting CD8+ cells, or enriching for CD62L+ cells while depleting CD62L- cells, or combinations thereof.
"T cell receptor" (TCR) or "TCR complex" refers to a multi-protein complex known as an immunoglobulin superfamily member (having a variable binding domain, a constant domain, a transmembrane region, and a short cytoplasmic tail; see, e.g., Janeway el al., Immunobiology: The Immune System in Health and Disease, 3rd Ed., Current Biology Publications, p. 4:33, 1997) capable of specifically binding to an antigen peptide bound to a MHC receptor. A TCR can be found on the surface of a cell or in soluble form and generally is comprised of a heterodimer having a and b chains (also known as TCRa and TOIb, respectively), or g and d chains (also known as TCRy and TCR6, respectively). Like immunoglobulins (i.e., antibodies), the extracellular portion of TCR chains (e.g, a-chain, b-chain) contain two immunoglobulin domains, a variable domain (e.g, a-chain variable domain or Vo, b-chain variable domain or Vp; typically amino acids 1 to 116 based on Rabat numbering (Rabat et al., "Sequences of
Proteins of Immunological Interest, US Dept. Health and Human Services, Public Health Service National Institutes of Health, 1991, 5th ed.) at the N-terminus, and one constant domain ( e.g ., a-chain constant domain or Ca, typically amino acids 117 to 259 based on Kabat, b-chain constant domain or C , typically amino acids 117 to 295 based on Kabat) adjacent to the cell membrane. Also, like immunoglobulins, the variable domains contain complementary determining regions (CDRs) separated by framework regions (FRs) (see, e.g., Jores et al., Proc. Nat’l Acad. Sci. U.S.A. 57:9138, 1990;
Chothia et al., EMBO J. 7:3745, 1988; see also Lefranc et al., Dev. Comp. Immunol. 27:55, 2003). The source of a TCR as used in the present disclosure may be from various animal species, such as a human, mouse, rat, rabbit or other mammal.
In certain embodiments, a TCR is found on the surface of T cells (or T lymphocytes) and associates with the CD3 complex. In certain embodiments, a TCR complex comprises a TCR or a functional portion thereof; a dimer comprising two H03z chains, or functional portions or variants thereof; a dimer comprising a CD35 chain and a CDe chain, or functional portions or variants thereof; and a dimer comprising a CD3y chain and a CDe chain, or functional portions or variants thereof, any one or more of which may be endogenous or heterologous to the T cell.
As used herein, a "TCR extracellular domain" refers to a portion of a TCR that comprises a TCR ectodomain or a portion thereof, such as a constant domain from a TCRa chain or a TOIb chain, or an ectodomain from CD3e, CD35, or CD3y;
optionally comprising a TCR variable domain (e.g., a Va and/or a Vp domain). In certain embodiments, a TCR extracellular domain (i) comprises or consists of a TCR ectodomain, or a portion thereof; (ii) does not comprise a TCR variable domain (e.g, does not comprise a Va and/or a Vp), or (iii) comprises or consists of a TCR constant domain or ectodomain, or a portion thereof, and does not comprise a TCR variable domain. In certain embodiments, a fusion protein of the instant disclosure does not comprise a TCR ectodomain.
"CD3" is a multi-protein complex of six chains (see, Abbas and Lichtman, 2003; Janeway et al, p. 172 and 178, 1999). In mammals, the complex generally comprises a CD3y chain, a CD35 chain, two CD3e chains, and a homodimer of CD3z chains. The CD3y, CD35, and CD3e chains are related cell surface proteins of the immunoglobulin
superfamily containing a single immunoglobulin domain. The transmembrane regions of the CD3y, CD35, and CD3e chains are negatively charged, which is thought to allow these chains to associate with positively charged regions of T cell receptor chains. The intracellular tails of the CD3y, CD35, and CD3e chains each contain a single conserved motif known as an immunoreceptor tyrosine-based activation motif or ITAM, whereas each Oϋ3z chain has three IT AMs (also referred to as 0)3z "(a)", "(b)", and "(c)" ITAMs herein). In general, IT AMs comprise an amino acid sequence motif "YxxL/I" (SEQ ID NO: 1), wherein xx may be any two (i.e., the same or different) amino acids.
In certain embodiments, an ITAM comprises a motif YxxL/Ix(6-8)YxxL/I (SEQ ID NO:2), wherein x may be any amino acid (i.e., a same or different amino acids over the length of the ITAM). In certain embodiments, an ITAM motif can comprise an amino acid sequence motif according to SEQ ID NO:3, SEQ ID NO:4, or both. Exemplary ITAMs of the present disclosure include those that comprise an amino acid sequence as shown in any one of SEQ ID NOs:6, 12, 15, and 18-20. Other ITAMs from human proteins include those found in B cell receptor-associated proteins ( e.g ., Iga, Igp), Fc receptor proteins (e.g., FcRyl, FcRy2a, FcRy2bl, FcRy2al, FcRy2b2, FcRy3a, FcRy3b, FcRpl, FceR), Natural Killer cell receptor proteins (e.g, DAP12), CD5, CDl6a,
CDl6b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, and CD66d. Exemplary amino acid sequences of these ITAM sequences and those from viruses (e.g, BLV gp30; EBV LMP2A) are described in Paul, Fundamental Immunology 307 (Wolters Kluwer; Lippincott; Wilkins & Wilkins; Seventh Ed., 2008). These ITAMs and functional fragments and variants thereof are also contemplated for use in the presently disclosed fusion proteins and host cells, and are hereby incorporated by reference.
CD3, as well as the protein subunits, domains, and sequences therefrom, may be from various animal species, including human, mouse, rat, or other mammals.
In addition to ITAMs, CD3e and Oϋ3z possess additional sequence features that may be involved in or required for T cell signaling; e.g, following recognition of antigenMHC by a TCR. Human CD3e includes a proline-rich sequence (PRS) that is N-terminal to the ITAM in the CD3e cytoplasmic domain. An exemplary PRS amino acid sequence is provided in SEQ ID NO:7. An exemplary fragment of a CD3e
cytoplasmic domain (also referred to as an endodomain) comprising a PRS and an ITAM is provided in SEQ ID NO:8. CD3e and Oϋz both contain at least one Basic Residue Sequence (BRS). In the case of human CD3e, a BRS is generally located near the junction of the transmembrane and cytoplasmic domains. An exemplary BRS from CD3e is provided in SEQ ID NO:9. An exemplary sequence of a human CD3e cytoplasmic domain containing a BRS, a PRS, and an ITAM is provided in SEQ ID SEQ ID NO: 111. In certain embodiments, an effector domain or a functional portion or variant thereof from a CD3e does not comprise a full-length CD3e and does not comprise an endodomain from CD3e. In the case of Oϋ3z, two BRS are generally located between ITAMs (a) and (b), and a third BRS is located between IT AMs (b) and (c). Exemplary BRS from Oϋ3z are provided in SEQ ID NOs:2l-23. An exemplary sequence of a human Oϋ3z cytoplasmic domain containing ITAMS and BRS is provided in SEQ ID NO: 17. In any of the embodiments described herein, a fusion protein of the instant disclosure can comprise an amino acid sequence having least 75% (e.g., at least 75%„ 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% identity, or more), to a reference amino acid sequence as set forth herein.
In certain embodiments, a fusion protein of the present disclosure, when expressed by a T cell, does not associate with or form a TCR complex (i.e., does not form or associate with a TCR complex comprising a TCR, a dimer comprising two Oϋ3z chains, a dimer comprising a CD35 chain and a CDe chain, and a dimer comprising a CD3y chain and a CDe chain, any one or more of which components may be endogenous or heterologous to the T cell). Whether two or more proteins form a complex can be determined by any suitable technique, such as, for example, imaging a T cell that expresses a detectably labeled (e.g, fluorescently labeled or bound by a labeled antibody) fusion protein of this disclosure and a fluorescently labeled TCR, co- precipitating a fusion protein and a TCR, or the like.
In certain embodiments, a fusion protein does not comprise an ectodomain and/or a transmembrane domain from CD35, CDe, or CD3y, or any combination thereof. In particular embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD35. In some embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a
portion thereof, from CD3e. In certain embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3y.
"Major histocompatibility complex molecules" (MHC molecules) refer to glycoproteins that deliver peptide antigens to a cell surface. MHC class I molecules are heterodimers consisting of a membrane spanning a chain (with three a domains) and a non-covalently associated b2 microglobulin. MHC class II molecules are composed of two transmembrane glycoproteins, a and b, both of which span the membrane. Each chain has two domains. MHC class I molecules deliver peptides originating in the cytosol to the cell surface, where a peptide:MHC complex is recognized by CD8+ T cells. MHC class II molecules deliver peptides originating in the vesicular system to the cell surface, where they are recognized by CD4+ T cells. An MHC molecule may be from various animal species, including human, mouse, rat, cat, dog, goat, horse, or other mammals.
"CD4" refers to an immunoglobulin co-receptor glycoprotein that assists the TCR in communicating with antigen-presenting cells (see, Campbell & Reece, Biology 909 (Benjamin Cummings, Sixth Ed., 2002); ETniProtKB P01730). CD4 is found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells, and includes four immunoglobulin domains (Dl to D4) that are expressed at the cell surface. During antigen presentation, CD4 is recruited, along with the TCR complex, to bind to different regions of the MHCII molecule (CD4 binds MHCII b2, while the TCR complex binds MHCII aΐ/bΐ).
As used herein, the term "CD8 co-receptor" or "CD8" means the cell surface glycoprotein CD8, either as an alpha-alpha homodimer or an alpha-beta heterodimer. The CD8 co-receptor assists in the function of cytotoxic T cells (CD8+) and functions through signaling via its cytoplasmic tyrosine phosphorylation pathway (Gao and Jakobsen, Immunol. Today 27:630-636, 2000; Cole and Gao, Cell. Mol. Immunol. 7:81- 88, 2004). In humans, there are five (5) different CD8 beta chains (see ETniProtKB identifier P 10966) and a single CD8 alpha chain (see ETniProtKB identifier P01732).
"Chimeric antigen receptor" (CAR) refers to a fusion protein of the present disclosure engineered to contain two or more naturally occurring (or engineered) amino acid sequences linked together in a way that does not occur naturally or does not occur
naturally in a host cell, which fusion protein can function as a receptor when present on a surface of a cell. CARs of the present disclosure include an extracellular portion comprising an antigen-binding domain ( e.g ., obtained or derived from an
immunoglobulin or immunoglobulin-like molecule, such as a scFv or scTCR derived from an antibody or TCR specific for a cancer antigen, or an antigen-binding domain derived or obtained from a killer immunoreceptor from an NK cell, or from another protein (natural, recombinant, or synthetic) that has, or is engineered to possess, the ability to specifically bind to an antigen) linked to a transmembrane domain and one or more intracellular signaling domains (optionally containing co-stimulatory domain(s)) (see, e.g., Sadelain et al, Cancer Discov., 3(4):388 (2013); see also Harris and Kranz, Trends Pharmacol. Sci., 37( 3):220 (2016); Stone et al, Cancer Immunol. Immunother., 63( 11): 1163 (2014)). In certain embodiments, a binding protein comprises a CAR comprising an antigen-specific TCR binding domain (see, e.g., Walseng et al.,
Scientific Reports 7: 10713, 2017; the TCR CAR constructs and methods of which are hereby incorporated by reference in their entirety).
The term "variable region" or "variable domain" refers to the domain of a TCR a-chain or b-chain (or g-chain and d-chain for gd TCRs), or of an antibody heavy or light chain, that is involved in binding to antigen (i.e., contains amino acids and/or other structures that contact antigen and result in binding). The variable domains of the a- chain and b-chain (Va and nb, respectively) of a native TCR generally have similar structures, with each domain comprising four generally conserved framework regions (FRs) and three CDRs. Variable domains of antibody heavy (VH) and light (VL) chains each also generally comprise four generally conserved framework regions (FRs) and three CDRs. In both TCRs and antibodies, framework regions separate CDRs and CDRs are situated between framework regions (i.e., in primary structure).
The terms "complementarity determining region," and "CDR," are synonymous with "hypervariable region" or "HVR," and are known in the art to refer to sequences of amino acids within TCR or antibody variable regions, which, in general, confer antigen specificity and/or binding affinity and are separated from one another in primary structure by framework sequence. In some cases, framework amino acids can also contribute to binding, e.g, may also contact the antigen or antigen-containing molecule.
In general, there are three CDRs in each variable region (i.e., three CDRs in each of the TCRa-chain and b-chain variable regions; 3 CDRs in each of the antibody heavy chain and light chain variable regions). In the case of TCRs, CDR3 is thought to be the main CDR responsible for recognizing processed antigen. CDR1 and CDR2 mainly interact with the MHC. Variable domain sequences can be aligned to a numbering scheme ( e.g ., Rabat, EU, International Immunogenetics Information System (IMGT) and Aho), which can allow equivalent residue positions to be annotated and for different molecules to be compared using Antigen receptor Numbering And Receptor
Classification (ANARCI) software tool (2016, Bioinformatics 15:298-300).
"Antigen" or "Ag" as used herein refers to an immunogenic molecule that provokes an immune response. This immune response may involve antibody production, activation of specific immunologically-competent cells (e.g., T cells), or both. An antigen (immunogenic molecule) may be, for example, a peptide,
glycopeptide, polypeptide, glycopolypeptide, polynucleotide, polysaccharide, lipid or the like. It is readily apparent that an antigen can be synthesized, produced
recombinantly, or derived from a biological sample. Exemplary biological samples that can contain one or more antigens include tissue samples, tumor samples, cells, biological fluids, or combinations thereof. Antigens can be produced by cells that have been modified or genetically engineered to express an antigen.
The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence or protein determinant that is recognized and specifically bound by a cognate binding molecule, such as an immunoglobulin, T cell receptor (TCR), chimeric antigen receptor, or other binding molecule, domain or protein. Epitopic determinants generally contain chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three dimensional structural characteristics, as well as specific charge characteristics.
"Treat" or "treatment" or "ameliorate" refers to medical management of a disease, disorder, or condition of a subject (e.g, a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat). In general, an appropriate dose or treatment regimen comprising a host cell expressing a fusion protein of the present disclosure, and optionally an adjuvant, is administered in an amount sufficient to elicit a
therapeutic or prophylactic benefit. Therapeutic or prophylactic/preventive benefit includes improved clinical outcome; lessening or alleviation of symptoms associated with a disease; decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease; stabilization of disease state; delay of disease progression; remission; survival; prolonged survival; or any
combination thereof.
A "therapeutically effective amount" or "effective amount" of a fusion protein or host cell expressing a fusion protein of this disclosure, refers to an amount of fusion proteins or host cells sufficient to result in a therapeutic effect, including improved clinical outcome; lessening or alleviation of symptoms associated with a disease;
decreased occurrence of symptoms; improved quality of life; longer disease-free status; diminishment of extent of disease, stabilization of disease state; delay of disease progression; remission; survival; or prolonged survival in a statistically significant manner. When referring to an individual active ingredient or a cell expressing a single active ingredient, administered alone, a therapeutically effective amount refers to the effects of that ingredient or cell expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amounts of active ingredients or combined adjunctive active ingredient with a cell expressing an active ingredient that results in a therapeutic effect, whether administered serially or simultaneously. A combination may also be a cell expressing more than one active ingredient, such as two different fusion proteins ( e.g ., CARs) that specifically bind a an antigen, or a fusion protein of the present disclosure.
The term "pharmaceutically acceptable excipient or carrier" or "physiologically acceptable excipient or carrier" refer to biologically compatible vehicles, e.g., physiological saline, which are described in greater detail herein, that are suitable for administration to a human or other non-human mammalian subject and generally recognized as safe or not causing a serious adverse event.
As used herein, "statistically significant" refers to a p-value of 0.050 or less when calculated using the Student’s t-test and indicates that it is unlikely that a particular event or result being measured has arisen by chance.
As used herein, the term "adoptive immune therapy" or "adoptive
immunotherapy" refers to administration of naturally occurring or genetically engineered, disease-antigen-specific immune cells ( e.g ., T cells). Adoptive cellular immunotherapy may be autologous (immune cells are from the recipient), allogeneic (immune cells are from a donor of the same species) or syngeneic (immune cells are from a donor genetically identical to the recipient).
Fusion Proteins
In certain aspects, the present disclosure provides fusion proteins, comprising: (a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain; and (c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof; (ii) an ITAM from CD3y, or a functional variant thereof;(iii) an ITAM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or OI)3z, or a functional variant thereof; or (vi) any combination of (i)-(v), wherein: (1) the extracellular domain does not comprise a TCR extracellular domain, preferably does not comprise a TCR ectodomain; and/or (2) the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
In certain embodiments, a fusion protein of the present disclosure, when expressed by a T cell or a cell that otherwise expresses TCR complex proteins, does not associate with or form a TCR complex (i.e., does not form or associate with a TCR complex comprising a TCR, a dimer comprising two OI)3z chains, a dimer comprising a CD35 chain and a CDe chain, and a dimer comprising a CD3y chain and a CDe chain, any one or more of which components may be endogenous or heterologous to the T cell). Whether two or more proteins form a complex can be determined by any suitable technique, such as, for example, imaging a T cell that expresses a detectably labeled (e.g., fluorescently labeled or bound by a labeled antibody) fusion protein of this disclosure and a fluorescently labeled TCR, co-precipitating a fusion protein and a TCR, or the like.
In certain embodiments, a fusion protein of the present disclosure does not comprise an ectodomain and/or a transmembrane domain from CDe, from CD3y, from CD35, or any combination thereof. In some embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e. In certain embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD35. In certain embodiments, a fusion protein does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3y.
In certain aspects, a fusion protein of the present disclosure comprises:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen; (b) a transmembrane domain; and (c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises: (i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional variant thereof; (ii) an ITAM from CD3y, or a functional variant thereof; (iii) an ITAM from CD35, or a functional variant thereof; (iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof; (v) a Basic Residue Sequence (BRS) from CD3e and/or Oϋ3z, or a functional variant thereof; or (vi) any combination of (i)-(v), and does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD35, and/or CD3y.
In any of the presently disclosed embodiments, the effector domain or functional portion thereof comprises an ITAM from CD3e, or a functional variant thereof, and a PRS from CD3e, or a functional variant thereof.
In certain embodiments, the fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
In certain embodiments, the effector domain or functional fragment thereof comprises an amino acid sequence having at least 75% (z.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the effector domain or functional fragment thereof comprises one, two, or three, four, or more of the amino acids of SEQ ID NO: 5 or SEQ ID NO: 111 that are immediately amino-terminal to and/or comprises one, two, or three, four, or more of the amino acids of SEQ ID
NO: 5 or SEQ ID NO: 111 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 8.
In certain embodiments, the effector domain comprises a BRS from CD3e, or a functional variant thereof.
In certain embodiments, the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:5 or 111.
In certain embodiments, the effector domain comprises: an IT AM from CD3y, or a functional variant thereof; and/or comprises an ITAM from CD35, or a functional variant thereof. In certain embodiments, the effector domain comprises: (i) an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 11, optionally wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO:l 1 is not a leucine, and is preferably an alanine or a glycine; and/or (ii) an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 14, optionally wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO: 14 is not a leucine, and is preferably an alanine or a glycine. In certain embodiments, the effector domain comprises a BRS from CD3e, or a functional portion or variant thereof.
In certain embodiments, the effector domain or functional fragment thereof comprises the amino acid sequence set forth in SEQ ID NO: 12 and further comprises one, two, or three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 10 or 11 that are immediately amino-terminal to and/or comprises one, two, or three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 10 or 11 that are immediately carboxy-terminal to the amino acid sequence of SEQ ID NO: 12.
In certain embodiments, the effector domain or functional fragment thereof comprises the amino acid sequence set forth in SEQ ID NO: 15 and further comprises one, two, three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 14 that are immediately amino-terminal to and/or comprises one, two, or
three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 14 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 15.
In certain embodiments, the effector domain further comprises an IT AM from Oϋ3z, or a functional portion or variant thereof. In further embodiments, the effector domain further comprises two or three of IT AMs (a), (b), and (c) from Oϋ3z, or functional portions or variants thereof. In certain embodiments, the effector domain comprises SEQ ID NO: 18, SEQ ID NO: 19, and/or SEQ ID NO:20, and further comprises one, two, three, four, five, six, seven, eight, nine, ten, or more of the amino acids of SEQ ID NO: 17 that are immediately amino-terminal to the amino acid sequence of SEQ ID NO: 18, 19, or 20, respectively, and/or comprises one, two, or three, four, five, six, seven, or eight of the amino acids of SEQ ID NO: 17 that are immediately carboxy -terminal to the amino acid sequence of SEQ ID NO: 18, 19, or 20, respectively.
In certain embodiments, the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: l7.
In any of the presently disclosed embodiments, a fusion protein can comprise an ITAM motif, a Lck-binding motif, a PRS, a BRS, or sequence comprising the same, having or comprising the amino acid sequence as set forth in any one of SEQ ID NOS: 1-9, 11, 12, 14, 15, 18-24, 27-32, or 111, or a functional variant or fragment thereof, or any combination thereof.
A "binding domain" (also referred to as a "binding region" or "binding moiety"), as used herein, refers to a molecule or portion thereof ( e.g ., peptide, oligopeptide, polypeptide, protein (e.g., a fusion protein)) that possesses the ability to specifically and non-covalently associate, unite, or combine with a target. A binding domain includes any naturally occurring, synthetic, semi -synthetic, or recombinantly produced binding partner for a biological molecule, a molecular complex (i.e., complex comprising two or more biological molecules), or other target of interest. Exemplary binding domains include single chain immunoglobulin variable regions (e.g, scTCR, scFv, Fab, TCR variable regions), receptor ectodomains, ligands (e.g, cytokines, chemokines), or
synthetic polypeptides selected for their specific ability to bind to a biological molecule, a molecular complex or other target of interest. In certain embodiments, the binding domain is a scFv, scTCR, or ligand. In certain embodiments, the binding domain is chimeric, human, or humanized.
In certain embodiments, the binding domain is a scFv comprising a VH domain, a VL domain, and a peptide linker. In particular embodiments, a scFv comprises a VH domain joined to a VL domain by a peptide linker, which can be in a VH-linker-VL orientation or in a VL-linker-VH orientation.
Any scFv of the present disclosure may be engineered so that the C-terminal end of the VL domain is linked by a short peptide sequence to the N-terminal end of the VH domain, or vice versa (i.e., (N)VL(C)-linker-(N)VH(C) or (N)VH(C)-linker-(N)VL(C). It will be appreciated that any scTCR of the present disclosure may be engineered so that the C-terminal end of the Va domain is linked by a short peptide sequence to the N- terminal end of the nb domain, or vice versa (i.e., (N)Va(C)-linker-(N)Vb(C) or (N)nb (C)-linker-(N) V a(C)) .
As used herein, "specifically binds" or "specific for" refers to an association or union of a binding protein ( e.g a T cell receptor or a chimeric antigen receptor) or a binding domain (or fusion protein comprising a binding domain) to a target molecule with an affinity or Ka (i.e., an equilibrium association constant of a particular binding interaction with units of l/M) equal to or greater than 105 M 1 (which equals the ratio of the on-rate [K0n] to the off rate [K0ff] for this association reaction), while not
significantly associating or uniting with any other molecules or components in a sample. Binding proteins or binding domains (or fusion proteins thereof) may be classified as "high-affinity" binding proteins or binding domains (or fusion proteins thereof) or as "low-affinity" binding proteins or binding domains (or fusion proteins thereof). "High-affinity" binding proteins or binding domains refer to those binding proteins or binding domains having a Ka of at least l07M_1, at least 108 M 1, at least 109 M l, at least 1010 M 1, at least 1011 M 1, at least l012M_1, or at least 1013 M 1. "Low- affinity" binding proteins or binding domains refer to those binding proteins or binding domains having a Ka of up to 107 M 1, up to 106 M 1, or up to 105 M 1. Alternatively,
affinity may be defined as an equilibrium dissociation constant (KD) of a particular binding interaction with units of M ( e.g ., 10 5 M to 10 13 M).
In further embodiments, a fusion protein of the instant disclosure specifically binds to a target antigen (e.g., a cancer antigen such as, for example, a CD 19, CD20, CD22, ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7,
Her2, Ll-CAM, Lewis A, Lewis Y, MUC1, MUC16, PSCA, PSMA, CD56, CD23, CD24, CD30, CD33, CD37, CD44v7/8, CD38, CD56, CD123, CA125, c-MET, FcRH5, WT1, folate receptor a, VEGF-a, VEGFR1, VEGFR2, IL-l3Ra2, IL-l lRa, MAGE-A1, MAGE- A3, MAGE-A4, SSX-2, PRAME, HA-l, PSA, ephrin A2, ephrin B2, an NKG2D, NY-ESO-l, TAG-72, mesothelin, NY-ESO, 5T4, BCMA, FAP, Carbonic anhydrase 9, ERBB2, BRAFV600E, CD79a, CD79b, SLAMF7, or CEA antigen; an autoimmune antigen; or an antigen associated with an infection).
Sources of binding domains specific for these antigens are known in the art. Exemplary binding domains specific for ROR1 and CD 19 antigens, including CDRs thereof, are disclosed SEQ ID NOs:55-l02. A fusion protein of the present disclosure can, in certain embodiments, comprise a variable domain and/or one or more CDRs (e.g. , three heavy chain CDRs and three light chain CDRs) according to any one of these exemplary binding domain sequences (e.g, from an anti-RORl or anti-CD 19 scFv, or Rl l antibody, R12 antibody, Y31 antibody, 2A2 antibody, or FMC63 antibody), or can comprise a functional variant sequence thereof.
In certain embodiments, a fusion protein of the instant disclosure is expressed by a host cell (e.g, an immune system cell such as, for example, a T cell) and the host cell specifically recognizes (i.e., comprising specific binding) and initiates an immune response to a target cell expressing a reduced (e.g., as compared to a reference baseline level of expression of the same or a different antigen (e.g, as compared to an average level among subjects or tumors having a same disease or disease state), or to a prior level of expression by a disease site, such as a tumor, in the subject) or low or intermediate level of the antigen). In certain embodiments, a reduced level of expression comprises at a reduction of at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, as compared to a reference baseline or previous subject level. In certain embodiments, a
reduced level of expression is a reduction of 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or lOO-fold, or more, as compared to a prior or reference level of expression. An expression level of an antigen can be determined using any art-accepted methodology, including, for example, use of labeled antibodies, Western Blot, RNA-Seq, or the like.
In certain embodiments, a low antigen density comprises less than about 10,000, less than about 9,000, less than about 8,000, less than about 7,000, less than about 6,000, less than about 5,000, less than about 4,000, less than about 3,000, less than about 2,000, less than about 1,000, less than about 500, less than about 200, less than about 190, less than about 180, less than about 170, less than about 160, less than about 150, less than about 140, less than about 130, less than about 120, less than about 110, about 100, less than about 90, less than about 80, less than about 70, less than about 60, less than about 50, less than about 40, less than about 30, less than about 20, or less than about 10 molecules of the antigen expressed on the surface of a target cell. In some embodiments, an intermediate antigen density comprises about 10,000 to about 20,000 molecules of antigen expressed on the surface of a target cell. In some embodiments, a high antigen density comprises about 20,000 molecules or more of antigen expressed on the surface of a target cell.
In certain embodiments, a receptor or binding domain may have "enhanced affinity," which refers to selected or engineered receptors or binding domains with stronger binding to a target antigen than a wild type (or parent) binding domain. For example, enhanced affinity may be due to a Ka (equilibrium association constant) for the target antigen that is higher than the wild type binding domain, due to a Kd
(dissociation constant) for the target antigen that is less than that of the wild type binding domain, due to an off-rate (k0ff) for the target antigen that is less than that of the wild type binding domain, or a combination thereof.
A variety of assays are known for identifying binding domains of the present disclosure that specifically bind a particular target, as well as determining binding domain or fusion protein affinities, such as Western blot, ELISA, analytical
ultracentrifugation, spectroscopy and surface plasmon resonance (Biacore®) analysis (see, e.g., Scatchard et al., Ann. N.Y. Acad. Sci. 51 :660, 1949; Wilson, Science 295: 2103, 2002; Wolff et al, Cancer Res. 53: 2560, 1993; and U.S. Patent Nos.
5,283,173, 5,468,614, or the equivalent). Assays for assessing affinity or apparent affinity or relative affinity are also known. In certain examples, apparent affinity for a fusion protein is measured by assessing binding to various concentrations of tetramers, for example, by flow cytometry using labeled tetramers. In some examples, apparent KD of a fusion protein is measured using 2-fold dilutions of labeled tetramers at a range of concentrations, followed by determination of binding curves by non-linear regression, apparent KD being determined as the concentration of ligand that yielded half-maximal binding.
As used herein, an "effector domain" is an intracellular portion or domain of a fusion protein or receptor that can directly or indirectly promote a biological or physiological response ( e.g ., an immune response) in a cell when receiving an appropriate signal. In certain embodiments, an effector domain is from a protein or portion thereof or protein complex that receives a signal when bound to a target or cognate molecule, or when the protein or portion thereof or protein complex binds directly to a target or cognate molecule and triggers a signal from the effector domain.
An effector domain may directly promote a cellular response (e.g., immune response) when it contains one or more signaling domains or motifs, such as an
Intracellular Tyrosine-based Activation Motif (ITAM), such as those found in costimulatory molecules. Without wishing to be bound by theory, it is believed that ITAMs are important for T cell activation following ligand (e.g, antigen) engagement by a T cell receptor or by a fusion protein comprising a T cell effector domain. In certain embodiments, the intracellular component or functional portion thereof comprises an ITAM. Exemplary effector domains include those from CD3e, CD35, OI)3z, CD25, CD79A, CD79B, CARD11, DAP 10, FcRa, FcRp, FcRy, Fyn, HVEM, ICOS, Lck, LAG3, LAT, LRP, NKG2D, NOTCH1, NOTCH2, NOTCH3, NOTCH4, Wnt, ROR2, Ryk, SLAMF1, Slp76, pTa, TCRa, TCRp, TRIM, Zap70, PTCH2, or any combination thereof. In certain embodiments, an effector domain comprises a lymphocyte receptor signaling domain (e.g, Eϋ3z or a functional portion or variant thereof).
In certain embodiments, the intracellular component of the fusion protein further comprises a costimulatory domain or a functional portion thereof selected from CD27,
CD28, 4-1BB (CD137), 0X40 (CD134), CD2, CD5, ICAM-l (CD54), LFA-l
(CD1 la/CDl8), ICOS (CD278), GITR, CD30, CD40, BAFF-R, HVEM, LIGHT, MKG2C, SLAMF7, NKp80, CD160, B7-H3, a ligand that specifically binds with CD83, or a functional variant thereof, or any combination thereof. In certain embodiments, the intracellular component comprises a CD28 costimulatory domain or a functional portion or variant thereof (which may optionally include a LL- GG mutation at positions 186-187 of the native CD28 protein (see Nguyen el al, Blood 702:4320, 2003)), a 4-1BB costimulatory domain or a functional portion or variant thereof, or both. Exemplary amino acid sequences of certain costimulatory domains are provided in SEQ ID NOs: and 25 and 47-49. In certain embodiments, a costimulatory domain or functional portion or variant thereof comprises or consists of an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to any one of SEQ ID NOs:25 and 47-49.
In certain embodiments, an effector domain comprises a Oϋ3z endodomain or a functional ( e.g ., signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises a CD27 endodomain or a functional (e.g., signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises a CD28 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises a 4-1BB endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises an 0X40 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises a CD2 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises a CD5 endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an effector domain comprises an ICAM-l endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain
embodiments, an effector domain comprises a LFA-l endodomain or a functional (e.g, signaling) portion thereof, or a functional variant thereof. In certain embodiments, an
effector domain comprises an ICOS endodomain or a functional ( e.g ., signaling) portion thereof, or a functional variant thereof.
In certain embodiments, the intracellular domain of a fusion protein according to the present disclosure comprises a costimulatory domain, an endodomain or effector domain from CD3z or a functional portion or variant thereof, and an effector domain from CD3e or a functional portion or variant thereof, wherein the effector domain from CD3e or functional portion or variant thereof optionally comprises or consists essentially of a PRS and an IT AM from CD3e.
In further embodiments, the effector domain from CD3e or functional portion or variant thereof is disposed between the costimulatory domain or functional portion or variant thereof and the endodomain or effector domain from CD3z or functional portion or variant thereof. In certain embodiments, the costimulatory domain or functional portion or variant thereof is from 4-1BB. In certain embodiments, the intracellular component of the fusion protein comprises, in amino-terminal to carboxy-terminal direction: (i) the costimulatory domain or functional portion or variant thereof; (ii) the effector domain from CD3e or functional portion or variant thereof; and (iii) the endodomain or effector domain from CD3z or functional portion or variant thereof.
In other embodiments, the endodomain or effector domain from CD3z or functional portion or variant thereof is disposed between the costimulatory domain and the effector domain from CD3e or functional portion or variant thereof. In certain embodiments, the costimulatory domain is from 4-1BB. In certain embodiments, the intracellular component of the fusion protein comprises, in amino-terminal to carboxy- terminal direction: (i) the costimulatory domain or functional portion or variant thereof; (ii) the endodomain or effector domain from Oϋ3z or functional portion or variant thereof; and (iii) the effector domain from CD3e or functional portion or variant thereof.
An extracellular component and an intracellular component of the present disclosure are connected by a transmembrane domain. A "transmembrane domain," as used herein, is a portion of a transmembrane protein that can insert into or span a cell membrane. Transmembrane domains have a three-dimensional structure that is thermodynamically stable in a cell membrane and generally range in length from about
15 amino acids to about 30 amino acids. The structure of a transmembrane domain may comprise an alpha helix, a beta barrel, a beta sheet, a beta helix, or any combination thereof. In certain embodiments, the transmembrane domain comprises or is derived from a known transmembrane protein ( e.g ., a CD4 transmembrane domain, a CD8 transmembrane domain, a CD27 transmembrane domain, a CD28 transmembrane domain, or any combination thereof). An exemplary CD28 transmembrane domain amino acid sequence is provided in SEQ ID NO:26. In certain embodiments, a transmembrane domain comprises or consists of an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity to SEQ ID NO:26.
In certain embodiments, the extracellular component of the fusion protein further comprises a linker disposed between the binding domain and the transmembrane domain. As used herein when referring to a component of a fusion protein that connects the binding and transmembrane domains, a "linker" may be an amino acid sequence having from about two amino acids to about 500 amino acids, which can provide flexibility and room for conformational movement between two regions, domains, motifs, fragments, or modules connected by the linker. For example, a linker of the present disclosure can position the binding domain away from the surface of a host cell expressing the fusion protein to enable proper contact between the host cell and a target cell, antigen binding, and activation (Patel et al, Gene Therapy 6: 412-419, 1999). Linker length may be varied to maximize antigen recognition based on the selected target molecule, selected binding epitope, or antigen binding domain size and affinity (see, e.g., Guest et al., J. Immunother. 28: 203-11, 2005; PCT Publication No. WO 2014/031687). Exemplary linkers include those having a glycine-serine amino acid chain having from one to about ten repeats of GlyxSery, wherein x and y are each independently an integer from 0 to 10, provided that x and y are not both 0 (e.g, (Gly4Ser)2; (Gly3Ser)2; GlyiSer; or a combination thereof, such as (Gly3Ser)2Gly2Ser).
In some embodiments, the extracellular domain comprises a glycine-serine linker that is not comprised in the binding domain; e.g., is disposed between the transmembrane domain and the binding domain. For example, in certain embodiments, a fusion protein comprises an extracellular domain comprising a first glycine-serine linker disposed
between the transmembrane domain and the binding domain, and the binding domain may comprise a scFv or an scTCR that comprises a second glycine-serine linker, wherein the first and second glycine-serine linkers may be a same or a different glycine- serine linker and may be of a same or a different length.
Exemplary linker amino acid sequences of the present disclosure are provided in SEQ ID NOs: 103-110.
Linkers of the present disclosure also include immunoglobulin constant regions (i.e., CH1, CH2, CH3, or CL, of any isotype) and portions and variants thereof. In certain embodiments, the linker comprises a CH3 domain, a CH2 domain, or both. In certain embodiments, the linker comprises a CH2 domain and a CH3 domain. In further embodiments, the CH2 domain and the CH3 domain are each a same isotype. In particular embodiments, the CH2 domain and the CH3 domain are an IgG4 or IgGl isotype. In other embodiments, the CH2 domain and the CH3 domain are each a different isotype. In specific embodiments, the CH2 comprises a N297Q mutation. Without wishing to be bound by theory, it is believed that CH2 domains with N297Q mutation do not bind FcyR (see, e.g., Sazinsky et al., PNAS 105(51):20167 (2008)). In certain embodiments, the linker comprises a human immunoglobulin constant region or a portion thereof. In certain embodiments, the linker comprises an extracellular domain from CD4, or a portion thereof. In some embodiments, the linker comprises an extracellular domain from CD8, or a portion thereof.
In any of the embodiments described herein, a linker may comprise a hinge region or a portion thereof. An exemplary hinge sequence of the present disclosure is provided in SEQ ID NO:33. Hinge regions are flexible amino acid polymers of variable length and sequence (typically rich in proline and cysteine amino acids) and connect typically larger and less-flexible regions of immunoglobulin proteins. For example, hinge regions connect the Fc and Fab regions of antibodies and connect the constant and transmembrane regions of TCRs. In certain embodiments, the linker comprises an immunoglobulin constant region or a portion thereof and a hinge region or a portion thereof. In certain embodiments, the linker comprises a glycine-serine linker as described herein.
In certain embodiments, one or more of the extracellular component, the binding domain, the linker, the transmembrane domain, the intracellular component, the effector domain, or the costimulatory domain further comprise one or more junction amino acids. "Junction amino acids" or "junction amino acid residues" refer to one or more ( e.g ., about 2-20) amino acid residues between two adjacent domains, motifs, regions, modules, or fragments of a protein, such as between a binding domain and an adjacent linker, between a transmembrane domain and an adjacent extracellular or intracellular domain, or on one or both ends of a linker that links two domains, motifs, regions, modules, or fragments (e.g., between a linker and an adjacent binding domain or between a linker and an adjacent hinge). Junction amino acids may result from the construct design of a fusion protein (e.g, amino acid residues resulting from the use of a restriction enzyme site or self-cleaving peptide sequences during the construction of a polynucleotide encoding a fusion protein). For example, a transmembrane domain of a fusion protein may have one or more junction amino acids at the amino-terminal end, carboxy -terminal end, or both.
Protein tags are unique peptide sequences that are affixed or genetically fused to, or are a part of, a protein of interest and can be recognized or bound by, for example, a heterologous or non-endogenous cognate binding molecule or a substrate (e.g, receptor, ligand, antibody, carbohydrate, or metal matrix) or a fusion protein of this disclosure. Protein tags can be useful for detecting, identifying, isolating, tracking, purifying, enriching for, targeting, or biologically or chemically modifying tagged proteins of interest, particularly when a tagged protein is part of a heterogeneous population of cell proteins or cells (e.g, a biological sample like peripheral blood). In certain embodiments, a protein tag of a fusion protein of this disclosure comprises a Myc tag, His tag, Flag tag, Xpress tag, Avi tag, Calmodulin tag, Polyglutamate tag, HA tag, Nus tag, S tag, X tag, SBP tag, Softag, V5 tag, CBP, GST, MBP, GFP, Thioredoxin tag, Strep tags (e.g, Strep-Tag; Strep-Tag II; and variants thereof, including those disclosed in, for example, Schmidt and Skerra, Nature Protocols, 2: 1528-1535 (2007), U.S. Patent No. 7,981,632; and PCT Publication No. WO 2015/067768, the strep-tag peptides, step-tag-pepti de-containing polypeptides, and sequences of the same, are incorporated herein by reference), or any combination thereof.
In any of the embodiments described herein, a fusion protein can be or can comprise a CAR or a TCR. Methods for making fusion proteins, including CARs, are described, for example, in U.S. Patent No. 6,410,319; U.S. Patent No. 7,446,191; U.S. Patent Publication No. 2010/065818; U.S. Patent No. 8,822,647; PCT Publication No. WO 2014/031687; U.S. Patent No. 7,514,537; Brentjens et al., 2007, Clin. Cancer Res. 13:5426, and Walseng et al., Scientific Reports 7:10713, 2017, the techniques of which are herein incorporated by reference.
Methods for producing engineered TCRs are described in, for example,
Bowerman et al, Mol. Immunol., 46{ 15):3000 (2009), the techniques of which are herein incorporated by reference. In certain embodiments, the antigen-binding fragment of the TCR comprises a single chain TCR (scTCR), which comprises both the TCR Va and nb domains TCR, but only a single TCR constant domain (Ca or Ob). In certain embodiments, the antigen-binding fragment of the TCR, or chimeric antigen receptor is chimeric ( e.g ., comprises amino acid residues or motifs from more than one donor or species), humanized (e.g., comprises residues from a non-human organism that are altered or substituted so as to reduce the risk of immunogenicity in a human), or human.
Methods useful for isolating and purifying recombinantly produced soluble fusion proteins, by way of example, may include obtaining supernatants from suitable host cell/vector systems that secrete the recombinant soluble fusion protein into culture media and then concentrating the media using a commercially available filter.
Following concentration, the concentrate may be applied to a single suitable
purification matrix or to a series of suitable matrices, such as an affinity matrix or an ion exchange resin. One or more reverse phase HPLC steps may be employed to further purify a recombinant polypeptide. These purification methods may also be employed when isolating an immunogen from its natural environment. Methods for large scale production of one or more of the isolated/recombinant soluble fusion protein described herein include batch cell culture, which is monitored and controlled to maintain appropriate culture conditions. Purification of the soluble fusion protein may be performed according to methods described herein and known in the art and that comport with laws and guidelines of domestic and foreign regulatory agencies.
Fusion proteins as described herein may be functionally characterized according to any of a large number of art-accepted methodologies for assaying host cell ( e.g .,
T cell) activity, including determination of T cell binding, activation or induction and also including determination of T cell responses that are antigen-specific. Examples include determination of intracellular calcium, T cell proliferation, T cell cytokine release, antigen-specific T cell stimulation, MHC-restricted T cell stimulation, CTL activity (e.g., by detecting 51Cr or Europium release from pre-loaded target cells), changes in T cell phenotypic marker expression, phosphorylation of certain T cell proteins, and other measures of T-cell functions. Procedures for performing these and similar assays are described herein and/or may be found, for example, in Lefkovits (Immunology Methods Manual: The Comprehensive Sourcebook of Techniques, 1998). See, also, Current Protocols in Immunology, Weir, Handbook of Experimental
Immunology, Blackwell Scientific, Boston, MA (1986); Mishell and Shigii (eds.) Selected Methods in Cellular Immunology, Freeman Publishing, San Francisco, CA (1979); Green and Reed, Science 281 : 1309 (1998) and references cited therein.
Levels of cytokines may be determined according to methods described herein and practiced in the art, including for example, ELISA, ELISPOT, intracellular cytokine staining, and flow cytometry and combinations thereof (e.g, intracellular cytokine staining and flow cytometry). Assays for determining intracellular calcium are known and include, for example, fluorescence microscopy using the Ca2+-sensitive dye Fluo-4 AM (BD Pharmingen™). Immune cell proliferation and clonal expansion resulting from an antigen-specific elicitation or stimulation of an immune response may be determined by isolating lymphocytes, such as circulating lymphocytes in samples of peripheral blood cells or cells from lymph nodes, stimulating the cells with antigen, and measuring cytokine production, cell proliferation and/or cell viability, such as by incorporation of tritiated thymidine or non-radioactive assays, such as MTT assays and the like. The effect of an immunogen described herein on the balance between a Thl immune response and a Th2 immune response may be examined, for example, by determining levels of Thl cytokines, such as IFN-g, IL-12, IL-2, and TNF-b, and Type 2 cytokines, such as IL-4, IL-5, IL-9, IL-10, and IL-13.
In any of the presently disclosed embodiments, a fusion protein, when expressed by a host cell, which optionally is an immune system cell such as a T cell, provides for or promotes: (i) improved cell signaling, and/or activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased and/or sustained cytokine production and/or release, and/or phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as LAT, PLC-g I , SLP-76, or any combination thereof; (ii) improved cell activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased mobilization of intracellular calcium , killing activity, proliferation, earlier activation in response to antigen, or any combination thereof; (iii) improved cell signaling and/or activity, relative to a host cell expressing a reference fusion protein, upon binding to a target antigen that is expressed at a low level or an intermediate level on a target cell surface; (iv) reducing or suppressing growth, area, volume, and/or spread of a tumor that expresses an antigen that is recognized and/or specifically bound by the fusion protein, of killing tumor cells, and/or of increasing survival of the subject to a greater degree and/or for a longer period of time as compared to a reference subject administered a host cell expressing a reference fusion protein; (iv) more efficient phosphorylation of LAT, SLP-76, and/or PLC-g I as compared to a reference fusion protein expressed by a host cell; (v) improved sensitivity to antigen as compared to a host cell expressing a reference fusion protein, but does not produce more, or substantially more, of a pro-inflammatory cytokine as compared to the host cell expressing the reference fusion protein; or (vi) any combination of (i)-(v).
In certain embodiments, the intracellular component of the fusion protein comprises a costimulatory domain, or a functional portion or variant thereof, from 4- 1BB. In certain embodiments, the reference protein comprises an intracellular domain comprising a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
In certain embodiments, the fusion protein and the reference protein each comprise an endodomain or effector domain from CD3z or a functional portion or variant thereof. In certain embodiments, the host cell expressing the fusion protein and
the host cell expressing the reference fusion protein are each an immune system cell, optionally a T cell, optionally a CD8 T cell, a CD4 T cell, or both.
Polynucleotides, Vectors, and Host Cells
In certain aspects, nucleic acid molecules are provided that encode any one or more of the fusion proteins as described herein. In certain embodiments, a
polynucleotide encoding a fusion protein comprises, or consists of, a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the nucleotide sequence set forth in any one of SEQ ID NOs.:34-46. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD3e intracellular sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:34. In certain
embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD3e_PRS_ITAM sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:35. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a O03z intracellular sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:36. In certain embodiments, a fusion- protein encoding polynucleotide comprises a polynucleotide that encodes a 4-1BB signaling sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:37. In certain embodiments, a fusion-protein encoding polynucleotide comprises a
polynucleotide that encodes a CD28 transmembrane sequence and has at least 70% identity to SEQ ID NO:38. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a hinge sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:39. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB signal_CD3e_PRS_ITAM Eϋ3z sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
or more) identity to SEQ ID NO:40. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB
8Ϊ§Mΐ_Eϋ3e_E03z sequence has at least 70% (i.e., at least 70%, 75%, 80%, 85%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:4l. In certain embodiments, a fusion-protein encoding polynucleotide comprises a polynucleotide that encodes a CD28tm_4-lBB 8^Mΐ_EO3z_E03e sequence and has at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:42. In certain embodiments, a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:43. In certain
embodiments, a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:44. In certain embodiments, a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:45. In certain embodiments, a fusion-protein encoding polynucleotide comprises or consists of a polynucleotide having at least 70% (i.e., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to SEQ ID NO:46.
In certain embodiments, a polynucleotide encoding a fusion protein further comprises a polynucleotide encoding a marker. Exemplary markers include green fluorescent protein, an extracellular domain of human CD2, a truncated human EGFR (huEGFRt, (see Wang et al, Blood 118: 1255, 2011), a truncated human CD19
(huCDl9t); a truncated human CD34 (huCD34t); or a truncated human NGFR
(huNGFRt). In certain embodiments, an encoded marker comprises EGFRt (e.g., SEQ ID NO:54), CDl9t, CD34t, or NGFRt.
In any of the embodiments described herein, a fusion protein-encoding polynucleotide can further comprise a polynucleotide that encodes a marker and a polynucleotide that encodes a self-cleaving polypeptide, wherein the polynucleotide encoding the self-cleaving polypeptide is located between the polynucleotide encoding
the fusion protein and the polynucleotide encoding the marker. When the fusion- protein encoding polynucleotide, marker-encoding polynucleotide, and self-cleaving polypeptide are expressed by a host cell, the fusion protein and the marker will be present on the host cell surface as separate molecules. In certain embodiments, a self cleaving polypeptide comprises a 2A peptide from porcine teschovirus-l (P2A, Thoseaasigna virus (T2A, equine rhinitis A virus (E2A), or foot-and-mouth disease virus (F2A)) (see, e.g., SEQ ID NOs.:50-53). Further exemplary nucleic acid and amino acid sequences of 2A peptides are set forth in, for example, Kim et al. ( PLOS One 6:el8556, 2011, which 2A nucleic acid and amino acid sequences are incorporated herein by reference in their entirety).
In any of the embodiments described herein, a self-cleaving polypeptide encoded by a chimeric polynucleotide of this disclosure encodes a P2A, a T2A, an E2A, or a F2A.
In any of the embodiments described herein, a polynucleotide of the present disclosure (e.g, a fusion protein-encoding polynucleotide or polynucleotide encoding a marker) may be codon-optimized for a host cell containing the polynucleotide (see, e.g, Scholten et al, Clin. Immunol. 779:135-145 (2006). Codon optimization can be performed using, e.g., the GenScript® Optimum Gene™ tool. Codon-optimized sequences include sequences that are partially codon-optimized (i.e., one or more of the codons is optimized for expression in the host cell) and those that are fully codon-optimized.
A polynucleotide encoding a desired fusion protein of this disclosure can be inserted into an appropriate vector (e.g, viral vector or non-viral plasmid vector) for introduction into a host cell of interest (e.g, an immune cell, such as a T cell).
In further aspects, expression constructs are provided, wherein the expression constructs comprise a polynucleotide of the present disclosure (e.g, a fusion protein encoding polynucleotide or a polynucleotide encoding a tagged marker) operably linked to an expression control sequence (e.g, a promoter). In certain embodiments, the expression construct is comprised in a vector. An exemplary vector may comprise a polynucleotide capable of transporting another polynucleotide to which it has been linked, or which is capable of replication in a host organism. Some examples of vectors include plasmids, viral vectors, cosmids, and others. Some vectors may be capable of
autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors), whereas other vectors may be integrated into the genome of a host cell or promote integration of the polynucleotide insert upon introduction into the host cell and thereby replicate along with the host genome (e.g, lentiviral vector, retroviral vector).
Additionally, some vectors are capable of directing the expression of genes to which they are operatively linked (these vectors may be referred to as "expression vectors"). According to related embodiments, it is further understood that, if one or more agents (e.g., polynucleotides encoding fusion proteins as described herein) are co-administered to a subject, that each agent may reside in separate or the same vectors, and multiple vectors (each containing a different agent or the same agent) may be introduced to a cell or cell population or administered to a subject.
In certain embodiments, polynucleotides of the present disclosure may be operatively linked to certain elements of a vector. For example, polynucleotide sequences that are needed to effect the expression and processing of coding sequences to which they are ligated may be operatively linked. Expression control sequences may include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion. Expression control sequences may be operatively linked if they are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
In certain embodiments, the vector comprises a plasmid vector or a viral vector (e.g, a vector selected from lentiviral vector or a g-retroviral vector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as ortho-myxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g., measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex
virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields et al ., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
"Retroviruses" are viruses having an RNA genome, which is reverse-transcribed into DNA using a reverse transcriptase enzyme, the reverse-transcribed DNA is then incorporated into the host cell genome. "Gammaretrovirus" refers to a genus of the retroviridae family. Examples of gammaretroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis viruses.
"Lentiviral vector," as used herein, means HIV-based lentiviral vectors for gene delivery, which can be integrative or non-integrative, have relatively large packaging capacity, and can transduce a range of different cell types. Lentiviral vectors are usually generated following transient transfection of three (packaging, envelope and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the cell surface. On entry, the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral integration into the DNA of infected cells.
In certain embodiments, the viral vector can be a gammaretrovirus, e.g. , Moloney murine leukemia virus (MLV)-derived vectors. In other embodiments, the viral vector can be a more complex retrovirus-derived vector, e.g. , a lentivirus-derived vector. HIV- 1 -derived vectors belong to this category. Other examples include lentivirus vectors derived from HIV-2, FIV, equine infectious anemia virus, SIV, and Maedi-Visna virus (ovine lentivirus). Methods of using retroviral and lentiviral viral vectors and packaging cells for transducing mammalian host cells with viral particles containing CAR transgenes are known in the art and have been previous described, for
example, in: U.S. Patent 8,119,772; Walchli et al, PLoS One 6: 327930, 2011; Zhao et al ., ./. Immunol. 777:4415, 2005; Engels e/ a/., Hum. Gene Ther. 77: 1155, 2003; Frecha et aI., MoI. Ther. 75: 1748, 2010; and Verhoeyen et al ., Methods Mol. Biol. 506:91 ,
2009. Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors also can be used for polynucleotide delivery including DNA viral vectors, including, for example adenovirus-based vectors and adeno-associated virus (AAV)-based vectors; vectors derived from herpes simplex viruses (HSVs), including amplicon vectors, replication-defective HSV and attenuated HSV (Krisky et al., Gene Ther. 5: 1517, 1998).
Other vectors developed for gene therapy uses can also be used with the compositions and methods of this disclosure. Such vectors include those derived from baculoviruses and a- viruses. (Jolly, D J. 1999. Emerging Viral Vectors pp 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plasmid vectors (such as sleeping beauty or other transposon vectors).
When a viral vector genome comprises a plurality of polynucleotides to be expressed in a host cell as separate transcripts, the viral vector may also comprise additional sequences between the two (or more) transcripts allowing for bicistronic or multi cistronic expression. Examples of such sequences used in viral vectors include internal ribosome entry sites (IRES), furin cleavage sites, viral 2A peptide, or any combination thereof.
Construction of an expression vector that is used for genetically engineering and producing a fusion protein of interest can be accomplished by using any suitable molecular biology engineering techniques known in the art. To obtain efficient transcription and translation, a polynucleotide in each recombinant expression construct includes at least one appropriate expression control sequence (also called a regulatory sequence), such as a leader sequence and particularly a promoter operably (i.e., operatively) linked to the nucleotide sequence encoding the immunogen.
In certain embodiments, polynucleotides of the present disclosure are used to transfect/transduce a host cell ( e.g ., a T cell) for use in adoptive transfer therapy (e.g, targeting a cancer antigen). Methods for transfecting/transducing T cells with desired nucleic acids have been described (e.g., U.S. Patent Application Pub. No. US
2004/0087025) as have adoptive transfer procedures using T cells of desired target- specificity ( e.g ., Schmitt et al., Hum. Gen. 20: 1240, 2009; Dossett et al., Mol. Ther. 77:742, 2009; Till et al. , Blood 772:2261, 2008; Wang et al. , Hum. Gene Ther. 75:712, 2007; Kuball et al, Blood 709:2331, 2007; US 2011/0243972; US 2011/0189141; Leen et al., Ann. Rev. Immunol. 25: 243, 2007), such that adaptation of these methodologies to the presently disclosed embodiments is contemplated, based on the teachings herein, including those directed to fusion proteins of the present disclosure.
In certain embodiments, the host cell is a hematopoietic progenitor cell or a human immune system cell. A "hematopoietic progenitor cell", as referred to herein, is a cell that can be derived from hematopoietic stem cells or fetal tissue and is capable of further differentiation into mature cells types (e.g., immune system cells). Exemplary hematopoietic progenitor cells include those with a CD24Lo Lin- CD117+ phenotype or those found in the thymus (referred to as progenitor thymocytes).
As used herein, an "immune system cell" means any cell of the immune system that originates from a hematopoietic stem cell in the bone marrow, which gives rise to two major lineages, a myeloid progenitor cell (which give rise to myeloid cells such as monocytes, macrophages, dendritic cells, megakaryocytes and granulocytes) and a lymphoid progenitor cell (which give rise to lymphoid cells such as T cells, B cells, natural killer (NK) cells, and NK-T cells). Exemplary immune system cells include a CD4+ T cell, a CD8+ T cell, a CD4 CD8 double negative T cell, a gd T cell, a regulatory T cell, a stem cell memory T cell, a natural killer cell (e.g, aNK cell or a NK-T cell), a B cell, and a dendritic cell. Macrophages and dendritic cells may be referred to as "antigen presenting cells" or "APCs," which are specialized cells that can activate T cells when a major histocompatibility complex (MHC) receptor on the surface of the APC complexed with a peptide interacts with a TCR on the surface of a T cell.
A "T cell" or "T lymphocyte" is an immune system cell that matures in the thymus and produces T cell receptors (TCRs). T cells can be naive (not exposed to antigen; increased expression of CD62L, CCR7, CD28, CD3, CD 127, and CD45RA, and decreased expression of CD45RO as compared to TCM), memory T cells (TM) (antigen-experienced and long-lived), and effector cells (antigen-experienced,
cytotoxic). TM can be further divided into subsets of central memory T cells (TCM, increased expression of CD62L, CCR7, CD28, CD 127, CD45RO, and CD95, and decreased expression of CD54RA as compared to naive T cells) and effector memory T cells (TEM, decreased expression of CD62L, CCR7, CD28, CD45RA, and increased expression of CD127 as compared to naive T cells or TCM).
Effector T cells (TE) refers to antigen-experienced CD8+ cytotoxic T
lymphocytes that have decreased expression of CD62L ,CCR7, CD28, and are positive for granzyme and perforin as compared to TCM. Helper T cells (TH) are CD4+ cells that influence the activity of other immune cells by releasing cytokines. CD4+ T cells can activate and suppress an adaptive immune response, and which of those two functions is induced will depend on presence of other cells and signals. T cells can be collected using known techniques, and the various subpopulations or combinations thereof can be enriched or depleted by known techniques, such as by affinity binding to antibodies, flow cytometry, or immunomagnetic selection. Other exemplary T cells include regulatory T cells, such as CD4+ CD25+ (Foxp3+) regulatory T cells and Tregl7 cells, as well as Trl, Th3, CD8+CD28 , and Qa-l restricted T cells.
"Cells of T cell lineage" refer to cells that show at least one phenotypic characteristic of a T cell, or a precursor or progenitor thereof that distinguishes the cells from other lymphoid cells, and cells of the erythroid or myeloid lineages. Such phenotypic characteristics can include expression of one or more proteins specific for T cells ( e.g ., CD3+, CD4+, CD8+), or a physiological, morphological, functional, or immunological feature specific for a T cell. For example, cells of the T cell lineage may be progenitor or precursor cells committed to the T cell lineage; CD25+ immature and inactivated T cells; cells that have undergone CD4 or CD8 linage commitment; thymocyte progenitor cells that are CD4+CD8+ double positive; single positive CD4+ or CD8+; TCRa.p or TCR gd; or mature and functional or activated T cells.
In certain embodiments, the immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell (e.g., NK cell or NK- T cell), a dendritic cell, a B cell, or any combination thereof. In certain embodiments, the T cell is a naive T cell, a central memory T cell, an effector memory T cell, a stem cell memory T cell, or any combination thereof.
A host cell may include any individual cell or cell culture which may receive a vector or the incorporation of nucleic acids or express proteins. The term also encompasses progeny of the host cell, whether genetically or phenotypically the same or different. Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate the vector or other material by use of a viral vector, transformation via calcium phosphate precipitation, DEAE-dextran,
electroporation, microinjection, or other methods. See , for example, Sambrook et al ., Molecular Cloning: A Laboratory Manual 2d ed. (Cold Spring Harbor Laboratory, 1989).
In any of the foregoing embodiments, a host cell that comprises a heterologous polynucleotide encoding a fusion protein is an immune cell which is modified to reduce or eliminate expression of one or more endogenous genes that encode a polypeptide product selected from PD-l, LAG-3, CTLA4, TIM3, TIGIT, an HLA molecule, a TCR molecule, or any component or combination thereof.
Without wishing to be bound by theory, certain endogenously expressed immune cell proteins may downregulate the immune activity of a modified immune host cell ( e.g ., PD-l, LAG-3, CTLA4, TIGIT), or may compete with a heterologous fusion protein of the present disclosure for expression by the host cell, or may interfere with the binding activity of a heterologously expressed fusion protein of the present disclosure and interfere with the immune host cell binding to a target cell that expresses an antigen , or any combination thereof. Further, endogenous proteins (e.g., immune host cell proteins, such as an HLA) expressed on a donor immune cell to be used in a cell transfer therapy may be recognized as foreign by an allogeneic recipient, which may result in elimination or suppression of the donor immune cell by the allogeneic recipient.
Accordingly, decreasing or eliminating expression or activity of such
endogenous genes or proteins can improve the activity, tolerance, and persistence of the host cells in an autologous or allogeneic host setting, and allows universal
administration of the cells (e.g., to any recipient regardless of HLA type). In certain embodiments, a modified host immune cell is a donor cell (e.g., allogeneic) or an
autologous cell. In certain embodiments, a modified immune host cell of this disclosure comprises a chromosomal gene knockout of one or more of a gene that encodes PD-l, LAG-3, CTLA4, TIM3, TIGIT, an HLA component (e.g., a gene that encodes an al macroglobulin, an a2 macroglobulin, an a3 macroglobulin, a bΐ microglobulin, or a b2 microglobulin), or a TCR component (e.g., a gene that encodes a TCR variable region or a TCR constant region) (see, e.g., Torikai el al., Nature Sci. Rep. 6: 21757 (2016); Torikai et al., Blood 179(24): 5697 (2012); and Torikai et al., Blood 722(8): 1341 (2013) the gene editing techniques, compositions, and adoptive cell therapies of which are herein incorporated by reference in their entirety). As used herein, the term
"chromosomal gene knockout" refers to a genetic alteration in a host cell that prevents production, by the host cell, of a functionally active endogenous polypeptide product. Alterations resulting in a chromosomal gene knockout can include, for example, introduced nonsense mutations (including the formation of premature stop codons), missense mutations, gene deletion, and strand breaks, as well as the heterologous expression of inhibitory nucleic acid molecules that inhibit endogenous gene expression in the host cell.
In certain embodiments, a chromosomal gene knock-out or gene knock-in is made by chromosomal editing of a host cell. Chromosomal editing can be performed using, for example, endonucleases. As used herein "endonuclease" refers to an enzyme capable of catalyzing cleavage of a phosphodiester bond within a polynucleotide chain. In certain embodiments, an endonuclease is capable of cleaving a targeted gene thereby inactivating or "knocking out" the targeted gene. An endonuclease may be a naturally occurring, recombinant, genetically modified, or fusion endonuclease. The nucleic acid strand breaks caused by the endonuclease are commonly repaired through the distinct mechanisms of homologous recombination or non-homologous end joining (NHEJ). During homologous recombination, a donor nucleic acid molecule may be used for a donor gene "knock-in", for target gene "knock-out", and optionally to inactivate a target gene through a donor gene knock in or target gene knock out event. NHEJ is an error- prone repair process that often results in changes to the DNA sequence at the site of the cleavage, e.g., a substitution, deletion, or addition of at least one nucleotide. NHEJ may
be used to "knock-out" a target gene. Examples of endonucleases include zinc finger nucleases, TALE-nucleases, CRISPR-Cas nucleases, meganucleases, and megaTALs.
As used herein, a "zinc finger nuclease" (ZFN) refers to a fusion protein comprising a zinc finger DNA-binding domain fused to a non-specific DNA cleavage domain, such as a Fokl endonuclease. Each zinc finger motif of about 30 amino acids binds to about 3 base pairs of DNA, and amino acids at certain residues can be changed to alter triplet sequence specificity (see, e.g., Desjarlais et al., Proc. Natl. Acad. Sci.
90: 2256-2260, 1993; Wolfe et al, J. Mol. Biol. 255: 1917-1934, 1999). Multiple zinc finger motifs can be linked in tandem to create binding specificity to desired DNA sequences, such as regions having a length ranging from about 9 to about 18 base pairs. By way of background, ZFNs mediate genome editing by catalyzing the formation of a site-specific DNA double strand break (DSB) in the genome, and targeted integration of a transgene comprising flanking sequences homologous to the genome at the site of DSB is facilitated by homology directed repair. Alternatively, a DSB generated by a ZFN can result in knock out of target gene via repair by non-homologous end joining (NHEJ), which is an error-prone cellular repair pathway that results in the insertion or deletion of nucleotides at the cleavage site. In certain embodiments, a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, made using a ZFN molecule.
As used herein, a "transcription activator-like effector nuclease" (TALEN) refers to a fusion protein comprising a TALE DNA-binding domain and a DNA cleavage domain, such as a Fokl endonuclease. A "TALE DNA binding domain" or "TALE" is composed of one or more TALE repeat domains/units, each generally having a highly conserved 33-35 amino acid sequence with divergent l2th and l3th amino acids. The TALE repeat domains are involved in binding of the TALE to a target DNA sequence. The divergent amino acid residues, referred to as the Repeat Variable Diresidue (RVD), correlate with specific nucleotide recognition. The natural (canonical) code for DNA recognition of these TALEs has been determined such that an HD (histine-aspartic acid) sequence at positions 12 and 13 of the TALE leads to the TALE binding to cytosine (C), NG (asparagine-glycine) binds to a T nucleotide, NI (asparagine-isoleucine) to A, NN (asparagine-asparagine) binds to a G or A nucleotide,
and NG (asparagine-glycine) binds to a T nucleotide. Non-canonical (atypical) RVDs are also known (see, e.g., U.S. Patent Publication No. US 2011/0301073, which atypical RVDs are incorporated by reference herein in their entirety). TALENs can be used to direct site-specific double-strand breaks (DSB) in the genome of T cells. Non- homologous end joining (NHEJ) ligates DNA from both sides of a double-strand break in which there is little or no sequence overlap for annealing, thereby introducing errors that knock out gene expression. Alternatively, homology directed repair can introduce a transgene at the site of DSB providing homologous flanking sequences are present in the transgene. In certain embodiments, a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, and made using a TALEN molecule.
As used herein, a "clustered regularly interspaced short palindromic
repeats/Cas" (CRISPR/Cas) nuclease system refers to a system that employs a CRISPR RNA (crRNA)-guided Cas nuclease to recognize target sites within a genome (known as protospacers) via base-pairing complementarity and then to cleave the DNA if a short, conserved protospacer associated motif (PAM) immediately follows 3’ of the complementary target sequence. CRISPR/Cas systems are classified into three types (i.e., type I, type II, and type III) based on the sequence and structure of the Cas nucleases. The crRNA-guided surveillance complexes in types I and III need multiple Cas subunits. Type II system, the most studied, comprises at least three components: an RNA-guided Cas9 nuclease, a crRNA, and a trans-acting crRNA (tracrRNA). The tracrRNA comprises a duplex forming region. A crRNA and a tracrRNA form a duplex that is capable of interacting with a Cas9 nuclease and guiding the
Cas9/crRNA:tracrRNA complex to a specific site on the target DNA via Watson-Crick base-pairing between the spacer on the crRNA and the protospacer on the target DNA upstream from a PAM. Cas9 nuclease cleaves a double-stranded break within a region defined by the crRNA spacer. Repair by NHEJ results in insertions and/or deletions which disrupt expression of the targeted locus. Alternatively, a transgene with homologous flanking sequences can be introduced at the site of DSB via homology directed repair. The crRNA and tracrRNA can be engineered into a single guide RNA (sgRNA or gRNA) (see, e.g., Jinek et al., Science 337:816-21, 2012). Further, the region of the guide RNA complementary to the target site can be altered or programed
to target a desired sequence (Xie et al. , PLOS One 9:el00448, 2014; U.S. Pat. Appl. Pub. No. US 2014/0068797, U.S. Pat. Appl. Pub. No. US 2014/0186843; U.S. Pat. No. 8,697,359, and PCT Publication No. WO 2015/071474; each of which is incorporated by reference). In certain embodiments, a gene knockout comprises an insertion, a deletion, a mutation or a combination thereof, and made using a CRISPR/Cas nuclease system.
Exemplary gRNA sequences and methods of using the same to knock out endogenous genes that encode immune cell proteins include those described in Ren et al., Clin. Cancer Res. 23(9):2255-2266 (2017), the gRNAs, CAS9 DNAs, vectors, and gene knockout techniques of which are hereby incorporated by reference in their entirety.
As used herein, a "meganuclease," also referred to as a "homing endonuclease," refers to an endodeoxyribonuclease characterized by a large recognition site (double stranded DNA sequences of about 12 to about 40 base pairs). Meganucleases can be divided into five families based on sequence and structure motifs: LAGLIDADG, GIY- YIG, HNH, His-Cys box and PD-(D/E)XK. Exemplary meganucleases include I-Scel, I-Ceul, PI-PspI, RI-Sce, 1-SceIV, I-Csml, I-Panl, I-Scell, I-Ppol, I-SceIII, I-Crel, I- TevI, I-TevII and I-TevIII, whose recognition sequences are known (see, e.g., U.S. Patent Nos. 5,420,032 and 6,833,252; Belfort et al., Nucleic Acids Res. 25: 3379-3388, 1997; Dujon et al ., Gene 82: 115-118, 1989; Perler et al., Nucleic Acids Res. 22:1125- 1127, 1994; Jasin, Trends Genet. 72:224-228, 1996; Gimble et al., J. Mol. Biol.
263: 163-180, 1996; Argast et al, J. Mol. Biol. 280: 345-353, 1998).
In certain embodiments, naturally-occurring meganucleases may be used to promote site-specific genome modification of a target selected from PD-l, LAG3,
TIM3, CTLA4, TIGIT, an HLA-encoding gene, or a TCR component-encoding gene.
In other embodiments, an engineered meganuclease having a novel binding specificity for a target gene is used for site-specific genome modification (see, e.g., Porteus et al, Nat. Biotechnol. 23:967-73, 2005; Sussman et al, J. Mol. Biol. 342: 31-41, 2004; Epinat et al, Nucleic Acids Res. 37:2952-62, 2003; Chevalier et al, Molec. Cell 70:895-905, 2002; Ashworth et al, Nature 441:656-659, 2006; Paques et al, Curr. Gene Ther. 7:49- 66, 2007; U.S. Patent Publication Nos. US 2007/0117128; US 2006/0206949; US
2006/0153826; US 2006/0078552; and US 2004/0002092). In further embodiments, a chromosomal gene knockout is generated using a homing endonuclease that has been modified with modular DNA binding domains of TALENs to make a fusion protein known as a megaTAL. MegaTALs can be utilized to not only knock-out one or more target genes, but to also introduce (knock in) heterologous or exogenous
polynucleotides when used in combination with an exogenous donor template encoding a polypeptide of interest.
In certain embodiments, a chromosomal gene knockout comprises an inhibitory nucleic acid molecule that is introduced into a host cell ( e.g ., an immune cell) comprising a heterologous polynucleotide encoding an antigen-specific receptor that specifically binds to a tumor associated antigen, wherein the inhibitory nucleic acid molecule encodes a target-specific inhibitor and wherein the encoded target-specific inhibitor inhibits endogenous gene expression (i.e., of PD-l, TIM3, LAG3, CTLA4, TIGIT, an HLA component, or a TCR component, or any combination thereof) in the host immune cell.
A chromosomal gene knockout can be confirmed directly by DNA sequencing of the host immune cell following use of the knockout procedure or agent.
Chromosomal gene knockouts can also be inferred from the absence of gene expression (e.g., the absence of an mRNA or polypeptide product encoded by the gene) following the knockout.
In certain embodiments, a host cell (e.g, immune cell) of the present disclosure is engineered so that expression of a presently disclosed fusion protein by the host cell is modulated (e.g, controlled) by binding of the host cell to an antigen that is not the same antigen as the antigen to which the fusion protein specifically binds.
For example, a host cell can comprise (i) a polynucleotide encoding an engineered (i.e., synthetic) Notch receptor comprising (a) an extracellular component comprising a binding domain that binds to an antigen, which is a different antigen than the antigen to which the fusion protein binds, (b) a Notch core domain, or a functional portion or variant thereof; and (c) an intracellular component comprising a
transcriptional factor (i.e., a polypeptide capable of activating or increasing, or inhibiting, repressing or reducing, transcription of a target nucleotide sequence (e.g., a
gene) or set of target nucleotide sequences); and (ii) the heterologous polynucleotide encoding a fusion protein as disclosed herein and comprising an expression control sequence that can be recognized or bound by the transcriptional factor, wherein binding of the engineered Notch receptor to antigen leads to release of the transcriptional factor from the engineered Notch receptor ( e.g ., by protease-driven cleavage), which can, in turn, drive transcription of the fusion protein. See, e.g., Morsut el al, Cell -/: 780-791 (2016) and PCT Published Application No. WO 2016/138034A1, which synthetic Notch constructs are incorporated herein by reference. Briefly, such "logic-gated" expression systems may be useful to modulate expression of a fusion protein of this disclosure so that the expression occurs only, or preferentially, when the host cell encounters a first antigen ( i.e ., that can be bound by the synthetic Notch receptor) that is only expressed by, or is principally expressed by, or has a higher expression level on cancer cells as compared to healthy cells. Such embodiments may reduce "on-target off-tissue" recognition by a fusion protein in circumstances where the antigen recognized by the fusion protein is expressed by healthy cells.
In other aspects, kits are provided comprising (a) a vector or an expression construct as described herein and (b) reagents for transducing the vector or the expression construct into a host cell.
Uses
The present disclosure also provides methods for treating a disease or condition, wherein the methods comprise administering to a subject in need thereof an effective amount of a host cell, composition, or unit dose of the present disclosure, wherein the disease or condition expresses or is otherwise associated with the antigen that is specifically bound by the fusion protein. In certain embodiments, the disease or condition is a hyperproliferative or proliferative disease, such as a cancer, an autoimmune disease, or an infectious disease (e.g, viral, bacterial, fungal, or parasitic).
As used herein, "hyperproliferative disorder" refers to excessive growth or proliferation as compared to a normal or undiseased cell. Exemplary hyperproliferative disorders include tumors, cancers, neoplastic tissue, carcinoma, sarcoma, malignant cells, pre-malignant cells, as well as non-neoplastic or non-malignant hyperproliferative disorders (e.g, adenoma, fibroma, lipoma, leiomyoma, hemangioma, fibrosis,
restenosis, as well as autoimmune diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, inflammatory bowel disease, or the like). Certain diseases that involve abnormal or excessive growth that occurs more slowly than in the context of a hyperproliferative disease can be referred to as "proliferative diseases", and include certain tumors, cancers, neoplastic tissue, carcinoma, sarcoma, malignant cells, pre malignant cells, as well as non-neoplastic or non-malignant disorders.
Furthermore, "cancer" may refer to any accelerated proliferation of cells, including solid tumors, ascites tumors, blood or lymph or other malignancies;
connective tissue malignancies; metastatic disease; minimal residual disease following transplantation of organs or stem cells; multi-drug resistant cancers, primary or secondary malignancies, angiogenesis related to malignancy, or other forms of cancer.
In certain embodiments, a cancer treatable according to the presently disclosed methods and uses comprises a carcinoma, a sarcoma, a glioma, a lymphoma, a leukemia, a myeloma, or any combination thereof. In certain embodiments, cancer comprises a cancer of the head or neck, melanoma, pancreatic cancer,
cholangiocarcinoma, hepatocellular cancer, breast cancer including triple-negative breast cancer (TNBC), gastric cancer, non-small-cell lung cancer, prostate cancer, esophageal cancer, mesothelioma, small-cell lung cancer, colorectal cancer,
glioblastoma, or any combination thereof. In certain embodiments, a cancer comprises Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, PNET, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans (DFSP), desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma,
gastrointestinal stromal tumor (GIST), hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, linitis plastic, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, renal cell carcinoma, Grawitz tumor, ependymoma, astrocytoma,
oligodendroglioma, brainstem glioma, optice nerve glioma, a mixed glioma, Hodgkin’s lymphoma, a B-cell lymphoma, non-Hodgkin’s lymphoma (NHL), Burkitt's lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma, Waldenstrom's macroglobulinemia, CD37+ dendritic cell lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extra- nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, adult T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, blastic NK cell lymphoma, Sezary syndrome, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, or any combination thereof.
In certain embodiments, the cancer comprises a solid tumor. In some embodiments, the solid tumor is a sarcoma or a carcinoma. In certain embodiments, the solid tumor is selected from: chondrosarcoma; fibrosarcoma (fibroblastic sarcoma); Dermatofibrosarcoma protuberans (DFSP); osteosarcoma; rhabdomyosarcoma; Ewing’s sarcoma; a gastrointestinal stromal tumor; Leiomyosarcoma; angiosarcoma (vascular sarcoma); Kaposi’s sarcoma; liposarcoma; pleomorphic sarcoma; or synovial sarcoma.
In certain ebmodiments, the solid tumor is selected from a lung carcinoma (e.g., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular carcinoma in situ (non-invasive), Invasive Ductal
Carcinoma, Invasive lobular carcinoma, Non-invasive Carcinoma); a liver carcinoma (e.g., Hepatocellular Carcinoma, Cholangiocarcinomas or Bile Duct Cancer); Large-cell undifferentiated carcinoma, Bronchioalveolar carcinoma); an ovarian carcinoma (e.g., Surface epithelial-stromal tumor (Adenocarcinoma) or ovarian epithelial carcinoma (which includes serous tumor, endometrioid tumor and mucinous cystadenocarcinoma), Epidermoid (Squamous cell carcinoma), Embryonal carcinoma and choriocarcinoma (germ cell tumors)); a kidney carcinoma (e.g., Renal adenocarcinoma, hypernephroma,
Transitional cell carcinoma (renal pelvis), Squamous cell carcinoma, Bellini duct carcinoma, Clear cell adenocarcinoma, Transitional cell carcinoma, Carcinoid tumor of the renal pelvis); an adrenal carcinoma (e.g., Adrenocortical carcinoma), a carcinoma of the testis (e.g., Germ cell carcinoma (Seminoma, Choriocarcinoma, Embryonal carciroma, Teratocarcinoma), Serous carcinoma); Gastric carcinoma (e.g.,
Adenocarcinoma); an intestinal carcinoma (e.g., Adenocarcinoma of the duodenum); a colorectal carcinoma; or a skin carcinoma (e.g., Basal cell carcinoma, Squamous cell carcinoma). In certain embodiments, the solid tumor is an ovarian carcinoma, an ovarian epithelial carcinoma, a cervical adenocarcinoma or small cell carcinoma, a pancreatic carcinoma, a colorectal carcinoma (e.g., an adenocarcinoma or squamous cell carcinoma), a lung carcinoma, a breast ductal carcinoma, or an adenocarcinoma of the prostate.
In any of the presently disclosed embodiments, the host cell is an allogeneic cell, a syngeneic cell, or an autologous cell.
Subjects that can be treated by the present invention are, in general, human and other primate subjects, such as monkeys and apes for veterinary medicine purposes. In any of the aforementioned embodiments, the subject may be a human subject. The subjects can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. Cells according to the present disclosure may be administered in a manner appropriate to the disease, condition, or disorder to be treated as determined by persons skilled in the medical art. In any of the above embodiments, a cell comprising a fusion protein as described herein is administered intravenously, intraperitoneally, intratumorally, into the bone marrow, into a lymph node, or into the cerebrospinal fluid so as to encounter the target antigen or cells. An appropriate dose, suitable duration, and frequency of administration of the compositions will be determined by such factors as a condition of the patient; size, type, and severity of the disease, condition, or disorder; the undesired type or level or activity of the tagged cells, the particular form of the active ingredient; and the method of
administration.
In any of the above embodiments, methods of the present disclosure comprise
administering a host cell expressing a fusion protein of the present disclosure, or a composition comprising the host cell. The amount of cells in a composition is at least one cell (for example, one fusion protein-modified CD8+ T cell subpopulation; one fusion protein-modified CD4+ T cell subpopulation) or is more typically greater than 102 cells, for example, up to 106, up to 107, up to 108 cells, up to 109 cells, or 1010 cells or more, such as about 1011 cells/m2. In certain embodiments, the cells are administered in a range from about 105 to about 1011 cells/m2, preferably in a range of about 105 or about 106 to about 109 or about 1010 cells/m2. The number of cells will depend upon the ultimate use for which the composition is intended as well the type of cells included therein. For example, cells modified to contain a fusion protein specific for a particular antigen will comprise a cell population containing at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of such cells. For uses provided herein, cells are generally in a volume of a liter or less, 500 mls or less,
250 mls or less, or 100 mls or less. In embodiments, the density of the desired cells is typically greater than 104 cells/ml and generally is greater than 107 cells/ml, generally 108 cells/ml or greater. The cells may be administered as a single infusion or in multiple infusions over a range of time. A clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 106, 107, 108, 109, 1010, or 1011 cells.
Unit doses are also provided herein which comprise a host cell ( e.g ., a modified immune cell comprising a polynucleotide of the present disclosure) or host cell composition of this disclosure. In certain embodiments, a unit dose comprises (i) a composition comprising at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% modified CD4+ T cells, combined with (ii) a composition comprising at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells (i.e., has less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less then about 1% the population of naive T
cells present in a unit dose as compared to a patient sample having a comparable number of PBMCs).
In some embodiments, a unit dose comprises (i) a composition comprising at least about 50% modified CD4+ T cells, combined with (ii) a composition comprising at least about 50% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells. In further embodiments, a unit dose comprises (i) a composition comprising at least about 60% modified CD4+ T cells, combined with (ii) a composition comprising at least about 60% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells. In still further embodiments, a unit dose comprises (i) a composition comprising at least about 70% modified CD4+ T cells, combined with (ii) a composition comprising at least about 70% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells. In some embodiments, a unit dose comprises (i) a composition comprising at least about 80% modified CD4+ T cells, combined with (ii) a composition comprising at least about 80% modified CD8+ T cells, in about a 1 :1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells. In some embodiments, a unit dose comprises (i) a composition comprising at least about 85% modified CD4+ T cells, combined with (ii) a composition comprising at least about 85% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells. In some embodiments, a unit dose comprises (i) a composition comprising at least about 90% modified CD4+ T cells, combined with (ii) a composition comprising at least about 90% modified CD8+ T cells, in about a 1 : 1 ratio, wherein the unit dose contains a reduced amount or substantially no naive T cells.
In any of the embodiments described herein, a unit dose comprises equal, or approximately equal numbers of engineered CD45RA CD3+ CD8+ and engineered CD45RA- CD3+ CD4+ TM cells.
Also contemplated are pharmaceutical compositions that comprise fusion proteins or cells expressing the fusion proteins as disclosed herein and a
pharmaceutically acceptable carrier, diluents, or excipient. Suitable excipients include water, saline, dextrose, glycerol, or the like and combinations thereof. In embodiments,
compositions comprising fusion proteins or host cells as disclosed herein further comprise a suitable infusion media. Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), 5% dextrose in water, Ringer's lactate can be utilized. An infusion medium can be supplemented with human serum albumin or other human serum components.
Pharmaceutical compositions may be administered in a manner appropriate to the disease or condition to be treated (or prevented) as determined by persons skilled in the medical art. An appropriate dose and a suitable duration and frequency of administration of the compositions will be determined by such factors as the health condition of the patient, size of the patient (i.e., weight, mass, or body area), the type and severity of the patient's condition, the undesired type or level or activity of the tagged cells, the particular form of the active ingredient, and the method of
administration. In general, an appropriate dose and treatment regimen provide the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (such as described herein, including an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity). For prophylactic use, a dose should be sufficient to prevent, delay the onset of, or diminish the severity of a disease associated with disease or disorder. Prophylactic benefit of the immunogenic compositions
administered according to the methods described herein can be determined by performing pre-clinical (including in vitro and in vivo animal studies) and clinical studies and analyzing data obtained therefrom by appropriate statistical, biological, and clinical methods and techniques, all of which can readily be practiced by a person skilled in the art.
Certain methods of treatment or prevention contemplated herein include administering a host cell (which may be autologous, allogeneic or syngeneic) comprising a desired polynucleotide as described herein that is stably integrated into the chromosome of the cell. For example, such a cellular composition may be generated ex vivo using autologous, allogeneic or syngeneic immune system cells ( e.g T cells, antigen-presenting cells, natural killer cells) in order to administer a desired, fusion protein-expressing T-cell composition to a subject as an adoptive immunotherapy. In
certain embodiments, the host cell is a hematopoietic progenitor cell or a human immune cell. In certain embodiments, the immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4 CD8 double-negative T cell, a gd T cell, a natural killer cell, a dendritic cell, or any combination thereof. In certain embodiments, the immune system cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof. In particular embodiments, the cell is a CD4+ T cell.
In particular embodiments, the cell is a CD8+ T cell.
As used herein, administration of a composition refers to delivering the same to a subject, regardless of the route or mode of delivery. Administration may be effected continuously or intermittently, and parenterally. Administration may be for treating a subject already confirmed as having a recognized condition, disease or disease state, or for treating a subject susceptible to or at risk of developing such a condition, disease or disease state. Co-administration with an adjunctive therapy may include simultaneous and/or sequential delivery of multiple agents in any order and on any dosing schedule ( e.g ., fusion protein-expressing recombinant (i.e., engineered) host cells with one or more cytokines; immunosuppressive therapy such as calcineurin inhibitors,
corticosteroids, microtubule inhibitors, low dose of a mycophenolic acid prodrug, or any combination thereof).
In certain embodiments, a plurality of doses of a recombinant host cell as described herein is administered to the subject, which may be administered at intervals between administrations of about two to about four weeks.
In still further embodiments, the subject being treated is further receiving immunosuppressive therapy, such as calcineurin inhibitors, corticosteroids, microtubule inhibitors, low dose of a mycophenolic acid prodrug, or any combination thereof. In yet further embodiments, the subject being treated has received a non-myeloablative or a myeloablative hematopoietic cell transplant, wherein the treatment may be administered at least two to at least three months after the non-myeloablative hematopoietic cell transplant.
An effective amount of a pharmaceutical composition (e.g., host cell, fusion protein, unit dose, or composition) refers to an amount sufficient, at dosages and for periods of time needed, to achieve the desired clinical results or beneficial treatment, as
described herein. An effective amount may be delivered in one or more
administrations. If the administration is to a subject already known or confirmed to have a disease or disease-state, the term "therapeutic amount" may be used in reference to treatment, whereas "prophylactically effective amount" may be used to describe administrating an effective amount to a subject that is susceptible or at risk of developing a disease or disease-state ( e.g ., recurrence) as a preventative course.
The level of a CTL immune response may be determined by any one of numerous immunological methods described herein and routinely practiced in the art. The level of a CTL immune response may be determined prior to and following administration of any one of the herein described fusion proteins expressed by, for example, a T cell. Cytotoxicity assays for determining CTL activity may be performed using any one of several techniques and methods routinely practiced in the art (see, e.g., Henkart et ah, "Cytotoxic T-Lymphocytes" in Fundamental Immunology, Paul (ed.) (2003 Lippincott Williams & Wilkins, Philadelphia, PA), pages 1127-50, and references cited therein).
Antigen-specific T cell responses are typically determined by comparisons of observed T cell responses according to any of the herein described T cell functional parameters (e.g, proliferation, cytokine release, CTL activity, altered cell surface marker phenotype, etc.) that may be made between T cells that are exposed to a cognate antigen in an appropriate context (e.g., the antigen used to prime or activate the T cells, when presented by immunocompatible antigen-presenting cells) and T cells from the same source population that are exposed instead to a structurally distinct or irrelevant control antigen. A response to the cognate antigen that is greater, with statistical significance, than the response to the control antigen signifies antigen-specificity.
A biological sample may be obtained from a subject for determining the presence and level of an immune response to a tagged protein or cell as described herein. A "biological sample" as used herein may be a blood sample (from which serum or plasma may be prepared), biopsy specimen, body fluids (e.g, lung lavage, ascites, mucosal washings, synovial fluid), bone marrow, lymph nodes, tissue explant, organ culture, or any other tissue or cell preparation from the subject or a biological source. Biological samples may also be obtained from the subject prior to receiving
any immunogenic composition, which biological sample is useful as a control for establishing baseline (i.e., pre-immunization) data.
The pharmaceutical compositions described herein may be presented in unit- dose or multi-dose containers, such as sealed ampoules or vials. Such containers may be frozen to preserve the stability of the formulation until. In certain embodiments, a unit dose comprises a recombinant host cell as described herein at a dose of about 107 cells/m2 to about 1011 cells/m2. The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., parenteral or intravenous administration or formulation.
If the subject composition is administered parenterally, the composition may also include sterile aqueous or oleaginous solution or suspension. Suitable non-toxic parenterally acceptable diluents or solvents include water, Ringer’s solution, isotonic salt solution, l,3-butanediol, ethanol, propylene glycol or polythethylene glycols in mixtures with water. Aqueous solutions or suspensions may further comprise one or more buffering agents, such as sodium acetate, sodium citrate, sodium borate or sodium tartrate. Of course, any material used in preparing any dosage unit formulation should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations. Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit may contain a predetermined quantity of recombinant cells or active compound calculated to produce the desired effect in association with an appropriate pharmaceutical carrier.
In general, an appropriate dosage and treatment regimen provides the active molecules or cells in an amount sufficient to provide therapeutic or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g, more frequent remissions, complete or partial, or longer disease-free survival) in treated subjects as compared to non-treated subjects. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which are routine in the art and may be performed using samples obtained from a subject before and after treatment.
In further aspects, kits are provided that comprise (a) a host cell, (b) a composition, or (c) a unit dose as described herein.
Methods according to this disclosure may further include administering one or more additional agents to treat the disease or disorder in a combination therapy. For example, in certain embodiments, a combination therapy comprises administering a fusion protein (or an engineered host cell expressing the same) with (concurrently, simultaneously, or sequentially) an immune checkpoint inhibitor. In some
embodiments, a combination therapy comprises administering fusion protein of the present disclosure (or an engineered host cell expressing the same) with an agonist of a stimulatory immune checkpoint agent. In further embodiments, a combination therapy comprises administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with a secondary therapy, such as chemotherapeutic agent, a radiation therapy, a surgery, an antibody, or any combination thereof.
As used herein, the term "immune suppression agent" or "immunosuppression agent" refers to one or more cells, proteins, molecules, compounds or complexes providing inhibitory signals to assist in controlling or suppressing an immune response. For example, immune suppression agents include those molecules that partially or totally block immune stimulation; decrease, prevent or delay immune activation; or increase, activate, or up regulate immune suppression. Exemplary immunosuppression agents to target ( e.g ., with an immune checkpoint inhibitor) include PD-l, PD-L1, PD- L2, LAG3, CTLA4, B7-H3, B7-H4, CD244/2B4, HVEM, BTLA, CD160, TIM3, GAL9, KIR, PVR1G (CD112R), PVRL2, adenosine, A2aR, immunosuppressive cytokines (e.g., IL-10, IL-4, IL-1RA, IL-35), IDO, arginase, VISTA, TIGIT, LAIR1, CEACAM-l, CEACAM-3, CEACAM-5, Treg cells, or any combination thereof.
An immune suppression agent inhibitor (also referred to as an immune checkpoint inhibitor) may be a compound, an antibody, an antibody fragment or fusion polypeptide (e.g., Fc fusion, such as CTLA4-Fc or LAG3-Fc), an antisense molecule, a ribozyme or RNAi molecule, or a low molecular weight organic molecule. In any of the embodiments disclosed herein, a method may comprise administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with
one or more inhibitor of any one of the following immune suppression components, singly or in any combination.
In certain embodiments, a fusion protein is used in combination with a PD-l inhibitor, for example a PD-l -specific antibody or binding fragment thereof, such as pidilizumab, nivolumab (Keytruda, formerly MDX-1106), pembrolizumab (Opdivo, formerly MK-3475), MEDI0680 (formerly AMP-514), AMP-224, BMS-936558 or any combination thereof. In further embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a PD-L1 specific antibody or binding fragment thereof, such as BMS-936559, durvalumab (MEDI4736), atezolizumab (RG7446), avelumab (MSB0010718C), MPDL3280A, or any combination thereof.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a LAG3 inhibitor, such as LAG525, IMP321, IMP701, 9H12, BMS-986016, or any combination thereof.
In certain embodiments, a fusion protein is used in combination with an inhibitor of CTLA4. In particular embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a CTLA4 specific antibody or binding fragment thereof, such as ipilimumab, tremelimumab, CTLA4-Ig fusion proteins (e.g., abatacept, belatacept), or any combination thereof.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a B7-H3 specific antibody or binding fragment thereof, such as enoblituzumab (MGA271), 376.96, or both. A B7-H4 antibody binding fragment may be a scFv or fusion protein thereof, as described in, for example, Dangaj et al, Cancer Res. 73:4820, 2013, as well as those described in U.S. Patent No. 9,574,000 and PCT Patent Publication Nos.
WO/201640724A1 and WO 2013/025779A1.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of CD244.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of BLTA, HVEM, CD 160, or any combination thereof. Anti CD- 160 antibodies are described in, for example, PCT Publication No. WO 2010/084158.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of TIM3.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of Gal 9.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of adenosine signaling, such as a decoy adenosine receptor.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of A2aR.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of KIR, such as lirilumab (BMS-986015).
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of an inhibitory cytokine (typically, a cytokine other than TGFP) or Treg development or activity.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an IDO inhibitor, such as levo-l-methyl tryptophan, epacadostat (INCB024360; Liu et al ., Blood
775:3520-30, 2010), ebselen (Terentis et al. , Biochem. 49:591-600, 2010), indoximod, NLG919 (Mautino el a/., American Association for Cancer Research l04th Annual Meeting 2013; Apr 6-10, 2013), 1 -methyl-tryptophan (l-MT)-tira-pazamine, or any combination thereof.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an arginase inhibitor, such as N(omega)-Nitro-L-arginine methyl ester (L-NAME), N-omega- hydroxy-nor-l-arginine (nor-NOHA), L-NOHA, 2(S)-amino-6-boronohexanoic acid (ABH), S-(2-boronoethyl)-L-cysteine (BEC), or any combination thereof.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of VISTA, such as CA-170 (Curis, Lexington, Mass.).
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of TIGIT such as, for example, COM902 (Compugen, Toronto, Ontario Canada), an inhibitor of CD155, such as, for example, COM701 (Compugen), or both.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of PVRIG, PVRL2, or both. Anti-PVRIG antibodies are described in, for example, PCT Publication No. WO 2016/134333. Anti-PVRL2 antibodies are described in, for example, PCT Publication No. WO 2017/021526.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with a LAIR1 inhibitor.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an inhibitor of CEACAM-l, CEACAM-3, CEACAM-5, or any combination thereof.
In certain embodiments, a fusion protein of the present disclosure (or an engineered host cell expressing the same) is used in combination with an agent that increases the activity (i.e., is an agonist) of a stimulatory immune checkpoint molecule. For example, a fusionprotein of the present disclosure (or an engineered host cell expressing the same) can be used in combination with a CD137 (4-1BB) agonist (such as, for example, urelumab), a CD 134 (OX-40) agonist (such as, for example,
MEDI6469, MEDI6383, or MEDI0562), lenalidomide, pomalidomide, a CD27 agonist (such as, for example, CDX-l 127), a CD28 agonist (such as, for example, TGN1412,
CD80, or CD86), a CD40 agonist (such as, for example, CP-870,893, rhuCD40L, or SGN-40), a CD122 agonist (such as, for example, IL-2) an agonist of GITR (such as, for example, humanized monoclonal antibodies described in PCT Patent Publication No. WO 2016/054638), an agonist of ICOS (CD278) (such as, for example,
GSK3359609, mAh 88.2, JTX-2011, Icos 145-1, Icos 314-8, or any combination thereof). In any of the embodiments disclosed herein, a method may comprise administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) with one or more agonist of a stimulatory immune checkpoint molecule, including any of the foregoing, singly or in any combination.
In certain embodiments, a combination therapy comprises a fusion protein of the present disclosure (or an engineered host cell expressing the same) and a secondary therapy comprising one or more of: an antibody or antigen binding-fragment thereof that is specific for a cancer antigen expressed by the non-inflamed solid tumor, a radiation treatment, a surgery, a chemotherapeutic agent, a cytokine, RNAi, or any combination thereof.
In certain embodiments, a combination therapy method comprises administering a fusion protein and further administering a radiation treatment or a surgery. Radiation therapy is well-known in the art and includes X-ray therapies, such as gamma- irradiation, and radiopharmaceutical therapies. Surgeries and surgical techniques appropriate to treating a given cancer or non-inflamed solid tumor in a subject are well- known to those of ordinary skill in the art.
In certain embodiments, a combination therapy method comprises administering a fusion protein of the present disclosure (or an engineered host cell expressing the same) and further administering a chemotherapeutic agent. A chemotherapeutic agent includes, but is not limited to, an inhibitor of chromatin function, a topoisomerase inhibitor, a microtubule inhibiting drug, a DNA damaging agent, an antimetabolite (such as folate antagonists, pyrimidine analogs, purine analogs, and sugar-modified analogs), a DNA synthesis inhibitor, a DNA interactive agent (such as an intercalating agent), and a DNA repair inhibitor. Illustrative chemotherapeutic agents include, without limitation, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and
cytarabine) and purine analogs, folate antagonists and related inhibitors
(mercaptopurine, thioguanine, pentostatin and 2- chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin,
chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, temozolamide, teniposide, triethylenethiophosphoramide and etoposide (VP 16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines
(hexamethylmelamine and thiotepa), alkyl sulfonates -busulfan, nitrosoureas
(carmustine (BCNU) and analogs, streptozocin), trazenes— dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin);
fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents;
antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK- 506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (TNP470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin
receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies
(trastuzumab, rituximab); chimeric antigen receptors; cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors
(doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-l l) and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylpednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers, toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin disruptors.
Cytokines are used to manipulate host immune response towards anticancer activity. See, e.g., Floros & Tarhini, Semin. Oncol. 42{ 4):539-548, 2015. Cytokines useful for promoting immune anticancer or antitumor response include, for example, IFN-a, IL-2, IL-3, IL-4, IL-10, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-21, IL-24, and GM-CSF, singly or in any combination with the binding proteins or cells expressing the same of this disclosure.
The present disclosure also includes the following exemplary embodiments.
Embodiment 1. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion or variant thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional portion or variant thereof;
(ii) an ITAM from CD3y, or a functional portion or variant thereof;
(iii) an ITAM from CD35, or a functional portion or variant thereof;
(iv) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof;
(v) a Basic Residue Sequence (BRS) from CD3e, or a functional portion or variant thereof; or
(vi) any combination of (i)-(v),
wherein
(1) the extracellular domain does not comprise a TCR ectodomain; and/or
(2) the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
Embodiment 2. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (IT AM) from CD3e, or a functional variant thereof;
(ii) an IT AM from CD3y, or a functional variant thereof;
(iii) an IT AM from CD35, or a functional variant thereof;
(iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof;
(v) a Basic Residue Sequence (BRS) from CD3e and/or E03z, or a functional variant thereof; or
(vi) any combination of (i)-(v),
and does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD35, and/or CD3y.
Embodiment 3. The fusion protein of embodiment 1 or 2, wherein the effector domain or functional portion thereof comprises an IT AM from CD3e, or a functional variant thereof, and a PRS from CD3e, or a functional variant thereof.
Embodiment 4. The fusion protein of any one of embodiments 1-3, wherein the fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
Embodiment 5. The fusion protein of any one of embodiments 1-4, wherein the effector domain or functional fragment thereof comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:8.
Embodiment 6. The fusion protein of any one of embodiments 1-3 or 5, wherein the effector domain comprises a BRS from CD3e, or a functional variant thereof.
Embodiment 7. The fusion protein of any one of embodiments 1-6, wherein the effector domain comprises an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO:5 or 111.
Embodiment 8. The fusion protein of any one of embodiments 1-7, wherein the effector domain comprises: an IT AM from CD3y, or a functional variant thereof; and/or comprises an ITAM from CD35, or a functional variant thereof.
Embodiment 9. The fusion protein of embodiment 8, wherein the effector domain comprises:
(i) an amino acid sequence having at least 75% (i.e., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) identity to the amino acid sequence shown in SEQ ID NO: 11, wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO: 11 is optionally not a leucine, and is preferably an alanine or a glycine; and/or
(ii) an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 14, wherein one or more of the amino acids
corresponding to positions 16 and 17 of SEQ ID NO: 14 optionally is not a leucine, and is preferably an alanine or a glycine.
Embodiment 10. The fusion protein of embodiment 8 or 9, wherein the effector domain comprises a BRS from CD3e, or a functional portion or variant thereof.
Embodiment 11. The fusion protein of any one of embodiments 1-10, wherein the effector domain further comprises an IT AM from Oϋ3z, or a functional portion or variant thereof.
Embodiment 12. The fusion protein of embodiment 11, wherein the effector domain further comprises two or three of IT AMs (a), (b), and (c) from E03z, or functional portions or variants thereof.
Embodiment 13. The fusion protein of embodiment 11 or 12, wherein the effector domain comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 17.
Embodiment 14. The fusion protein of any one of embodiments 1-13, further comprising a costimulatory domain or a functional portion or variant thereof.
Embodiment 15. The fusion protein of embodiment 14, wherein the costimulatory domain or functional portion or variant thereof is from 4-1BB, CD28, 0X40, CD27, CD2, CD5, ICAM-l (CD54), LFA-l (CD 11 a/CD 18), ICOS (CD278), GITR, CD30, CD40, BAFF-R, HVEM, LIGHT, MKG2C, SLAMF7, NKp80, CD 160, B7-H3, a ligand that specifically binds with CD83, or any combination thereof.
Embodiment 16. The fusion protein of embodiment 15, wherein the costimulatory domain comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
Embodiment 17. The fusion protein of any one of embodiments 14-16, wherein the intracellular domain comprises a costimulatory domain, an endodomain or effector domain from Oϋ3z or a functional portion or variant thereof, and an effector domain from CD3e or a functional portion or variant thereof, wherein the effector domain from CD3e or functional portion or variant thereof optionally comprises or consists essentially of a PRS and an IT AM from CD3e.
Embodiment 18. The fusion protein of embodiment 17, wherein the effector domain from CD3e or functional portion or variant thereof is disposed between the costimulatory domain and the endodomain or effector domain from Oϋ3z or functional portion or variant thereof.
Embodiment 19. The fusion protein of embodiment 17, wherein the endodomain or effector domain from Oϋ3z or functional portion or variant thereof is
disposed between the costimulatory domain and the effector domain from CD3e or functional portion or variant thereof.
Embodiment 20. The fusion protein of any one of embodiments 1-19, wherein the transmembrane domain comprises or is a CD28 transmembrane domain, a CD27 transmembrane domain, a CD4 transmembrane domain, a CD8 transmembrane domain, or any combination thereof.
Embodiment 21. The fusion protein of any one of embodiments 1-20, wherein the extracellular domain comprises a CH1, a CH2, a CH3, a CL, a CD8 extracellular domain, a CD28 extracellular domain, a CD4 extracellular domain, an IgG hinge, a glycine-serine linker comprising from about one to about ten repeats of GlyxSery (SEQ ID NO: 108), a linker having an amino acid sequence as set forth in any one of SEQ ID NOs.: 103-107, 109, or 110, or a functional variant or portion thereof, or a combination thereof.
Embodiment 22. The fusion protein of any one of embodiments 1-21, wherein the extracellular domain comprises a linker disposed between the binding domain and the transmembrane domain.
Embodiment 23. The fusion protein of embodiment 22, wherein the linker comprises a hinge region or a portion thereof.
Embodiment 24. The fusion protein of any one of embodiments 1-23, wherein the binding domain comprises or consists of a scFv, a Fab, a scTCR, or a ligand.
Embodiment 25. The fusion protein of embodiment 23, wherein the binding domain comprises a scFv.
Embodiment 26. The fusion protein of any one of embodiments 1-25, wherein the binding domain is chimeric, human, or humanized.
Embodiment 27. The fusion protein of any one of embodiments 1-26, wherein the binding domain specifically binds to an antigen that is expressed by or is associated with a cancer.
Embodiment 28. The fusion protein of embodiment 27, wherein the cancer comprises a solid tumor.
Embodiment 29. The fusion protein of any one of embodiments 1-28, wherein the antigen is selected from a ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7, Her2, Ll-CAM, Lewis A, Lewis Y, MUC1, MUC16, PSCA, PSMA, CD 19, CD20, CD22, CD56, CD23, CD24, CD30, CD33, CD37, CD44v7/8, CD38, CD56, CD123, CA125, c-MET, FcRH5, WT1, folate receptor a, VEGF-a, VEGFR1, VEGFR2, IL-l3Ra2, IL-l lRa, MAGE-A1, PSA, ephrin A2, ephrin B2, NKG2D, NY-ESO-l, TAG-72, mesothelin, NY-ESO, 5T4, BCMA, FAP, Carbonic anhydrase 9, ERBB2, BRAFV600E, MAGE- A3, MAGE-A4, SSX-2, PRAME, HA-l, CD79a, CD79b, SLAMF7, or CEA antigen.
Embodiment 30. The fusion protein of embodiment 29, wherein the antigen is a ROR1 antigen.
Embodiment 31. The fusion protein of any one of embodiments 1-30, further comprising a protein tag.
Embodiment 32. The fusion protein of any one of embodiments 1-31, wherein the fusion protein, when expressed by a host cell, optionally an immune system cell, provides for or promotes:
(i) improved cell signaling, and/or activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased and/or sustained cytokine production and/or release, and/or phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as LAT, PLC-g I , SLP-76, or any combination thereof;
(ii) improved cell activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased mobilization of intracellular calcium , killing activity, proliferation, earlier activation in response to antigen, or any combination thereof;
(iii) improved cell signaling and/or activity, relative to a host cell expressing a reference fusion protein, upon binding to a target antigen that is expressed at a low level or an intermediate level on a target cell surface;
(iv) reducing or suppressing growth, area, volume, and/or spread of a tumor that expresses an antigen that is recognized and/or specifically bound by the fusion
protein, of killing tumor cells, and/or of increasing survival of the subject to a greater degree and/or for a longer period of time as compared to a reference subject
administered a host cell expressing a reference fusion protein;
(iv) more efficient phosphorylation of LAT, SLP-76, and/or PLC-g I as compared to a reference fusion protein expressed by a host cell;
(v) improved sensitivity to antigen as compared to a host cell expressing a reference fusion protein, but does not produce more, or substantially more, of a pro- inflammatory cytokine as compared to the host cell expressing the reference fusion protein; or
(vi) any combination of (i)-(v).
Embodiment 33. The fusion protein of embodiment 32, wherein the intracellular component comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
Embodiment 34. The fusion protein of embodiment 32 or 33, wherein the reference protein comprises an intracellular domain comprising a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
Embodiment 35. The fusion protein of any one of embodiments 32-34, wherein the fusion protein and the reference protein each comprise an endodomain or effector domain from OI)3z or a functional portion or variant thereof.
Embodiment 36. The fusion protein of any one of embodiments 32-35, wherein the host cell expressing the fusion protein and the host cell expressing the reference fusion protein are each a T cell, optionally a CD8+ T cell.
Embodiment 37. An isolated polynucleotide, encoding the fusion protein of any one of embodiments 1-36.
Embodiment 38. The isolated polynucleotide of embodiment 37, further comprising a polynucleotide encoding a transduction marker.
Embodiment 39. The isolated polynucleotide of embodiment 38, wherein the encoded transduction marker comprises EGFRt, CDl9t, CD34t, or NGFRt.
Embodiment 40. The isolated polynucleotide of any one of embodiments 38 or 39, further comprising a polynucleotide encoding a self-cleaving polypeptide.
Embodiment 41. The isolated polynucleotide of embodiment 40, wherein the fusion protein-encoding polynucleotide is separated from the transduction marker encoding polynucleotide by the polynucleotide encoding a self-cleaving polypeptide.
Embodiment 42. The isolated polynucleotide of embodiment 40 or 41, wherein the encoded self-cleaving polypeptide comprises a P2A, an F2A, a T2A, an E2A, or a variant thereof.
Embodiment 43. The isolated polynucleotide of any one of embodiments 37-42, wherein the polynucleotide is codon optimized for expression in a host cell.
Embodiment 44. The isolated polynucleotide of any one of embodiments 37-43, wherein the polynucleotide comprises a polynucleotide having at least 70% identity to the nucleotide sequence set forth in any one of SEQ ID NOs.:34-46.
Embodiment 45. An expression vector, comprising the isolated
polynucleotide of any one of embodiments 37-44 operably linked to an expression control sequence.
Embodiment 46. The expression vector of embodiment 45, wherein the vector is capable of delivering the polynucleotide to a host cell.
Embodiment 47. The expression vector of embodiment 46, wherein the host cell is a hematopoietic progenitor cell or a human immune system cell.
Embodiment 48. The expression vector of embodiment 47, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
Embodiment 49. The expression vector of embodiment 47 or 48, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
Embodiment 50. The expression vector of any one of embodiments 45-49, wherein the vector is a viral vector.
Embodiment 51. The expression vector of embodiment 50, wherein the viral vector is a lentiviral vector or a g-retroviral vector.
Embodiment 52. A host cell, comprising the polynucleotide of any one of embodiments 37-44.
Embodiment 53. A host cell, expressing at its cell surface the fusion protein of any one of embodiments 1-36.
Embodiment 54. The host cell of embodiment 53, further expressing a transduction marker at its cell surface.
Embodiment 55. The host cell of any one of embodiments 52-54, wherein the host cell is a hematopoietic progenitor cell or a human immune system cell.
Embodiment 56. The host cell of embodiment 55, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
Embodiment 57. The host cell of embodiment 55 or 56, wherein the host cell comprises a T cell.
Embodiment 58. The host cell of embodiment 56 or 57, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
Embodiment 59. The host cell of any one of embodiments 52-58, comprising a chromosomal gene knockout or a mutation of a PD-l gene; a LAG3 gene; a TIM3 gene; a CTLA4 gene; an HLA component gene; a TCR component gene, or any combination thereof.
Embodiment 60. A composition, comprising a fusion protein of any one of embodiments 1-36 and a pharmaceutically acceptable carrier, excipient, or diluent.
Embodiment 61. A composition, comprising a host cell of any one of embodiments 52-59, and a pharmaceutically acceptable carrier, excipient, or diluent.
Embodiment 62. A unit dose, comprising an effective amount of the host cell of any one of embodiments 52-59, or of the host cell composition of embodiment 61.
Embodiment 63. The unit dose of embodiment 62, comprising (i) a composition comprising at least about 30% CD4+ T host cells, combined with (ii) a composition comprising at least about 30% CD8+ T host cells, in about a 1 : 1 ratio.
Embodiment 64. A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of the host cell
of any one of embodiments 52-59, the composition of embodiment 60 or 61, or the unit dose of embodiment 62 or 63, wherein the disease or condition is characterized by the presence of the antigen.
Embodiment 65. A method of eliciting an immune response against an antigen that is specifically bound by the fusion protein of any one of embodiments 1-36, the method comprising administering to a subject comprising or expressing the antigen an effective amount of the host cell of any one of embodiments 52-59, the composition of embodiment 60 or 61, or the unit dose of embodiment 62 or 63.
Embodiment 66. The method of embodiment 64, wherein the disease or condition comprises a hyperproliferative disease or a proliferative disease.
Embodiment 67. The method of embodiment 64 or 66, wherein the disease or condition is a cancer.
Embodiment 68. The method of embodiment 67, wherein the cancer comprises a carcinoma, a sarcoma, a glioma, a lymphoma, a leukemia, a myeloma, or any combination thereof.
Embodiment 69. The method of embodiment 67 or 68, wherein the cancer comprises a cancer of the head or neck, melanoma, pancreatic cancer,
cholangiocarcinoma, hepatocellular cancer, breast cancer including triple-negative breast cancer (TNBC), gastric cancer, non-small-cell lung cancer, prostate cancer, esophageal cancer, mesothelioma, small-cell lung cancer, colorectal cancer,
glioblastoma, or any combination thereof.
Embodiment 70. The method of any one of embodiments 67-69, wherein the cancer comprises Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, PNET, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans (DFSP), desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal
osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST),
hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma,
rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, linitis plastic, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, renal cell carcinoma, Grawitz tumor, ependymoma, astrocytoma, oligodendroglioma, brainstem glioma, optice nerve glioma, a mixed glioma, Hodgkin’s lymphoma, a B-cell lymphoma, non-Hodgkin’s lymphoma (NHL), Burkitf s lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma, Waldenstrom's macroglobulinemia, CD37+ dendritic cell lymphoma,
lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extra-nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, adult T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, enteropathy-associated T-cell lymphoma,
hepatosplenic T-cell lymphoma, blastic NK cell lymphoma, Sezary syndrome, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, or any combination thereof.
Embodiment 71. The method of any one of embodiments 67-70, wherein the cancer comprises a solid tumor.
Embodiment 72. The method of embodiment 71, wherein the solid tumor is a sarcoma or a carcinoma.
Embodiment 73. The method of embodiment 72, wherein the solid tumor is selected from: chondrosarcoma; fibrosarcoma (fibroblastic sarcoma);
Dermatofibrosarcoma protuberans (DFSP); osteosarcoma; rhabdomyosarcoma; Ewing’s sarcoma; a gastrointestinal stromal tumor; Leiomyosarcoma; angiosarcoma (vascular sarcoma); Kaposi’s sarcoma; liposarcoma; pleomorphic sarcoma; or synovial sarcoma.
Embodiment 74. The method of embodiment 72 or 73, wherein the solid tumor is selected from a lung carcinoma ( e.g ., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular
carcinoma in situ (non-invasive), Invasive Ductal Carcinoma, Invasive lobular carcinoma, Non-invasive Carcinoma); a liver carcinoma ( e.g ., Hepatocellular
Carcinoma, Cholangiocarcinomas or Bile Duct Cancer); Large-cell undifferentiated carcinoma, Bronchioalveolar carcinoma); an ovarian carcinoma (e.g., Surface epithelial-stromal tumor (Adenocarcinoma) or ovarian epithelial carcinoma (which includes serous tumor, endometrioid tumor and mucinous cystadenocarcinoma), Epidermoid (Squamous cell carcinoma), Embryonal carcinoma and choriocarcinoma (germ cell tumors)); a kidney carcinoma (e.g., Renal adenocarcinoma, hypernephroma, Transitional cell carcinoma (renal pelvis), Squamous cell carcinoma, Bellini duct carcinoma, Clear cell adenocarcinoma, Transitional cell carcinoma, Carcinoid tumor of the renal pelvis); an adrenal carcinoma (e.g., Adrenocortical carcinoma), a carcinoma of the testis (e.g., Germ cell carcinoma (Seminoma, Choriocarcinoma, Embryonal carciroma, Teratocarcinoma), Serous carcinoma); Gastric carcinoma (e.g.,
Adenocarcinoma); an intestinal carcinoma (e.g., Adenocarcinoma of the duodenum); a colorectal carcinoma; or a skin carcinoma (e.g., Basal cell carcinoma, Squamous cell carcinoma).
Embodiment 75. The method of embodiment 72 or 73, wherein the solid tumor is an ovarian carcinoma, an ovarian epithelial carcinoma, a cervical
adenocarcinoma or small cell carcinoma, a pancreatic carcinoma, a colorectal carcinoma (e.g., an adenocarcinoma or squamous cell carcinoma), a lung carcinoma, a breast ductal carcinoma, or an adenocarcinoma of the prostate.
Embodiment 76. The method of any one of embodiments 64-75, wherein the host cell is an allogeneic cell, a syngeneic cell, or an autologous cell.
Embodiment 77. The method of any one of embodiments 64-76, wherein the method comprises administering a plurality of unit doses to the subject.
Embodiment 78. The method of embodiment 77, wherein the plurality of unit doses are administered at intervals between administrations of about two, three, four, five, six, seven, eight, or more weeks.
Embodiment 79. The method according to any one of embodiments 64-78, wherein the unit dose comprises about 105 cells/m2 to about 1011 cells/m2.
Embodiment 80. The method of any one of embodiments 57-79, wherein the subject is receiving, has received, or will receive one or more of:
(i) chemotherapy;
(ii) radiation therapy;
(iii) an inhibitor of an immune suppression component
(iv) an agonist of a stimulatory immune checkpoint agent;
(v) RNAi;
(vi) a cytokine;
(vii) a surgery;
(viii) a monoclonal antibody and/or an antibody-drug conjugate; or
(ix) any combination of (i)-(viii), in any order.
Embodiment 81. ETse of the polynucleotide of any one of embodiments 37- 44, or the expression vector of any one of embodiments 45-51, the host cell of any one of embodiments 52-59, or the composition of any one of embodiments 60 or 61, in the manufacture of a medicament for the treatment of a disease; e.g ., a disease
characterized by or associated with expression of an antigen that is specifically bound by the fusion protein of any one of embodiments 1-36.
Embodiment 82. ETse of the polynucleotide of any one of embodiments 37- 44, or the expression vector of any one of embodiments 45-51, the host cell of any one of embodiments 52-59, or the composition of any one of embodiments 60 or 61, in the treatment of a disease; e.g. , a disease characterized by or associated with expression of an antigen that is specifically bound by the fusion protein of any one of embodiments 1-
36.
Embodiment 83. The use according to embodiment 81 or 82, wherein the disease is a cancer.
Embodiment 84. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion or variant thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional portion or variant thereof;
(ii) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof; or
(iii) both of (i) and (ii),
wherein
(1) the extracellular domain does not comprise a TCR ectodomain; and/or
(2) the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
Embodiment 85. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional portion or variant thereof;
(ii) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof; or
(iii) both of (i) and (ii).
Embodiment 86. The fusion protein of embodiment 84 or 85, wherein the intracellular component comprises an ITAM from CD3e and a PRS from CD3e, and further comprises an endodomain or effector domain from E03z or functional portion or variant thereof.
Embodiment 87. The fusion protein of embodiment 86, wherein the ITAM from CD3e comprises or consists of the amino acid sequence set forth in SEQ ID NO:6.
Embodiment 88. The fusion protein of embodiment 86 or 87, wherein the PRS from CD3e comprises or consists of the amino acid sequence set forth in SEQ ID NO:7 or 8.
Embodiment 89. The fusion protein of any one of embodiments 85-88, wherein the intracellular component further comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
Embodiment 90. The fusion protein of embodiment 89, wherein the intracellular component comprises or consists of any amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to the amino acid sequence set forth in any one of SEQ ID NOs:6-8, 24, 25, or 27-32.
Embodiment 91. An isolated polynucleotide encoding the fusion protein of any one of embodiments 85-90.
Embodiment 92. A host cell, comprising the polynucleotide of embodiment 91, wherein the host cell is optionally an immune system cell, further optionally a T cell.
EXAMPLES
EXAMPLE 1
ANALYSIS AND COMPARISON OF TCR- AND CAR-INDUCED
PHOSPHOPROTEIN SIGNALING CD 19-specific CAR T cells are a FDA-approved therapy for individuals with relapsed or refractory B cell malignancies. Generally, greater than 70% of acute lymphocytic leukemia patients who are treated with CAR T cells achieve a complete response (Majzner & Mackall, Cancer Discov. 5: 1219-1226 (2018)). However, a significant proportion relapse with leukemia blasts expressing little to no detectable CD19 (see, e.g. , Turtle el ah, Sci. Transl. Med. 5:355ral 16 (2016); Park et ah, N. Engl. J. Med. 378: 449-459 (2018); Maude et al, N. Engl. J. Med. 378: 439-448 (2018); Fry et al., Nature Medicine 24: 20-28 (2018)). A clinical trial of BCMA-specific CAR T cells in relapsed or refractory multiple myeloma also demonstrates that outgrowth of BCMA-
negative myeloma cells is a potential cause of relapse (Brudno et al. , J. Clin. Oncol. 36.22: 2267-80 (2018)). In some cases, solid epithelial tumors do not homogenously or highly express lineage defining markers like CD 19 or BCMA, but can share lineage defining markers with normal tissues. Addressing antigen downregulation and loss of tumor-specific antigens is an important objective to for obtaining complete and durable responses to CAR T cell therapies.
TCRs can detect peptide antigens presented by MHC molecules with high sensitivity. It has been reported that as few as one to ten agonist pMHC complexes in a sea of thousands of self-pMHC can trigger T cell activation through the TCR (e.g, Sykulev et al., Immunity 7:565-571 (1996); Huang et al. , Immunity 39:846-857 (2013)). In contrast, it has been reported that CARs require at least 200 molecules of antigen on the target cell to initiate CAR T cell cytotoxicity and thousands of molecules to elicit full effector function (e.g., Watanabe et al, J. Immunol. 797:911-920 (2015); Walker et al., Mol. Ther. 25:2189-2201 (2017); Fried an et al, Hum. Gene Ther. 29:585-601 (2018)). Whether these requirements for increased antigen density apply to all CARs or can be improved upon is an open question.
In general, other functional differences between naturally occurring TCRs and CARs include higher binding affinity of CARs for antigen (see, e.g, Hogquist & Jameson, Nat. Immunol. 75:815-823 (2014); Chmielewski et al, J. Immunol. 773:7647- 7653 (2004); and Hudecek et al, Clin. Cancer Res. 79:3153-3164 (2013)), which may have implications for receptor off-rate and repeated triggering. Additionally, TCRs are thought to form complexes with multiple CD3 proteins following binding to
antigemMHC and associate with various downstream signaling proteins, while CARs generally contain only a Oϋ3z signaling endodomain in a single molecule comprising a binding domain, a transmembrane domain, and a costimulatory domain from CD28, 4- 1BB, or ICOS. In the case of CARs, variation in the stoichiometric ratios of signaling molecules or the absence of certain signaling components at the immunological synapse may alter antigen sensitivity and signal intensity. Indeed, initial images of CAR immunological synapses were distinct from those formed by TCRs (see James & Vale, Nature 757:64-69 (2012)).
To comprehensively compare TCR and CAR ligation-induced phosphoprotein signaling events, a mass spectrometry (MS) platform was developed to analyze TCR or CAR signaling in a single population of primary T cells possessing a mono-specific TCR or CAR. Bi-specific T cells were engineered that endogenously express an EBV- specific TCR and were transduced to express a RORl-specific CAR (Figure 1 A). Bi- specific T cells offer the advantages of: 1) comparing TCR and CAR function in one cell population with a single culture history and phenotype, and 2) utilizing the endogenous TCR, which negates potential effects of reduced TCR expression or TCRa and TCRP chain mispairing after transduction of an engineered TCR. Briefly,
CD8+CD45RO+ memory T cells from HLA-B8+ EBV seropositive donors were stimulated with autologous irradiated and EBV peptide-pulsed peripheral blood mononuclear cells. Dividing cells were then transduced with a lentiviral vector encoding a RORl-specific E028/Eϋ3z CAR. Bi-specific T cells that bound to an HLA-B8/EBV-RAK tetramer and expressed the CAR transduction marker, tCDl9, were purified by fluorescence-activated cell sorting (FACS) and expanded (Figure 1B).
Stimulating EBV/ROR1 bi-specific T cells with tumor cells expressing TCR or CAR antigens was an attractive strategy to initiate phosphoprotein signaling, but antigen-presenting cells contaminated the cellular lysate and were not amenable for MS analysis (data not shown). Therefore, microbeads coated with recombinant single chain timers (SCT) of EBV RAKFKQLL peptide, HLA-B8, and b2 microglobulin, or recombinant ROR1 ectodomain were formulated and used to initiate cell signaling (Figure 1C) (see Yu et al. , ./. Immunol. 168:3145-3149 (2002)). SCT or ROR1 beads activated T cell signaling and the amount of protein coated on the beads was titrated down (Figure 1D), as was as the bead to cell ratio (Figure 1E) to levels that reduced reagent costs while still saturating P04 of the CAR, TCR, and PLC-gE A CD28 mAh was also added to SCT beads so that TCR bead-based stimulation delivered 'signal G and 'signal 2' and would be functionally equivalent to Eϋ28L2ϋ3z CAR stimulation. Consistent with the known additive role of CD28 costimulation, SCT/CD28 beads increased PLC-yl Tyr783 P04 and T cell proliferation after stimulation compared to SCT beads (Figures 1F, 1G).
To determine whether microbead-based TCR or CAR stimulation could effectively substitute for cell-based stimulation, T cell effector functions and signaling profiles initiated by beads or cells were compared. Expanded bi-specific T cells were incubated with either SCT/CD28 or ROR1 microbeads, or K562 cells expressing HLA- B8 alongside endogenously processed EBV peptides or full-length human ROR1. TCR stimulation using either SCT/CD28 beads or K562/B8/EBV cells elicited greater cell division than CAR stimulation using either ROR1 beads or K562/B8/ROR1 cells (Figure 1H). TCR stimulation with either beads or cells also led to greater frequencies of cells producing IFN-g, IL-2, and TNF-a than CAR stimulation (Figures 1I-1L). To further validate a bead-based approach, P04 of key signaling intermediates was measured in in bi-specific T cells after 45 minutes of stimulation with K562 APC or ligand-coated beads. P04 of native OI)3z or exogenous CAR-CD3 z chains at Tyr142 appeared nearly identical after antigen presentation by APC or beads, and P04 of SLP- 76 Ser376 and PLC-g I Tyr783 were highly similar (Figure 1M). Taken together, these results confirmed the ability of microbeads to substitute for K562 antigen-presenting cells, although the overall magnitude of the effector responses after bead stimulation were more modest, possibly due to the absence of adhesion and costimulatory molecules on the magnetic beads that were present on K562 cells.
Fluorescence microscopy using the Ca2+-sensitive dye Fluo-4 AM was also used to measure Ca2+ flux after antigen engagement and provide an index of the relative antigen sensitivity of the TCR and CAR. Recombinant SCT and ROR1 ectodomain were biotinylated and coated onto a supported lipid bilayer via biotin/streptavidin linkage. The responses of hundreds of individual T cells to TCR or CAR stimulation were compared using the fraction of cells exhibiting high intracellular calcium as a metric of the response amplitude. In these experiments, antigen density was modulated by incorporating a small mole fraction (<l%) of biotinylated PE into the supported bilayer, followed by sequential labeling with excess concentrations of streptavidin and biotinylated SCT or ROR1. At two unique antigen densities, a greater fraction of bi- specific T cells was triggered by TCR stimulation than by CAR stimulation (Figure 1N). At both antigen densities, the TCR response appeared nearly saturated because similar frequencies of T cells responded over time. In contrast, the fraction of triggered
T cells diminished as R0R1 density was reduced. Because TCR and CAR triggering were quantified at identical SCT and R0R1 densities, these results demonstrated that TCRs possessed increased antigen sensitivity as compared to a 0028/003z CAR.
MS identifies common protein phosphorylation events after TCR or CAR stimulation To measure protein P04 signaling events initiated by TCR or CAR stimulation by MS, three independent experiments were performed in which EBV/ROR1 bi- specific T cells were incubated with SCT/CD28, ROR1, or uncoated (control) magnetic beads for 10, 45, or 90 minutes prior to cell lysis (Figure 2A). Bi-specific T cells generated from two different donors were used in two experiments; a third experiment utilized bi-specific T cells independently derived from one of the two donors. Cell phenotyping prior to TCR (SCT/CD28) or CAR (ROR1) stimulation showed that bi- specific T cells expressed CD45RO, CD62L, and CD28, and that >83% of cells were in the G0/G1 cell cycle phase, consistent with a resting memory phenotype (Figure 2B). Using identical phosphopeptide labeling and enrichment techniques, a total of 30,669 P04 sites corresponding to 4,997 gene products were detected from these three experiments (Figure 2C). Among P04 sites, 715 (2.3%) were phosphotyrosines, 5,056 (16.5%) were phosphothreonines, and 24,898 (81.2%) were phosphoserines (Figure 2D). For each PO4 site, log2 fold-change (log2FC) values comparing TCR stimulation to control treatment or CAR stimulation to control treatment were consistent across experiments (Figure 2E).
Phosphorylation events mediated by TCRs and CARs differ in kinetics and magnitude Statistical analysis (limma in the R statistical computing framework) was performed to identify PO4 sites that were up- or down-modulated by TCR or CAR stimulation. A PO4 site was determined to be CAR stimulation-responsive if it was detected in at least two of the three experiments, displayed an average |log2FC| > 1 between stimulated and unstimulated conditions at 10 or 45 minutes, and met a 5% FDR cutoff. Few PO4 sites met log2FC and false discovery rate (FDR) cutoffs after 10 minutes of TCR or CAR stimulation, but hundreds of PO4 sites were up- or down- modulated after 45 or 90 minutes of TCR and CAR stimulation (Figure 2F; additional data not shown). On a global level, TCR stimulation induced greater fold changes in protein PO4 at the 10 minute time point compared to CAR stimulation. These
differences became less apparent after 45 and 90 minutes of stimulation (Figures 2G and 2H, respectively). Network analysis of stimulation-responsive P04 sites revealed that both TCR and CAR stimulation altered the P04 of proteins in the KEGG T cell receptor signaling, RNA transport, and actin cytoskeleton regulatory pathways (data not shown).
To confirm that bead stimulation activated TCR and CAR signaling
intermediates, the dataset was interrogated for P04 sites on Eϋ3z, CD28, ZAP-70, and PLC-gT P04 of all three Eϋ3z ITAMs, CD28 tyrosine residues, ZAP-70 regulatory sites, and PLC-g I Ser1248 increased after TCR or CAR stimulation (Figures 2I-2L, respectively). E03z and CD28 were more intensely phosphorylated by CAR
stimulation than TCR stimulation at the 10 and 45 minute time points. However, the more robust P04 of Eϋ3z and CD28 after CAR stimulation did not translate into substantially greater ZAP-70 P04 as ZAP-70 P04 sites displayed similar increases in P04 after TCR and CAR stimulation (Figure 2K). PLC-g I Ser1248 was also more weakly phosphorylated by CAR than TCR stimulation (Figure 2L). Thus, it appeared that CAR stimulation led to more intense CAR P04, but that this strong signal intensity was not as efficiently converted into ZAP-70 P04 as after TCR stimulation. These findings were surprising, since the more intense 0)3z and CD28 P04 after CAR stimulation might be expected to result in increased PLC-y l P04.
E03z and CD28 proteins in bi-specific T cells are encoded by both the endogenous genes and the CAR transgene, and LC-MS/MS cannot differentiate identical peptides in trypsin digested lysates that are derived from distinct sources. Because the CAR protein is larger than endogenous E03z, Western blot analysis was performed on analyzed undigested whole cell lysates. These experiments confirmed selective TCR and CAR activation as well as more intense P04 of the CAR E03z domain after CAR ligation than the TCR E03z domain after TCR ligation (Figure 2M). In contrast, SLP-76 Ser376 and PLC-yl Tyr783 were more intensely phosphorylated after TCR stimulation than after CAR stimulation. These data demonstrate that TCR stimulation more efficiently converts small amounts of 0)3z P04 into intense ZAP-70, SLP-76, and PLC-z! P04 and suggest that CAR stimulation requires greater receptor P04 to initiate intracellular signaling than TCR stimulation.
CAR stimulation promotes less intense PO4 of CD 3 chains and signaling adaptors
Functional and signaling data suggested that TCR stimulation more efficiently converts initial receptor P04 into downstream signals that give rise to more potent effector functions. To investigate further, changes in protein P04 after CAR or TCR stimulation were directly compared. At the earliest (10-minute) stimulation time point, hundreds of PO4 sites were more intensely modulated by TCR than CAR stimulation (Figure 3 A). Signaling intermediates (AHNAK, CBLB, IKBKB, INPP4A, RAPGEF1, RAPGEF2 and SHC1) as well as RNA binding proteins (DDX17, EIF6, EIF4B, and RBM25) were also phosphorylated by TCR stimulation, but not by CAR stimulation (Figure 3D). After 45 minutes and 90 minutes, a strong correlation between PO4 site changes in TCR and CAR stimulated samples was observed. Only 30 sites at the 45- minute time point possessed fold change values that differed by more than 2-fold between TCR and CAR treated samples (Figure 3B). Among these, CD35, CD3e, CD3y, LAT, LAX1 and PAG1 were all more intensely phosphorylated by TCR than CAR stimulation. After 90 minutes of stimulation, 41 sites possessed fold change values that differed by more than 2-fold between TCR and CAR treated samples (Figure 3C). CD3e and CD3y remained more intensely phosphorylated by TCR and CAR stimulation, and preferential PO4 of TAGAP, SOS1, STAT3, STAT5A/B, and NR4A1 was detected after TCR, but not CAR, stimulation. Plotting individual sites across time further demonstrated that signaling adaptors known to be critical for TCR signaling were less intensely phosphorylated by CAR stimulation than TCR stimulation (Figures 3E-3H). These differences were consistent with the weaker SLP-76 and PLC- gΐ P04 measured after CAR stimulation by Western blot (Figure 2M), and indicated that CARs may not recapitulate all TCR-induced signaling events. EXAMPLE 2
DESIGN AND TESTING OF CARs CONTAINING CD3E DOMAINS
CD 3e sequences improve CAR T cell recognition o/RORP0 tumor cells
The relatively weaker PO4 of key TCR signaling adaptors after CAR stimulation may be responsible for increased antigen density requirements. To determine whether
CARs could more efficiently engage LAT, ITK and NCK1/2, additional IT AMs and/or protein recruitment domains were considered for inclusion in the CAR backbone. The CD3e endodomain was chosen for incorporation into an existing 4- 1 BBL2ϋ3z CAR backbone because cross-linking endogenous CD3e is sufficient for T cell activation and 4-1BBL3ϋ3z CAR signaling appears less likely to promote T cell exhaustion in vivo than E028L/S)3z CAR signaling (Salter et ah, Sci. Signal. 11 :eaat6753 (2018);
Cherkassky et al. , ./. Clin. Invest. 72(5:3130-3144 (2016)). The CD3e endodomain includes three known signaling motifs. A basic residue-rich sequence (BRS) lies adjacent the membrane at the N-terminal portion of the endodomain and is known to bind Lck (see Li et l., PNAS U.S.A. 774:E589l-5899 (2017)). A proline-rich sequence (PRS) resides further within the endodomain, and may enhance TCR sensitivity to certain antigens by interacting with Nckl (see Tailor et al, J. Immunol. 757:243-255 (2008); Mingueneau et al, Nat. Immunol. 9: 522-532 (2008)). An IT AM is positioned furthest from the membrane and P04 of its tyrosine residues is believed to activate ZAP-70 (see Brownlie & Zamoyska, Nat. Rev. Immunol. 73:257-269 (2013)). Prior experiments indicated that additional Lck increases CAR signal strength (data not shown). To provide additional capacities without increased CAR-Lck association due to the CD3e BRS, a CAR variant containing only the CD3e PRS and ITAM was also designed ("CD3e PRS ITAM").
All or a portion of the CD3e endodomain was placed either before or after the OI)3z domain in CDl9-specific or RORl-specific 4-1BB/OI)3z CARs (Figure 4A). T cells expressing these constructs were examined to determine whether the CAR could augment recognition of low-density antigens. CARs contained an STII sequence to allow measurement of cell surface expression. The addition of full-length CD3s either before or after CD3z resulted in lower CAR surface expression, however the CAR containing only the CD3s PRS and ITAM domains was expressed at similar levels to a 4-1BB/OI)3z CAR on the cell surface (Figures 4B and 4C). CD 19-specific CARs including the full length endodomain of CD3e or the PRS ITAM domain of CD3e efficiently activated T cells after STII microbead crosslinking, although placing the entire CD3e endodomain between the 4-1BB and CD3z domains surprisingly led to relatively weaker SLP-76 Ser376 and PLC-g! Tyr783 P04 after stimulation (Figure 4D).
CDl9-specific CD3e CAR T cell variants were then co-cultured with K562/CD19 cells that were previously sorted for high or lower CD 19 expression (Figure 4E). The addition of all or a signaling portion of the CD3e endodomain did not enhance CAR T cell cytokine production at either antigen density (Figures 4F and 4G). Furthermore, in vitro stimulation of ROR1 -specific CAR T cells with ROR 1 hl K562/ROR1 or RORlmed MDA-MB-231 tumor cell lines demonstrated that 4- 1 BB/CD3CPRS P AM/Eϋ3z CAR T cells secreted similar levels of pro-inflammatory cytokines to 4-1BB/Oϋ3z CAR T cells, and these cytokine levels were markedly less than those secreted by Oϋ28L2ϋ3z CAR T cells (Figures 4H, 41 and 5). Despite similar cytokine production, 4- lBB/CD3cPRS_FrAMAiTl^ CAR T cells proliferated to a greater extent upon co- culture with RORlintMDA-MB-231 and ROR110 NCI-H358 cells (Figures 4J and 4K).
Antigen sensitivity of the highly expressed 4-1BBL2O3erk5_itAM/O03z was compared to a conventional 4-1BB/Oϋ3z CAR. Fluorescence microscopy
measurements of Ca2+ mobilization using Fluo-4 AM showed clear differences between CAR constructs in the kinetics and fraction of activated CAR T cells within minutes of antigen encounter. At low antigen density, fewer than 10% of 4-1BB/Oϋ3z CAR T cells were activated during 20 minutes of exposure to the antigen-containing bilayer. In contrast, significantly a greater fraction of 4- 1 BB/CD3CPRS pΆM^ϋOz CAR T cells was triggered (Figure 4L). The enhanced Ca2+ mobilization responses of 4- 1 BB/CD3CPRS p-AM^03z compared to 4-1 BBL7ϋ3z persisted through a range of ROR1 densities. These results indicate that CAR antigen sensitivity can be augmented by without marked increases in pro-inflammatory cytokine production, which has been associated with a CD28 costimulatory domain and can lead severe cytokine release syndrome (Maloney, Nat. Rev. Clin. Oncol. 2018 15:4 16, 279-280 (2019)).
CD3e sequences enhance CAR antitumor function in antigen1™ settings
Consistent with improved antigen sensitivity, 4-1 BB/CD3CPRS pΆM^ϋOz CAR T cells displayed improved in vivo antitumor function in a xenograft tumor model of RORlmt MDA-MB-23 l breast adenocarcinoma (Figure 4M, Figure 5). Infusion of a sub-curative dose of CD8+ CAR T cells into tumor-bearing mice demonstrated that 4- 1 BB/CD3CPRS p-AM^03z CAR T cells better controlled tumor at both early and late time points compared to 4-1 BBL7ϋ3z CAR T cells (Figures 4M, 4N (left)). The
improved tumor control occurred despite similar intratumor CAR T cell frequencies that did not meet statistical significance (Figure 4N (right)).
Demonstrating that 4-1BBL2ϋ3z CARs containing CD3e sequences possessed higher antigen sensitivity and antitumor function posed the question of whether the additional signaling domains made the CAR T cells signal and behave more like T cells expressing a conventional 0028/003z CAR (Hamieh et al. , Nature 545:423 (2019); Drent et al., Clin. Cancer Res. 25: 4014-4025 (2019)). To this end, CAR signaling was studied by Western blot. 10 minutes of 4- 1 BB/CD3epRS p AM/0"ϋ3z stimulation promoted increased P04 of LAT Tyr191, SLP-76 Ser376, or PLC-yl Tyr783 PO4 relative to 4-1BB/Oϋ3z CAR T cells (Figure 40). Notably, Oϋ3z Tyr142 was not
phosphorylated as strongly after stimulation of the novel CAR as with Oϋ28/Oϋ3z CARs, but yielded similar levels of LAT and PLC-yl PO4. Thus, the novel CARs, informed by the results comparing signaling with TCRs, more efficiently convert CAR GOS z P04 into downstream PO4 of signaling intermediates.
It has previously been shown that Oϋ28/Oϋ3z CAR T cells are less effective than 4-1BB/Oϋ3z CAR T cells at low doses for treating lymphoma and leukemia xenografts in NSG mice due to the rapid development of Oϋ28/Oϋ3z CAR T cell exhaustion (see Salter el al. (supra), Cherkassky el al. (supra), Feucht el al, Nat. Med. 545: 423 (2018)). The antitumor function of 4-lBB/CD3epRS ITAM/CD3C CAR T cells was therefore compared to conventional Oϋ28/Oϋ3z and 4- 1 BB/Oϋ3z CAR T cells in a second tumor model of RORlmt mantle cell lymphoma. In this model, treatment with Oϋ28L2ϋ3z CAR T cells resulted in rapid tumor outgrowth. In contrast, adoptive transfer of 4-1BB/Oϋ3z and 4-1 BB/CD3epRS ΐΊ AM/01ϋ3z CAR T cells resulted in sustained antitumor function and improved survival (Figure 4Q). To further examine the antitumor capabilities of 4-1BB/Oϋ3erk5_itAML2ϋ3z CAR T cells, CAR T cells were injected into NSG mice bearing disseminated CDl9+ Raji lymphoma. The 4- 1 BB/CD3epRS p AM/01ϋ3z CAR design slightly reduced antitumor function and median survival compared to mice treated with conventional 4-1BBL2ϋ3z CAR T cells, but still outperformed Oϋ28/O03z CAR T cells (Figure 4P). Thus, the signals provided by 4- 1 BB/CD3epRS p-AM^03z CARs differed qualitatively from those provided by
CD28/CD3C CARs.
EXAMPLE 3
MATERIALS AND METHODS
Acquisition of peripheral blood T cells from healthy donors
Healthy adults (>18 years-old) were enrolled in Institutional Review Board- approved studies for peripheral blood collection or leukapheresis. Informed consent was obtained from all enrollees. Researchers were provided only donor age and a nondescript donor ID number and blinded to all personally identifiable information about study participants. CD4+ and CD8+ T cells were isolated using the EasySep Human CD4+ and CD8+ T Cell Isolation Kits (StemCell Technologies). For the three shotgun mass spectrometry experiments, CD8+CD45RO+ T cells were enriched by EasySep Human Memory CD8+ T Cell Enrichment Kit (StemCell Technologies). Isolations were performed in accordance with manufacturer’s instructions.
Cell Culture
LentiX cells (Clontech) were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum, lmM L-glutamine (Gibco), 25mM HEPES (Gibco), and lOOU/mL penicillin/streptomycin (Gibco). K562 (CCL-243), NCI-H358 (CRL-5807), MDA-MB-231 (HTB-26), and Raji (CCL-86) cells were obtained from American Type Culture Collection and cultured in RPMI-1640 (Gibco) supplemented with 5% fetal bovine serum, lmM L-glutamine, 25mM HEPES, and lOOU/mL
penicillin/streptomycin. The generation of K562/CD19 and K562/ROR1 cells was previously described (Salter:20l8ft). Primary human T cells were cultured in CTL medium consisting of RPMI-1640 supplemented with 10% human serum, 2mM L- glutamine, 25mM HEPES, lOOU/mL penicillin/streptomycin, 50mM b-mercaptoethanol (Sigma), and 50 U/mL IL-2 (Prometheus). All cells were cultured at 37°C and 5% C02, and tested bi-monthly for the absence of mycoplasma using MycoAlert
Mycoplasma Detection Kit (Lonza).
Generation of chimeric antigen receptors (CARs) and recombinant lentiviral vectors
CDl9-specific and RORl-specific 4-lBB/CD3C and CD28/CD3C CAR constructs with an R12 scFv and IgG4 hinge have been previously described
(Hudecek:20l3ek; Sommermeyer:20l6ky). CD3e CARs were constructed by inserting
a single Strep-tag II sequence and two G4S linkers between the FMC63 or R12 single chain variable fragment and IgG4 hinge (Liu:20l6hy). These were linked to the 27- amino acid transmembrane domain of human CD28 (UniProt: P 10747), a signaling module comprising the 42 amino acid cytoplasmic domain of human 4-1BB (UniProt: Q07011), and the 1 l2-amino acid cytoplasmic domain of isoform 3 of human O03z (UniProt: P20963-3). The entire CD3e endodomain (UniProt: P07766) or a truncated endodomain (amino acids 179-207) containing PRS and IT AM components was inserted either immediately before or after the O03z endodomain. All CAR constructs were linked by T2A sequence to a truncated CD 19 (CDl9t) or epidermal growth factor receptor (EGFRt), codon-optimized, and cloned into a HIV7 lentiviral vector. All cloning was performed by PCR, enzyme digest, and/or Gibson assembly. Plasmids were verified by capillary sequencing and restriction digest.
Lentivirus preparation and transduction
Lentivirus was generated by transient transfection of LentiX cells using psPAX2, pMD2.G, and a CAR encoding lentiviral vector. Primary human T cells were activated and transduced as described in Salter et al. {supra). To prepare K562 cells expressing HLA-B8, LentiX cells were transiently transfected with psPAX2, pMD2.G, and a HIV7 lentiviral vector encoding HLA-B8. To prepare K562/B8 cells expressing EBV antigens or ROR1, LentiX cells were transiently transfected with MLV g/p, 10A1, and a mp7l retroviral vector encoding GFP and an EBV peptide minigene, or human ROR1. The mp7l retroviral vector was a gift of Dr. Wolfgang Uckert, Max Delbruck Center for Molecular Medicine. To prepare Raji/ffluc cells, LentiX cells were transiently transfected with psPAX2, pMD2.G, and an HIV7 lentiviral vector encoding GFP and firefly luciferase. Two days later, viral supernatant was filtered using a 0.45pm PES syringe filter and added to K562 or Raji cells. Five days later, transduced cells were stained monoclonal antibodies specific for HLA-B8 (REA145, Miltenyi Biotec) and ROR1 (2A2, Miltenyi Biotec) and FACS-sorted on a FACSAria II to greater than 97% purity.
T cell expansion for mass spectrometric and junctional analyses
FACS-sorted CD8+tetramer+CDl9t+ or CD8+EGFRt+ cells were expanded over a single stimulation cycle prior to MS and/or functional analyses. Bi-specific and
ROR1 -specific CAR T cells were expanded using a rapid expansion protocol containing purified OKT3, irradiated LCL, and irradiated PBMC, and assayed 11 days after stimulation. CDl9-specific CAR T cells were expanded by co-culture with irradiated CD19+ lymphoblastoid cell lines (LCL) in a 1 :7 (T celfLCL) ratio and assayed 8 days after stimulation. During expansion, cultures were fed with fresh CTL media containing 50 IU/mL IL-2 every 2-3 days.
Flow cytometry and cell phenotyping
T cells were stained with a 1 : 100 dilution of fluorophore-conjugated monoclonal antibodies specific for human CD4 (RPA-T4), CD8 (SK1), CD 19 (HIB19), CD28 (CD28.2), CD45 (HI30), CD45RO (UCHL1), CD62L (DREG56) or CD279 (eBioJl05) purchased from BD Biosciences, ThermoFisher, or Biolegend. T cells were also stained with isotype control fluorophore-conjugated antibodies when appropriate.
Cetuximab (anti-EGFR, Bristol Myers Squibb) was biotinylated using the EZ-Link Sulfo-NHS-Biotin kit (ThermoFisher) followed by cleanup with a Zeba Spin Desalting Column (ThermoFisher) and used to stain T cells in conjunction with Streptavidin-APC (ThermoFisher). DNA content staining was performed by fixing T cells with 70% ice- cold ethanol, permeabilizing cells with 1% Triton-X (Sigma), degrading RNA with l00Dg/mL RNAse A (ThermoFisher), and staining DNA with 20pg/mL Propidium Iodide (ThermoFisher). All data was collected on a FACSCanto II or FACSAria II (BD Biosciences).
SCT, SCT/CD28, RORl, STII and control microbead preparation
Recombinant single chain turner (SCT) and human RORl were produced at the Fred Hutchinson Cancer Research Center. lmL Streptavidin-Coated Magnetic Particles (Spherotech) was washed once in excess lx PBS supplemented with 100 U/mL penicillin/streptomycin (PBS+P/S) using a benchtop magnet. SCT and RORl microbeads were prepared by resuspending beads in lmL PBS+P/S and then slowly adding recombinant protein while vortexing the solution. Protein was added at the indicated molar ratios according to manufacturer’s predetermined molar binding capacities. SCT/CD28 microbeads were prepared by resuspending beads in lmL PBS+P/S and then slowly adding recombinant SCT protein and biotinylated CD28 mAb (CD28.2, ThermoFisher) at a 3 : 1 molar ratio. STII microbeads were prepared by
resuspending beads in lmL PBS+P/S and then slowly adding l6.67pg anti-STII biotin mAb (GenScript) while vortexing the bead solution. All microbeads were incubated overnight at 4°C on a 3D orbital shaker, washed three times with excess PBS+P/S using a benchtop magnet, and resuspended in 4mL PBS+P/S for STII microbeads or lmL PBS+P/S for control, SCT, SCT/CD28 and ROR1 beads. To make control beads, lmL Streptavidin-Coated Magnetic Particles was washed once using a benchtop magnet and the bead pellet was resuspended in lmL PBS+P/S. All beads were stored at 4°C.
Cell stimulations, protein lysates, RNA isolation
CAR T cells were washed and resuspended in warm CTL medium. T cells were brought to a concentration of 2xl07 cells per mL and incubated with control, SCT, SCT/CD28, ROR1, or STII microbeads in a 37°C water bath. After the allotted time, cells were quickly washed twice using ice-cold PBS, then lysed in a 6M Urea, 25mM Tris (pH 8.0), lmM EDTA, lmM EGTA solution supplemented with protease (Sigma) and phosphatase inhibitors (Sigma) at a 1 : 100 dilution, hereon referred to as lysis buffer. Lysates were sonicated for 15 seconds prior to centrifuging at l0,000xg and 4°C for 10 minutes. Beads were removed during lysate clearing.
Protein digestion, TMT labeling, and phosphotyrosine (pTyr) peptide
immunoprecipitation
Protein was quantified in lysates by Micro BCA Assay (Therm oFisher), and lysates were diluted to 2mg/mL using lysis buffer. Lysates were reduced in 24mM TCEP (ThermoFisher) for 30 minutes at 37°C with shaking, followed by alkylation with 48mM iodoacetamide (Sigma) in the dark at room temperature for 30 minutes. Lysates were then diluted with 200mM Tris (pH 8.0), to a urea concentration of 2M. Lys-C (Wako) was dissolved in 25mM Tris (pH 8.0) at 200ug/mL and added to lysates at 1 : 100 (enzyme: protein) ratio by mass and incubated for 2 hours at 37°C with shaking. Samples were further diluted with 200mM Tris (pH 8.0) to a urea
concentration of 1M before adding trypsin at a 1 :50 trypsimprotein ratio. After 2 hours, a second trypsin aliquot was added at a 1 : 100 trypsimprotein ratio. Digestion was carried out overnight at 37°C with shaking. After 16 hours, the reaction was quenched with formic acid to a final concentration 1% by volume. Samples were desalted using Oasis HLB 96-well plates (Waters) and a positive pressure manifold (Waters). The
plate wells were washed with 3 x 400pL of 50% MeCN/0.1% FA, and then equilibrated with 4 x 400pL of 0.1% FA. The digests were applied to the wells, then washed with 4 x 400pL 0.1% FA before being eluted drop by drop with 3 x 400pL of 50%
MeCN/0.1% FA. The eluates were lyophilized, followed by storage at -80°C until use. For TMT labeling (ThermoFisher), desalted peptides were resuspended in 50 mM HEPES at lmg/mL based on starting protein mass. TMT reagents were resuspended in 257pL MeCN and transferred to the peptide sample. Samples were incubated at room temperature for 1 hour with mixing. Labeling reactions were quenched by the addition of 50pL of 5% hydroxyl Amine (Sigma) and incubated for 15 minutes at room temperature with mixing. The independent labeling reactions were then pooled together and lyophilized. The labeled peptides were desalted as above and then lyophilized and stored at -80°C. Immunoprecipitation of pTyr peptides was performed using the PTMScan P-Tyr-l000 Kit (Cell Signaling). The enriched pTyr peptide fraction was purified using a C18 Spin Tip (ThermoFisher), lyophilized, and stored at -80°C until analysis. The flow-through fraction was desalted, lyophilized, and stored at -80°C.
Basic (high pH) reverse phase liquid chromatography
The desalted and pTyr peptide-depleted flow-through was fractionated by high- pH reverse phase (RP) liquid chromatography. 4 mg of the protein digest was loaded onto a LC system consisting of an Agilent 1200 HPLC with mobile phases of 5mM NH4HC03 (pH 10) (A) and 5mM NH4HC03 in 90% MeCN (pH 10) (B). The peptides were separated by a 4.6 mm x 250 mm Zorbax Extend-Cl8, 3.5pm, column (Agilent) over 96 minutes at a flow rate of l.OmL/min by the following timetable: hold 0% B for 9 minutes, gradient from 0 to 10% B for 4 minutes, 10 to 28.5% B for 50 minutes, 28.5 to 34% B for 5.5 minutes, 34 to 60% B for 13 minutes, hold at 60% B for 8.5 minutes, 60 to 0% B for 1 minute, re-equilibrate at 0% B for 5 minutes. 1 minute fractions were collected from 0-96 minutes by the shortest path by row in a 1 mL deep well plate (ThermoFisher). The high pH RP fractions were concatenated into 24 samples by every other plate column starting at minute 15 ( e.g ., sample 1 contained fractions from wells B10, D10, F10, etc). The remaining fractions were combined such that fractions from 12 to 14 minutes were added to sample 1, all fractions after 86 minutes were added to sample 24, and all fractions from 0 to 11 minutes were combined
into sample‘A’. 95% of every l2th fraction of the 24 samples was combined (1,13; 2,14; ...) to generate 12 more samples, which were dried down and stored at -80°C prior to phosphopeptide enrichment by immobilized metal affinity chromatography.
Immobilized metal affinity chromatography (IMAC)
IMAC enrichment was performed using Ni-NTA-agarose beads (Qiagen) stripped with EDTA and incubated in a lOmM FeCl3 solution to prepare Fe3+-NTA- agarose beads. Fractionated lysate was reconstituted in 200pL of 0.1% TFA in 80% MeCN and incubated for 30 minutes with lOOpL of the 5% bead suspension while mixing at room temperature. After incubation, beads were washed 3 times with 300pL of 0.1% TFA in 80% MeCN. Phosphorylated peptides were eluted from the beads using 200pL of 70% ACN, 1% Ammonium Hydroxide for 1 minute with agitation at room temperature. Samples were transferred into a fresh tube containing 60pL of 10% FA, dried down and re-suspended in 0.1% FA, 3% MeCN. Samples were frozen at - 80°C until analysis.
Nano-liquid chromatography-tandem mass spectrometry
Phosphopeptide-enriched samples were analyzed by LC-MS/MS on an Easy- nLC 1000 (ThermoFisher) coupled to an LTQ-Orbitrap Fusion mass spectrometer (ThermoFisher) operated in positive ion mode. The LC system, configured in a vented format consisted of a fused-silica nanospray needle (PicoTip emitter, 50pm ID x 20cm, New Objective) packed in-house with ReproSil-Pur C18-AQ, 3pm and a trap
(IntegraFrit Capillary, lOOpm ID x 2 cm, New Objective) containing the same resin as in the analytical column with mobile phases of 0.1% FA in water (A) and 0.1% FA in MeCN (B). The peptide sample was diluted in 20 pL of 0.1% FA, 3% MeCN, and 8.5pL was loaded onto the column and separated over 210 minutes at a flow rate of 300 nL/min with a gradient from 5 to 7% B for 2 minutes, 7 to 35% B for 150 minutes, 35 to 50% B for 1 minute, hold 50% B for 9 minutes, 50 to 95% B for 2 minutes, hold 95% B for 7 minutes, 95 to 5% B for 1 minute, re-equilibrate at 5% B for 38 minutes. A spray voltage of 2000 V was applied to the nanospray tip. MS/MS analysis occurred over a 3 second cycle time consisting of 1 full scan MS from 350-1500 m/z at resolution 120,000 followed by data dependent MS/MS scans using HCD activation
with 27% normalized collision energy of the most abundant ions. Selected ions were dynamically excluded for 45 seconds after a repeat count of 1.
Western blotting
Equal masses of protein lysate were loaded into 4-12% Bis-Tris NuPAGE Gels (ThermoFisher). After protein transfer onto nitrocellulose membranes (Therm oFisher), membranes were blocked with Western Blocking Reagent (Sigma). Membranes were stained with primary and secondary antibodies diluted in SuperBlock (ThermoFisher) supplemented with 0.1% Tween. The following antibodies were used: anti-CD247 (8D3, BD Biosciences), anti-CD247 pTyr142 (K25-407.69, BD Biosciences), anti-SLP- 76 (polyclonal, Cell Signaling), anti-SLP-76 pSer376 (D9D6E, Cell Signaling), anti- PLC-yl (D9H10, Cell Signaling), anti-PLC-g 1 pTyr783 (D6M9S, Cell Signaling), anti mouse horseradish peroxidase (HRP) (polyclonal, Cell Signaling), and anti-rabbit HRP (polyclonal, Cell Signaling). Typical antibody dilutions ranged from 1 : 10,000 to 1 :2500.
In vitro functional assays
CAR T cells were co-cultured with tumor cells at a T cell to tumor cell ratio of 2: 1 or beads at a ratio of 7.5pL beads per lxlO6 cells. Intracellular cytokine staining was performed by incubating T cells with tumor cells or beads and GolgiStop (BD Biosciences) for 5 hours. Cells were fixed and permeabilized using
FoxP3/Transcription Factor Staining Buffers (ThermoFisher) and stained with fluorochrome-labeled monoclonal antibodies specific for IFN-g (B27), IL-2 (MQ1- 17H12), and TNF-a (Mabl 1) purchased from Biolegend and BD Biosciences. Cytokine concentrations in cellular supernatant were quantified by ELISA (ThermoFisher) 24 hours after stimulation. T cell proliferation was quantified by staining CAR T cells with a 0.2mM solution of carboxyfluorescein succinimidyl ester (CFSE) dye
(ThermoFisher) and incubating T cells with tumor cells or beads for 72 hours.
Transfer of T cells in NOD S( 'll) vc- - (NSG) mice
Six- to eight- week-old male or female NSG mice were obtained from the Jackson Laboratory or bred in-house. Mice were engrafted via tail vein with 5x 105 Raji/ffluc, MDA-MB-23 l/ffluc, or Jeko/ffluc cells and, 7 days later, injected
intravenously with a defined product of CAR T cells. For Raji experiments, CD8+ and CD4+ CAR T cells were mixed together in a 1 : 1 ratio. For MDA-MB-231 and Jeko experiments, CD8+ T cells were infused. Bioluminescence imaging was performed as described and mice were followed for survival. Mice handlers were blinded to group allocation. The Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee approved all experimental procedures.
Shotgun mass spectrometry data analysis
Raw MS/MS spectra from each replicate experiment were searched together against the reviewed Human Universal Protein Resource (UniProt) sequence database (release 2016 01) with common laboratory contaminants using the
MaxQuant/ Andromeda search engine version 1.6.0.1 (Cox:2008ir). The search was performed with a tryptic enzyme constraint for up to two missed cleavages. Variable modifications were oxidized methionine, phosphorylated serine, phosphorylated threonine, and phosphorylated tyrosine. Carbamidomethylated cysteine was set as a static modification. Peptide MH+ mass tolerances were set at 20 ppm. The overall FDR was set at < 1% using a reverse database target decoy approach.
For the three TMT experiments, phosphopeptide site localization was determined by MaxQuant and converted to phosphorylation sites using Perseus version 1.6.0.7 (Tyanova:20l6ds). At this step, reverse hits and potential contaminants were excluded from further analysis. Data normalization was performed by scaling each TMT channel to the channel median, followed by a log2transformation. Stimulation vs. control ratios were calculated by subtracting the appropriate control channels from stimulated channels. Due to incomplete MS sampling, some phosphorylation sites (features) were only found in one or two replicate experiments, and a much smaller minority (< 1%) of sites were not found in every TMT channel.
Differential expression analyses over P04 sites were performed using the limma statistical framework and associated R package (Ritchie:20l5fa, Smyth :2004gh). For these analyses, only those features were kept that had values in at least two experiments and all TMT channels, leaving 19,608 quantified P04 sites. A linear model was fitted to each P04 site, and empirical Bayes moderated t-statistics were used to assess differences in expression/abundance. Contrasts comparing stimulation vs control
treatments were tested. Intraclass correlations were estimated using the
duplicateCorrelation function of the limma package to account for measures originating from the same patients and the same antigens (Smyth:2005iy). An absolute log2fold change cutoff (stimulation versus control) of 1 and a false discovery rate (FDR) cutoff of 5% were used to determine differentially expressed P04 sites. Analyses of signaling networks and KEGG Pathways were performed using StringDB.
Analysis of T cell phenotype, function, and in vivo experiments
FlowJo version 9 (Treestar) was used to analyze flow cytometry files. Prism version 7 (GraphPad Software) was used to plot data and calculate statistics. P values meeting an a = 0.05 level of significance are indicated in the figures. The precise statistical tests used are indicated in the figure legends.
The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, including U.S. Provisional Patent Application No. 62/735,702, filed September 24, 2018, and U.S. Provisional Patent Application No. 62/901,194, filed September 16, 2019, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.
These and other changes can be made to the embodiments in light of the above- detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
Claims
1. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion or variant thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (ITAM) from CD3e, or a functional portion or variant thereof;
(ii) an ITAM from CD3y, or a functional portion or variant thereof;
(iii) an ITAM from CD35, or a functional portion or variant thereof;
(iv) a Proline Rich Sequence (PRS) from CD3e, or a functional portion or variant thereof;
(v) a Basic Residue Sequence (BRS) from CD3e, or a functional portion or variant thereof; or
(vi) any combination of (i)-(v),
wherein
(1) the extracellular domain does not comprise a TCR ectodomain; and/or
(2) the fusion protein does not associate with or form a TCR complex when expressed by a T cell.
2. A fusion protein, comprising:
(a) an extracellular component comprising a binding domain that specifically binds to an antigen;
(b) a transmembrane domain; and
(c) an intracellular component comprising an effector domain or a functional portion thereof, wherein the effector domain or functional portion thereof comprises:
(i) an Intracellular Tyrosine-based Activation Motif (IT AM) from CD3e, or a functional variant thereof;
(ii) an IT AM from CD3y, or a functional variant thereof;
(iii) an IT AM from CD35, or a functional variant thereof;
(iv) a Proline Rich Sequence (PRS) from CD3e, or a functional variant thereof;
(v) a Basic Residue Sequence (BRS) from CD3e and/or CD3 z, or a functional variant thereof; or
(vi) any combination of (i)-(v),
and does not comprise an ectodomain or a transmembrane domain, or a portion thereof, from CD3e, CD35, and/or CD3y.
3. The fusion protein of claim 1 or 2, wherein the effector domain or functional portion thereof comprises an ITAM from CD3e, or a functional variant thereof, and a PRS from CD3e, or a functional variant thereof.
4. The fusion protein of any one of claims 1-3, wherein the fusion protein does not comprise a BRS from CD3e, or a functional variant thereof.
5. The fusion protein of any one of claims 1-4, wherein the effector domain or functional fragment thereof comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 8.
6. The fusion protein of any one of claims 1-3 or 5, wherein the effector domain comprises a BRS from CD3e, or a functional variant thereof.
7. The fusion protein of any one of claims 1-6, wherein the effector domain comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 5 or 111.
8. The fusion protein of any one of claims 1-7, wherein the effector domain comprises: an IT AM from CD3y, or a functional variant thereof; and/or comprises an ITAM from CD35, or a functional variant thereof.
9. The fusion protein of claim 8, wherein the effector domain comprises:
(i) an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 11, wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO: 11 is optionally not a leucine, and is preferably an alanine or a glycine; and/or
(ii) an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 14, wherein one or more of the amino acids corresponding to positions 16 and 17 of SEQ ID NO: 14 is optionally not a leucine, and is preferably an alanine or a glycine.
10. The fusion protein of claim 8 or 9, wherein the effector domain comprises a BRS from CD3e, or a functional portion or variant thereof.
11. The fusion protein of any one of claims 1-10, wherein the effector domain further comprises an ITAM from Oϋ3z, or a functional portion or variant thereof.
12. The fusion protein of claim 11, wherein the effector domain comprises two or three of IT AMs (a), (b), and (c) from CDS z, or functional portions or variants thereof.
13. The fusion protein of claim 11 or 12, wherein the effector domain comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO: 17.
14. The fusion protein of any one of claims 1-13, further comprising a costimulatory domain or a functional portion or variant thereof.
15. The fusion protein of claim 14, wherein the costimulatory domain or functional portion or a variant thereof is from 4-1BB, CD28, 0X40, CD27, CD2, CD5, ICAM-l (CD54), LFA-l (CD 11 a/CD 18), ICOS (CD278), GITR, CD30, CD40, BAFF- R, HVEM, LIGHT, MKG2C, SLAMF7, NKp80, CD 160, B7-H3, a ligand that specifically binds with CD83, or any combination thereof.
16. The fusion protein of claim 15, wherein the costimulatory domain comprises a costimulatory domain, or a functional portion or variant thereof, from 4-1BB.
17. The fusion protein of any one of claims 14-16, wherein the intracellular domain comprises the costimulatory domain or functional portion or variant thereof, an endodomain or effector domain from CD3z or a functional portion or variant thereof, and an effector domain from CD3e or a functional portion or variant thereof, wherein the effector domain from CD3e or functional portion or variant thereof optionally comprises or consists essentially of a PRS and an IT AM from CD3e.
18. The fusion protein of claim 17, wherein the effector domain from CD3e or functional portion or variant thereof is disposed between the costimulatory domain or functional portion or variant thereof and the endodomain or effector domain from Oϋ3z or functional portion or variant thereof.
19. The fusion protein of claim 17, wherein the endodomain or effector domain from Oϋ3z or functional portion or variant thereof is disposed between the
costimulatory domain or functional portion or variant thereof and the effector domain from CD3e or functional portion or variant thereof.
20. The fusion protein of any one of claims 1-19, wherein the
transmembrane domain comprises or is a CD28 transmembrane domain, a CD27 transmembrane domain, a CD4 transmembrane domain, a CD8 transmembrane domain, or any combination thereof.
21. The fusion protein of any one of claims 1-20, wherein the extracellular domain comprises a CH1, a CH2, a CH3, a CL, a CD8 extracellular domain, a CD28 extracellular domain, a CD4 extracellular domain, an IgG hinge, a glycine-serine linker comprising from about one to about ten repeats of GlyxSery (SEQ ID NO: 108), a linker having an amino acid sequence as set forth in any one of SEQ ID NOs.: 103-107, 109, or 110, or a functional variant or portion thereof, or a combination thereof.
22. The fusion protein of any one of claims 1-21, wherein the extracellular domain comprises a linker disposed between the binding domain and the
transmembrane domain.
23. The fusion protein of claim 22, wherein the linker comprises a hinge region or a portion thereof.
24. The fusion protein of any one of claims 1-23, wherein the binding domain comprises or consists of a scFv, a Fab, a scTCR, or a ligand.
25. The fusion protein of claim 23, wherein the binding domain comprises a scFv.
26. The fusion protein of any one of claims 1-25, wherein the binding domain is chimeric, human, or humanized.
27. The fusion protein of any one of claims 1-26, wherein the binding domain specifically binds to an antigen that is expressed by or is associated with a cancer.
28. The fusion protein of claim 27, wherein the cancer comprises a solid tumor.
29. The fusion protein of any one of claims 1-28, wherein the antigen is selected from a ROR1, EGFR, EGFRvIII, EGP-2, EGP-40, GD2, GD3, HPV E6, HPV E7, Her2, Ll-CAM, Lewis A, Lewis Y, MUC1, MUC16, PSCA, PSMA, CD 19, CD20, CD22, CD56, CD23, CD24, CD30, CD33, CD37, CD44v7/8, CD38, CD56, CD123, CA125, c-MET, FcRH5, WT1, folate receptor a, VEGF-a, VEGFR1, VEGFR2, IL- l3Ra2, IL-l lRa, MAGE-A1, PSA, ephrin A2, ephrin B2, NKG2D, NY-ESO-l, TAG- 72, mesothelin, NY-ESO, 5T4, BCMA, FAP, Carbonic anhydrase 9, ERBB2,
BRAFV600E, MAGE- A3, MAGE-A4, SSX-2, PRAME, HA-l, CD79a, CD79b, SLAMF7, or CEA antigen.
30. The fusion protein of claim 29, wherein the antigen is a ROR1 antigen.
31. The fusion protein of any one of claims 1-30, further comprising a protein tag.
32. The fusion protein of any one of claims 1-31, wherein the fusion protein, when expressed by a host cell, optionally an immune system cell, provides for or promotes:
(i) improved cell signaling, and/or activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased and/or sustained cytokine production and/or release, and/or phosphorylation of one or more protein associated with an immune cell response to antigen-binding, or the like, such as LAT, PLC-g I , SLP-76, or any combination thereof;
(ii) improved cell activity in response to antigen relative to a host cell expressing a reference fusion protein, wherein improved cell signaling optionally comprises increased mobilization of intracellular calcium , killing activity, proliferation, earlier activation in response to antigen, or any combination thereof;
(iii) improved cell signaling and/or activity, relative to a host cell expressing a reference fusion protein, upon binding to a target antigen that is expressed at a low level or an intermediate level on a target cell surface;
(iv) reducing or suppressing growth, area, volume, and/or spread of a tumor that expresses an antigen that is recognized and/or specifically bound by the fusion protein, of killing tumor cells, and/or of increasing survival of the subject to a greater degree and/or for a longer period of time as compared to a reference subject
administered a host cell expressing a reference fusion protein;
(iv) more efficient phosphorylation of LAT, SLP-76, and/or PLC-g I as compared to a reference fusion protein expressed by a host cell;
(v) improved sensitivity to antigen as compared to a host cell expressing a reference fusion protein, but does not produce more, or substantially more, of a pro- inflammatory cytokine as compared to the host cell expressing the reference fusion protein; or
(vi) any combination of (i)-(v).
33. The fusion protein of claim 32, wherein the intracellular component comprises a costimulatory domain, or a functional portion or variant thereof, from 4- 1BB.
34. The fusion protein of claim 32 or 33, wherein the reference protein comprises an intracellular domain comprising a 4-1BB costimulatory domain and/or a CD28 costimulatory domain.
35. The fusion protein of any one of claims 32-34, wherein the fusion protein and the reference protein each comprise an endodomain or effector domain from CD3z or a functional portion or variant thereof.
36. The fusion protein of any one of claims 32-35, wherein the host cell expressing the fusion protein and the host cell expressing the reference fusion protein are each a T cell, optionally a CD8+ T cell.
37. An isolated polynucleotide, encoding the fusion protein of any one of claims 1-36.
38. The isolated polynucleotide of claim 37, further comprising a polynucleotide encoding a transduction marker.
39. The isolated polynucleotide of claim 38, wherein the encoded transduction marker comprises EGFRt, CDl9t, CD34t, or NGFRt.
40. The isolated polynucleotide of any one of claims 38 or 39, further comprising a polynucleotide encoding a self-cleaving polypeptide.
41. The isolated polynucleotide of claim 40, wherein the fusion protein encoding polynucleotide is separated from the transduction marker-encoding polynucleotide by the polynucleotide encoding a self-cleaving polypeptide.
42. The isolated polynucleotide of claim 40 or 41, wherein the encoded self cleaving polypeptide comprises a P2A, an F2A, a T2A, an E2A, or a variant thereof.
43. The isolated polynucleotide of any one of claims 37-42, wherein the polynucleotide is codon optimized for expression in a host cell.
44. The isolated polynucleotide of any one of claims 37-43, wherein the polynucleotide comprises a polynucleotide having at least 70% identity to the nucleotide sequence set forth in any one of SEQ ID NOs.:34-42.
45. An expression vector, comprising the isolated polynucleotide of any one of claims 37-44 operably linked to an expression control sequence.
46. The vector of claim 45, wherein the vector is capable of delivering the polynucleotide to a host cell.
47. The expression vector of claim 46, wherein the host cell is a
hematopoietic progenitor cell or a human immune system cell.
48. The expression vector of claim 47, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4 CD8 double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
49. The expression vector of claim 47 or 48, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
50. The expression vector of any one of claims 45-49, wherein the vector is a viral vector.
51. The expression vector of claim 50, wherein the viral vector is a lentiviral vector or a g-retroviral vector.
52. A host cell, comprising the polynucleotide of any one of claims 37-44.
53. A host cell, expressing at its cell surface the fusion protein of any one of claims 1-36.
54. The host cell of claim 53, further expressing a transduction marker at its cell surface.
55. The host cell of any one of claims 52-54, wherein the host cell is a hematopoietic progenitor cell or a human immune system cell.
56. The host cell of claim 55, wherein the human immune system cell is a CD4+ T cell, a CD8+ T cell, a CD4- CD8- double negative T cell, a gd T cell, a natural killer cell, a natural killer T cell, a dendritic cell, or any combination thereof.
57. The host cell of claim 55 or 56, wherein the host cell comprises a T cell.
58. The host cell of claim 56 or 57, wherein the T cell is a naive T cell, a central memory T cell, a stem cell memory T cell, an effector memory T cell, or any combination thereof.
59. The host cell of any one of claims 52-58, comprising a chromosomal gene knockout or a mutation of a PD-l gene; a LAG3 gene; a TIM3 gene; a CTLA4 gene; an HLA component gene; a TCR component gene, or any combination thereof.
60. A composition, comprising a fusion protein of any one of claims 1-36 and a pharmaceutically acceptable carrier, excipient, or diluent.
61. A composition, comprising a host cell of any one of claims 52-59, and a pharmaceutically acceptable carrier, excipient, or diluent.
62. A unit dose, comprising an effective amount of the host cell of any one of claims 52-59, or of the host cell composition of claim 61.
63. The unit dose of claim 62, comprising (i) a composition comprising at least about 30% CD4+ T host cells, combined with (ii) a composition comprising at least about 30% CD8+ T host cells, in about a 1 : 1 ratio.
64. A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of the host cell of any one of claims 52-59, the composition of claim 60 or 61, or the unit dose of claim 62 or 63, wherein the disease or condition is characterized by the presence of the antigen.
65. A method of eliciting an immune response against an antigen that is specifically bound by the fusion protein of any one of claims 1-36, the method comprising administering to a subject comprising or expressing the antigen an effective amount of the host cell of any one of claims 52-59, the composition of claim 60 or 61, or the unit dose of claim 62 or 63.
66. The method of claim 64, wherein the disease or condition comprises a hyperproliferative disease or a proliferative disease.
67. The method of claim 64 or 66, wherein the disease or condition is a cancer.
68. The method of claim 67, wherein the cancer comprises a carcinoma, a sarcoma, a glioma, a lymphoma, a leukemia, a myeloma, or any combination thereof.
69. The method of claim 67 or 68, wherein the cancer comprises a cancer of the head or neck, melanoma, pancreatic cancer, cholangiocarcinoma, hepatocellular cancer, breast cancer including triple-negative breast cancer (TNBC), gastric cancer, non-small-cell lung cancer, prostate cancer, esophageal cancer, mesothelioma, small cell lung cancer, colorectal cancer, glioblastoma, or any combination thereof.
70. The method of any one of claims 67-69, wherein the cancer comprises Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, PNET, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans (DFSP), desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma,
extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma,
gastrointestinal stromal tumor (GIST), hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, linitis plastic, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, renal cell carcinoma, Grawitz tumor, ependymoma, astrocytoma, oligodendroglioma, brainstem glioma, optice nerve glioma, a mixed glioma, Hodgkin’s lymphoma, a B-cell lymphoma, non-Hodgkin’s lymphoma (NHL), Burkitf s lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma, Waldenstrom's macroglobulinemia, CD37+ dendritic cell lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extra- nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, adult T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, blastic NK cell lymphoma, Sezary syndrome, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, or any combination thereof.
71. The method of any one of claims 67-70, wherein the cancer comprises a solid tumor.
72. The method of claim 71, wherein the solid tumor is a sarcoma or a carcinoma.
73. The method of claim 72, wherein the solid tumor is selected from:
chondrosarcoma; fibrosarcoma (fibroblastic sarcoma); Dermatofibrosarcoma protuberans (DFSP); osteosarcoma; rhabdomyosarcoma; Ewing’s sarcoma; a
gastrointestinal stromal tumor; Leiomyosarcoma; angiosarcoma (vascular sarcoma); Kaposi’s sarcoma; liposarcoma; pleomorphic sarcoma; or synovial sarcoma.
74. The method of claim 72 or 73, wherein the solid tumor is selected from a lung carcinoma ( e.g ., Adenocarcinoma, Squamous Cell Carcinoma (Epidermoid Carcinoma); Squamous cell carcinoma; Adenocarcinoma; Adenosquamous carcinoma; anaplastic carcinoma; Large cell carcinoma; Small cell carcinoma; a breast carcinoma (e.g., Ductal Carcinoma in situ (non-invasive), Lobular carcinoma in situ (non- invasive), Invasive Ductal Carcinoma, Invasive lobular carcinoma, Non-invasive Carcinoma); a liver carcinoma (e.g., Hepatocellular Carcinoma, Cholangiocarcinomas or Bile Duct Cancer); Large-cell undifferentiated carcinoma, Bronchi oalveolar carcinoma); an ovarian carcinoma (e.g., Surface epithelial-stromal tumor
(Adenocarcinoma) or ovarian epithelial carcinoma (which includes serous tumor, endometrioid tumor and mucinous cystadenocarcinoma), Epidermoid (Squamous cell carcinoma), Embryonal carcinoma and choriocarcinoma (germ cell tumors)); a kidney carcinoma (e.g., Renal adenocarcinoma, hypernephroma, Transitional cell carcinoma (renal pelvis), Squamous cell carcinoma, Bellini duct carcinoma, Clear cell
adenocarcinoma, Transitional cell carcinoma, Carcinoid tumor of the renal pelvis); an adrenal carcinoma (e.g., Adrenocortical carcinoma), a carcinoma of the testis (e.g., Germ cell carcinoma (Seminoma, Choriocarcinoma, Embryonal carciroma,
Teratocarcinoma), Serous carcinoma); Gastric carcinoma (e.g., Adenocarcinoma); an intestinal carcinoma (e.g., Adenocarcinoma of the duodenum); a colorectal carcinoma; or a skin carcinoma (e.g., Basal cell carcinoma, Squamous cell carcinoma).
75. The method of claim 72 or 73, wherein the solid tumor is an ovarian carcinoma, an ovarian epithelial carcinoma, a cervical adenocarcinoma or small cell carcinoma, a pancreatic carcinoma, a colorectal carcinoma (e.g., an adenocarcinoma or squamous cell carcinoma), a lung carcinoma, a breast ductal carcinoma, or an adenocarcinoma of the prostate.
76. The method of any one of claims 64-75, wherein the host cell is an allogeneic cell, a syngeneic cell, or an autologous cell.
77. The method of any one of claims 64-76, wherein the method comprises administering a plurality of unit doses to the subject.
78. The method of claim 77, wherein the plurality of unit doses are administered at intervals between administrations of about two, three, four, five, six, seven, eight, or more weeks.
79. The method according to any one of claims 64-78, wherein the unit dose comprises about 105 cells/m2 to about 1011 cells/m2.
80. The method of any one of claims 57-79, wherein the subject is receiving, has received, or will receive one or more of:
(i) chemotherapy;
(ii) radiation therapy;
(iii) an inhibitor of an immune suppression component
(iv) an agonist of a stimulatory immune checkpoint agent;
(v) RNAi;
(vi) a cytokine;
(vii) a surgery;
(viii) a monoclonal antibody and/or an antibody-drug conjugate; or
(ix) any combination of (i)-(viii), in any order.
81. Use of the polynucleotide of any one of claims 37-44, or the expression vector of any one of claims 45-51, the host cell of any one of claims 52-59, or the composition of any one of claims 60 or 61, in the manufacture of a medicament for the treatment of a disease; e.g ., a disease characterized by or associated with expression of an antigen that is specifically bound by the fusion protein of any one of claims 1-36.
82. Use of the polynucleotide of any one of claims 37-44, or the expression vector of any one of claims 45-51, the host cell of any one of claims 52-59, or the composition of any one of claims 60 or 61, in the treatment of a disease; e.g ., a disease characterized by or associated with expression of an antigen that is specifically bound by the fusion protein of any one of claims 1-36.
83. The use according to claim 81 or 82, wherein the disease is a cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862735702P | 2018-09-24 | 2018-09-24 | |
US62/735,702 | 2018-09-24 | ||
US201962901194P | 2019-09-16 | 2019-09-16 | |
US62/901,194 | 2019-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020068702A1 true WO2020068702A1 (en) | 2020-04-02 |
Family
ID=68344980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/052492 WO2020068702A1 (en) | 2018-09-24 | 2019-09-23 | Chimeric receptor proteins and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020068702A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112500492A (en) * | 2019-09-13 | 2021-03-16 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
CN113980137A (en) * | 2020-07-27 | 2022-01-28 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor containing CD3 epsilon intracellular basic amino acid enrichment region motif and application thereof |
CN113980136A (en) * | 2020-07-27 | 2022-01-28 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor containing CD3 epsilon intracellular domain with Y/F mutation and application thereof |
WO2022020456A3 (en) * | 2020-07-21 | 2022-03-03 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
WO2022251120A3 (en) * | 2021-05-24 | 2023-02-16 | Kite Pharma, Inc. | Nkg2d-based chimeric antgen receptor |
WO2023028583A1 (en) * | 2021-08-26 | 2023-03-02 | The Regents Of The University Of Colorado, A Body Corporate | Cd3 epsilon chimeric antigen receptors and methods of use thereof |
WO2023069936A1 (en) * | 2021-10-18 | 2023-04-27 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
WO2023186079A1 (en) * | 2022-04-02 | 2023-10-05 | 杭州尚健生物技术有限公司 | Cd80 protein variant and cd80 fusion protein |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
CA136551A (en) | 1911-08-03 | 1911-10-31 | Hedwig Heeron | Rolling mill |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US20040002092A1 (en) | 2002-03-15 | 2004-01-01 | Sylvain Arnould | Hybrid and single chain meganucleases and use thereof |
US20040087025A1 (en) | 1995-06-07 | 2004-05-06 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6833252B1 (en) | 1992-05-05 | 2004-12-21 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SecI and the uses thereof |
US20060153826A1 (en) | 2003-01-28 | 2006-07-13 | Sylvain Arnould | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
US20070117128A1 (en) | 2005-10-18 | 2007-05-24 | Smith James J | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US7446191B2 (en) | 2001-04-11 | 2008-11-04 | City Of Hope | DNA construct encoding CE7-specific chimeric T cell receptor |
US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20100065818A1 (en) | 2008-02-22 | 2010-03-18 | Kim Jae-Hyun | Layers and patterns of nanowire or carbon nanotube using chemical self assembly and fabricating method in liquid crystal display device thereby |
WO2010084158A1 (en) | 2009-01-21 | 2010-07-29 | Monoclonal Antibodies Therapeutics | Anti-cd 160 monoclonal antibodies and uses thereof |
US7981632B2 (en) | 2001-03-21 | 2011-07-19 | Iba Gmbh | Sequentially arranged streptavidin-binding modules as affinity tags |
US20110189141A1 (en) | 2009-05-19 | 2011-08-04 | Max-Delbrück-Centrum für Molekulare Medizin | Multiple target t cell receptor |
US20110243972A1 (en) | 2005-01-13 | 2011-10-06 | Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
US20110301073A1 (en) | 2010-05-17 | 2011-12-08 | Sangamo Biosciences, Inc. | Novel DNA-binding proteins and uses thereof |
US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
US20140068797A1 (en) | 2012-05-25 | 2014-03-06 | University Of Vienna | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
WO2015067768A1 (en) | 2013-11-07 | 2015-05-14 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
WO2015071474A2 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
CN104910279A (en) * | 2015-06-05 | 2015-09-16 | 重庆倍思益生物科技有限公司 | Chimeric antigen receptor of targeted carcino-embryonic antigens, lentiviral expression vector as well as preparation methods and applications thereof |
WO2016040724A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2016134333A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
WO2017021526A1 (en) | 2015-08-05 | 2017-02-09 | Amgen Research (Munich) Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
US9574000B2 (en) | 2012-12-19 | 2017-02-21 | Medimmune, Llc | Anti-human B7-H4 antibodies and their uses |
US9573988B2 (en) * | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
CN106520806A (en) * | 2016-11-03 | 2017-03-22 | 山东维真生物科技有限公司 | Recombinant CAR gene and carrier, CAR-T cell and application thereof |
US20170204177A1 (en) * | 2014-07-17 | 2017-07-20 | Carsgen Therapeutics Ltd. | Immunologic effector cell of targeted cld18a2, and preparation method and use thereof |
US20170281682A1 (en) * | 2014-09-09 | 2017-10-05 | Unum Therapeutics Inc. | Chimeric receptors and uses thereof in immune therapy |
-
2019
- 2019-09-23 WO PCT/US2019/052492 patent/WO2020068702A1/en active Application Filing
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
CA136551A (en) | 1911-08-03 | 1911-10-31 | Hedwig Heeron | Rolling mill |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5468614A (en) | 1990-01-24 | 1995-11-21 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US6833252B1 (en) | 1992-05-05 | 2004-12-21 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SecI and the uses thereof |
US20040087025A1 (en) | 1995-06-07 | 2004-05-06 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US7981632B2 (en) | 2001-03-21 | 2011-07-19 | Iba Gmbh | Sequentially arranged streptavidin-binding modules as affinity tags |
US7446191B2 (en) | 2001-04-11 | 2008-11-04 | City Of Hope | DNA construct encoding CE7-specific chimeric T cell receptor |
US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20040002092A1 (en) | 2002-03-15 | 2004-01-01 | Sylvain Arnould | Hybrid and single chain meganucleases and use thereof |
US20060078552A1 (en) | 2002-03-15 | 2006-04-13 | Sylvain Arnould | Hybrid and single chain meganucleases and use thereof |
US20060153826A1 (en) | 2003-01-28 | 2006-07-13 | Sylvain Arnould | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
US20110243972A1 (en) | 2005-01-13 | 2011-10-06 | Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
US20070117128A1 (en) | 2005-10-18 | 2007-05-24 | Smith James J | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
US20100065818A1 (en) | 2008-02-22 | 2010-03-18 | Kim Jae-Hyun | Layers and patterns of nanowire or carbon nanotube using chemical self assembly and fabricating method in liquid crystal display device thereby |
US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
WO2010084158A1 (en) | 2009-01-21 | 2010-07-29 | Monoclonal Antibodies Therapeutics | Anti-cd 160 monoclonal antibodies and uses thereof |
US20110189141A1 (en) | 2009-05-19 | 2011-08-04 | Max-Delbrück-Centrum für Molekulare Medizin | Multiple target t cell receptor |
US20110301073A1 (en) | 2010-05-17 | 2011-12-08 | Sangamo Biosciences, Inc. | Novel DNA-binding proteins and uses thereof |
WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
US20140068797A1 (en) | 2012-05-25 | 2014-03-06 | University Of Vienna | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
US9574000B2 (en) | 2012-12-19 | 2017-02-21 | Medimmune, Llc | Anti-human B7-H4 antibodies and their uses |
US9573988B2 (en) * | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
WO2015067768A1 (en) | 2013-11-07 | 2015-05-14 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
WO2015071474A2 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
US20170204177A1 (en) * | 2014-07-17 | 2017-07-20 | Carsgen Therapeutics Ltd. | Immunologic effector cell of targeted cld18a2, and preparation method and use thereof |
US20170281682A1 (en) * | 2014-09-09 | 2017-10-05 | Unum Therapeutics Inc. | Chimeric receptors and uses thereof in immune therapy |
WO2016040724A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2016134333A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
CN104910279A (en) * | 2015-06-05 | 2015-09-16 | 重庆倍思益生物科技有限公司 | Chimeric antigen receptor of targeted carcino-embryonic antigens, lentiviral expression vector as well as preparation methods and applications thereof |
WO2017021526A1 (en) | 2015-08-05 | 2017-02-09 | Amgen Research (Munich) Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
CN106520806A (en) * | 2016-11-03 | 2017-03-22 | 山东维真生物科技有限公司 | Recombinant CAR gene and carrier, CAR-T cell and application thereof |
Non-Patent Citations (108)
Title |
---|
"Selected Methods in Cellular Immunology", 1979, FREEMAN PUBLISHING |
"UniProt", Database accession no. P20963-3 |
"UniProtKB", Database accession no. P 10966 |
AGNIESZKA MORGENROTH ET AL: "Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells", PROSTATE., vol. 67, no. 10, 1 July 2007 (2007-07-01), US, pages 1121 - 1131, XP055463180, ISSN: 0270-4137, DOI: 10.1002/pros.20608 * |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3379 - 3388 |
ARGAST ET AL., J. MOL. BIOL., vol. 280, 1998, pages 345 - 353 |
ASHWORTH ET AL., NATURE, vol. 441, 2006, pages 656 - 659 |
BIOINFORMATICS, vol. 15, 2016, pages 298 - 300 |
BOWERMAN ET AL., MOL. IMMUNOL., vol. 46, no. 15, 2009, pages 3000 |
BRENTJENS ET AL., CLIN. CANCER RES., vol. 13, 2007, pages 5426 |
BRENTJENS ET AL., SCI TRANSL MED, vol. 5, no. 177, 2013, pages 177ra38 |
BROWNLIEZAMOYSKA, NAT. REV. IMMUNOL., vol. 13, 2013, pages 257 - 269 |
BRUDNO ET AL., J. CLIN. ONCOL., vol. 36.22, 2018, pages 2267 - 80 |
CHERKASSKY ET AL., J. CLIN. INVEST., vol. 126, 2016, pages 3130 - 3144 |
CHEVALIER ET AL., MOLEC. CELL, vol. 10, 2002, pages 895 - 905 |
CHMIELEWSKI ET AL., J. IMMUNOL., vol. 173, 2004, pages 7647 - 7653 |
CHOTHIA ET AL., EMBO J., vol. 7, 1988, pages 3745 |
COFFIN, J. M. ET AL.: "Fundamental Virology", 1996, LIPPINCOTT-RAVEN PUBLISHERS, article "Retroviridae: The viruses and their replication" |
COIFFIER ET AL., N ENGL J MED, vol. 346, no. 4, 2002, pages 235 - 42 |
COLEGAO, CELL. MOL. IMMUNOL., vol. 1, 2004, pages 81 - 88 |
CREIGHTON: "Proteins", 1984, W.H. FREEMAN AND COMPANY |
DANGAJ ET AL., CANCER RES., vol. 73, 2013, pages 4820 |
DESJARLAIS ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 2256 - 2260 |
DOSSETT ET AL., MOL. THER., vol. 17, 2009, pages 742 |
DRENT ET AL., CLIN. CANCER RES., vol. 25, 2019, pages 4014 - 4025 |
DUJON ET AL., GENE, vol. 82, 1989, pages 115 - 118 |
ENGELS ET AL., HUM. GENE THER., vol. 14, 2003, pages 1155 |
EPINAT ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 2952 - 62 |
FEUCHT ET AL., NAT. MED., vol. 545, 2018, pages 423 |
FLOROSTARHINI, SEMIN. ONCOL., vol. 42, no. 4, 2015, pages 539 - 548 |
FRECHA ET AL., MOL. THER., vol. 18, 2010, pages 1748 |
FRIEDMAN ET AL., HUM. GENE THER., vol. 29, 2018, pages 585 - 601 |
FRY ET AL., NATURE MEDICINE, vol. 24, 2018, pages 20 - 28 |
GAOJAKOBSEN, IMMUNOL. TODAY, vol. 21, 2000, pages 630 - 636 |
GEURTS ET AL., MOL. THER., vol. 8, 2003, pages 108 |
GIMBLE ET AL., J. MOL. BIOL., vol. 263, 1996, pages 163 - 180 |
GREENREED, SCIENCE, vol. 281, 1998, pages 1309 |
GUEST ET AL., J. IMMUNOTHER., vol. 28, 2005, pages 203 - 11 |
HAMIEH ET AL., NATURE, vol. 545, 2019, pages 423 |
HARRISKRANZ, TRENDS PHARMACOL. SCI., vol. 37, no. 3, 2016, pages 220 |
HENKART ET AL.: "Fundamental Immunology", 2003, LIPPINCOTT WILLIAMS & WILKINS, article "Cytotoxic T-Lymphocytes", pages: 1127 - 50 |
HOGQUISTJAMESON, NAT. IMMUNOL., vol. 15, 2014, pages 815 - 823 |
HUANG ET AL., IMMUNITY, vol. 39, 2013, pages 846 - 857 |
HUDECEK ET AL., CLIN. CANCER RES., vol. 19, 2013, pages 3153 - 3164 |
JAMES ET AL., J IMMUNOL, vol. 180, no. 10, 2008, pages 7028 - 38 |
JAMESVALE, NATURE, vol. 487, 2012, pages 64 - 69 |
JANEWAY ET AL.: "Current Biology Publications", 1997, article "Immunobiology: The Immune System in Health and Disease", pages: 4.33 |
JASIN, TRENDS GENET., vol. 12, 1996, pages 224 - 228 |
JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 21 |
JOLLY, D J: "The Development of Human Gene Therapy", 1999, COLD SPRING HARBOR LAB, article "Emerging Viral Vectors", pages: 209 - 40 |
JORES ET AL., PROC. NAT'L ACAD. SCI. U.S.A., vol. 87, 1990, pages 9138 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES |
KALOS ET AL., SCI TRANSL MED, vol. 3, no. 95, 2011, pages 95ra73 |
KIM ET AL., PLOS ONE, vol. 6, 2011, pages e18556 |
KOCHENDERFER ET AL., J CLIN ONCOL, vol. 33, no. 6, 2015, pages 540 - 9 |
KRISKY ET AL., GENE THER., vol. 5, 1998, pages 1517 |
KUBALL ET AL., BLOOD, vol. 109, 2007, pages 2331 |
LEE ET AL., LANCET, vol. 385, no. 9967, 2015, pages 517 - 28 |
LEEN ET AL., ANN. REV. IMMUNOL., vol. 25, 2007, pages 243 |
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 |
LI ET AL., PNAS U.S.A., vol. 114, 2017, pages E5891 - 5899 |
LIU ET AL., BLOOD, vol. 115, 2010, pages 3520 - 30 |
MAJZNERMACKALL, CANCER DISCOV., vol. 8, 2018, pages 1219 - 1226 |
MALONEY, NAT. REV. CLIN. ONCOL. 2018, vol. 15, 2019, pages 4 16,279 - 280 |
MATES ET AL., NAT. GENET., vol. 41, 2009, pages 753 |
MAUDE ET AL., N. ENGL. J. MED., vol. 378, 2018, pages 439 - 448 |
MAUTINO ET AL., AMERICAN ASSOCIATION FOR CANCER RESEARCH 104TH ANNUAL MEETING 2013, 6 April 2013 (2013-04-06) |
MINGUENEAU ET AL., NAT. IMMUNOL., vol. 9, 2008, pages 522 - 532 |
MORSUT ET AL., CELL, vol. 164, 2016, pages 780 - 791 |
NGUYEN ET AL., BLOOD, vol. 102, 2003, pages 4320 |
PAQUES ET AL., CURR. GENE THER., vol. 7, 2007, pages 49 - 66 |
PATEL ET AL., GENE THERAPY, vol. 6, 1999, pages 412 - 419 |
PERLER ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 1125 - 1127 |
PORTER ET AL., SCI TRANSL 25 MED, vol. 7, no. 303, 2015, pages 303ra139 |
PORTEUS ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 967 - 73 |
REN ET AL., CLIN. CANCER RES., vol. 23, no. 9, 2017, pages 2255 - 2266 |
SADELAIN ET AL., CANCER DISCOV., vol. 3, no. 4, 2013, pages 388 |
SALTER ET AL., SCI. SIGNAL., vol. 11, 2018, pages eaat6753 |
SAVOLDO ET AL., J CLIN INVEST, vol. 121, no. 5, 2011, pages 1822 - 6 |
SAZINSKY ET AL., PNAS, vol. 105, no. 51, 2008, pages 20167 |
SCATCHARD ET AL., ANN. N.Y. ACAD. SCI., vol. 51, 1949, pages 660 |
SCHMIDTSKERRA, NATURE PROTOCOLS, vol. 2, 2007, pages 1528 - 1535 |
SCHMITT ET AL., HUM. GEN., vol. 20, 2009, pages 1240 |
SCHOLTEN ET AL., CLIN. IMMUNOL., vol. 119, 2006, pages 135 - 145 |
STONE ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 63, no. 11, 2014, pages 1163 |
SUSSMAN ET AL., J. MOL. BIOL., vol. 342, 2004, pages 31 - 41 |
SYKULEV ET AL., IMMUNITY, vol. 4, 1996, pages 565 - 571 |
TAILOR ET AL., J. IMMUNOL., vol. 181, 2008, pages 243 - 255 |
TERENTIS ET AL., BIOCHEM., vol. 49, 2010, pages 591 - 600 |
TILL ET AL., BLOOD, vol. 112, no. 6, 2008, pages 2261 - 71 |
TORIKAI ET AL., BLOOD, vol. 119, no. 24, 2012, pages 5697 - 50 |
TORIKAI ET AL., BLOOD, vol. 122, no. 8, 2013, pages 1341 - 74 |
TORIKAI ET AL., NATURE SCI. REP., vol. 6, 2016, pages 21757 |
TURTLE ET AL., SCI. TRANSL. MED., vol. 8, 2016, pages 355ra1 16 |
VERHOEYEN ET AL., METHODS MOL. BIOL., vol. 506, 2009, pages 97 |
WALCHLI ET AL., PLOS ONE, vol. 6, 2011, pages 327930 |
WALKER ET AL., MOL. THER., vol. 25, 2017, pages 2189 - 2201 |
WALSENG ET AL., SCIENTIFIC REPORTS, vol. 7, 2017, pages 10713 |
WANG ET AL., BLOOD, vol. 118, 2011, pages 1255 |
WANG ET AL., HUM. GENE THER., vol. 18, 2007, pages 712 |
WATANABE ET AL., J. IMMUNOL., vol. 194, 2015, pages 911 - 920 |
WEIR: "Handbook of Experimental Immunology", 1986, BLACKWELL SCIENTIFIC, article "Current Protocols in Immunology" |
WILSON, SCIENCE, vol. 295, 2002, pages 2103 |
WOLFE ET AL., J. MOL. BIOL., vol. 285, 1999, pages 1917 - 1934 |
WOLFF ET AL., CANCER RES., vol. 53, 1993, pages 2560 |
XIE ET AL., PLOS ONE, vol. 9, 2014, pages e100448 |
YU ET AL., J. IMMUNOL., vol. 168, 2002, pages 3145 - 3149 |
ZHAO ET AL., J. IMMUNOL., vol. 174, 2005, pages 4415 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112500492A (en) * | 2019-09-13 | 2021-03-16 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
WO2021249549A1 (en) * | 2019-09-13 | 2021-12-16 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and use thereof |
CN112500492B (en) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
WO2022020456A3 (en) * | 2020-07-21 | 2022-03-03 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
CN113980137A (en) * | 2020-07-27 | 2022-01-28 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor containing CD3 epsilon intracellular basic amino acid enrichment region motif and application thereof |
CN113980136A (en) * | 2020-07-27 | 2022-01-28 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor containing CD3 epsilon intracellular domain with Y/F mutation and application thereof |
CN113980136B (en) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor comprising CD3 epsilon intracellular region with Y/F mutation and application thereof |
CN113980137B (en) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor containing CD3 epsilon intracellular basic amino acid enrichment region motif and application thereof |
WO2022251120A3 (en) * | 2021-05-24 | 2023-02-16 | Kite Pharma, Inc. | Nkg2d-based chimeric antgen receptor |
WO2023028583A1 (en) * | 2021-08-26 | 2023-03-02 | The Regents Of The University Of Colorado, A Body Corporate | Cd3 epsilon chimeric antigen receptors and methods of use thereof |
WO2023069936A1 (en) * | 2021-10-18 | 2023-04-27 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
WO2023186079A1 (en) * | 2022-04-02 | 2023-10-05 | 杭州尚健生物技术有限公司 | Cd80 protein variant and cd80 fusion protein |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102375033B1 (en) | High affinity MAGE-A1-specific TCR and uses thereof | |
WO2020068702A1 (en) | Chimeric receptor proteins and uses thereof | |
WO2019079777A1 (en) | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression | |
JP7407701B2 (en) | strep tag-specific chimeric receptors and their uses | |
US20210145882A1 (en) | Methods for adoptive cell therapy targeting ror1 | |
EP3759130A1 (en) | Compositions and methods for cellular immunotherapy | |
CN112912387A (en) | Immunotherapy targeting KRAS or HER2 antigens | |
JP2023030005A (en) | Methods for improving adoptive cell therapy | |
CA3090700A1 (en) | Cyclin a1 specific t cell receptors and uses thereof | |
WO2019109047A1 (en) | Binding proteins specific for 5t4 and uses thereof | |
US20220009992A1 (en) | T cell receptors specific for mesothelin and their use in immunotherapy | |
US20220401537A1 (en) | Chimeric receptor proteins and uses thereof | |
WO2022066965A2 (en) | Immunotherapy targeting sox2 antigens | |
WO2023288281A2 (en) | Chimeric polypeptides | |
WO2023220718A1 (en) | Binding proteins specific for ras neoantigens and uses thereof | |
EP4259651A2 (en) | Compositions and methods for cellular immunotherapy | |
WO2023212507A1 (en) | Compositions and methods for cellular immunotherapy | |
WO2023230014A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
WO2023164439A2 (en) | Cd4+ t cell markers, compositions, and methods for cancer | |
CN114555790A (en) | WT-1 specific T cell immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19794737 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19794737 Country of ref document: EP Kind code of ref document: A1 |